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Annabel Taylor - Heterogeneity in vascular smooth muscle cell gene expression and its association 
with clonal proliferation in models of vascular disease. 
 
Deregulation of vascular smooth muscle cell (VSMC) phenotypic switching is implicated in vascular 
disease development and VSMCs produce the majority of cells in late-stage atherosclerotic plaques. 
However, VSMC accumulation in mouse models of vascular disease arises from clonal expansion of 
very few medial cells. The source of these cells and mechanism of their selection are unknown. 
 
Hypothesising that VSMCs which expand in disease would be distinctive within the healthy population, 
single cell RNA sequencing (scRNA-seq) was combined with mouse VSMC-specific lineage tracing to 
profile VSMC transcriptomes from healthy aorta and two in vivo disease models (CL – carotid ligation 
and HFD – high-fat diet-induced atherosclerosis). This identified VSMCs expressing stem cell antigen-1 
(Sca1), which lacked expression of conventional VSMC markers, but were also distinct from adventitial 
and endothelial cell profiles. Induction of Sca1 was evident in phenotypically switched VSMCs in vitro 
and in both in vivo disease models. Notably, Sca1+ VSMCs were a rare subset in the healthy aorta, but 
more prevalent in the two disease datasets and expressed an activated, responsive gene signature in 
all three environments. This gene signature contains known regulators of plaque progression; 
suggestive that they may be candidates for those cells selectively proliferating in disease. 
 
Focusing on VSMCs from CL, the scRNA-seq dataset lacked discrete clusters of gene expression. Instead 
a transition in expression profiles could be seen, allowing for cells to be mapped onto a linear 
trajectory, using an unbiased approach. This trajectory showed contractile marker downregulation 
over pseudotime, corresponding to increased expression of Sca1 and proliferation marker Ki67. 
Moreover, Ki67+Sca1+ VSMCs were identified post-CL via flow cytometry, indicating that Sca1+ VSMCs 
indeed expand in disease. Investigation of candidate genes with differential expression across this 
pseudotime revealed enrichment for VSMC activation and disease-relevant gene ontology pathways. 
Further disease relevance of these candidates was highlighted using immunostaining of mouse and 
human plaque sections and comparison to other scRNA-seq datasets. 
 
Finally, a lineage traced tissue explant model was developed to study clonal VSMC proliferation in vitro. 
Traditional dissociated primary cell culture causes spontaneous VSMC phenotypic switching and 
general proliferation, which is not representative of the in vivo VSMC response. The explant model 
presented here maintains cell-cell and cell-extracellular matrix contact, resulting in limited 
proliferation of VSMCs and formation of monoclonal patches of VSMCs, comparable to those seen in 
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vivo. Additionally, the model replicated published observations of differences in proliferation of VSMCs 
derived from two distinct aortic regions and increased proliferation with growth factor treatment. 
Lentiviral transduction of the explanted VSMCs allowed for genetic manipulation, providing a platform 
to test the influence of individual genes on VSMC clonal expansion. 
 
In summary, this work identified a rare Sca1+ VSMC population which may represent a source of 
clonally expanding VSMCs. A comprehensive resource of transcriptional data from healthy and disease 
associated VSMCs has been generated and interrogation revealed commonality in activated Sca1+ 
VSMC expression profiles. Further investigation demonstrated a trajectory of gene expression, 
implicating many disease-relevant genes in VSMC activation. When combined with the in vitro lineage 
labelled model of VSMC proliferation, this provides a basis for identification and screening of genes 
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Chapter 1 Introduction 
 
1.1 Project context: examining VSMCs as a major contributor to cardiovascular disease 
Cardiovascular disease (CVD) is a group of disorders involving the heart and blood vessels, including 
coronary or ischaemic heart disease, stroke, peripheral arterial disease and heart failure. CVD is the 
leading cause of mortality worldwide and was responsible for 17.8 million deaths globally in 2017. This 
accounts for a third of global mortality, at almost double the number of deaths from the second leading 
cause, cancer (Roth et al., 2018). Moreover, CVD is also the largest contributor to global disease 
burden, a measure which incorporates patient morbidity and suffering as a consequence of their 
condition, resulting in 35.6 million years lived with disability or 366 million disability-adjusted life years 
lost (Kyu et al., 2018; Mensah et al., 2019). Economically, CVD was estimated to cost £660 billion 
globally in 2010, including £360 billion in healthcare costs and £300 billion in productivity losses. This 
figure is expected to rise by 22% to almost £800 billion by 2030 (Bloom et al., 2011).  
 
Atherosclerosis, the major cause of CVD, is a chronic and complex condition involving the development 
of large lipid-rich plaques within the blood vessels which can impair and eventually block their function 
(Singh et al., 2002). Vascular smooth muscle cells (VSMCs) are key players in the development of 
atherosclerosis, becoming activated under disease conditions and producing a major proportion of 
cells resident within a plaque (Shankman et al., 2015; Y. Wang et al., 2019). However, VSMC 
contributions to atherosclerosis are non-uniform and several recent publications have highlighted a 
clonal origin for VSMC-derived plaque cells (Chappell et al., 2016; Feil et al., 2014; Jacobsen et al., 
2017a). The mechanism behind this clonal source is unclear. Within this thesis, I use single-cell RNA 
sequencing of fluorescent lineage traced VSMCs from healthy mice and mouse models of vascular 
disease with an aim to identify genes involved in VSMC activation. I also develop an in vitro model in 




1.2 The architecture and function of the blood vessel wall 
The mammalian cardiovascular system relies on a network of vessels to transport blood from the heart 
around the body, ensuring that each cell is connected to a supply of oxygen and nutrients, as well as a 
means to remove its carbon dioxide and other waste products. Large blood vessels comprise three 
layers each with a different cellular composition (Figure 1.1): an outer adventitia of diverse cell types, 
adjacent media composed of VSMCs and an inner intima of endothelial cells (ECs), which function 




Figure 1.1 - Organisation of the aortic vessel wall. 
a) Cross-sectional view of the aorta, with the boxed region showing the position of the vessel wall 
enlarged in panel (b). b) Schematic of the three layers which compose the aortic wall: an external 
adventitia, middle media and inner intima. c) Further detail of components within the three layers in 
(b). The adventitial cells within the adventitia are separated from the layers of medial VSMCs by an 
external elastic lamina. In turn, an internal elastic lamina separates the VSMCs from single layer of ECs. 
Figure was modified from SMART (Servier Medical Art), licensed under a Creative Common Attribution 
3.0 Generic Licence. http://smart.servier.com/  
 
The outer adventitial layer is made up of a collagen-rich extracellular matrix containing nerves, 
lymphatic vessels and a variety of cell types including fibroblasts and immune cells, thought to regulate 
vascular cell trafficking, process external stimuli and mediate the growth or regression of nascent 
microvessels (Majesky et al., 2011; Stenmark et al., 2013). More recently the adventitia has also been 
suggested to be a niche for vascular stem or progenitor cells, primed to respond in vascular injury, 
including endothelial and mesenchymal progenitor cells (EPCs and MPCs), smooth muscle cell 
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progenitors, haematopoietic and mesenchymal stem cells (HSCs and MSCs) (Stenmark et al., 2013). In 
contrast to the complex adventitia, the intima is a single-cell layer of ECs in contact with the blood in 
the vessel lumen. As such, EC selective permeability governs component exchange between the blood 
and underlying vessel layers (Claesson-Welsh, 2015), also regulating vascular tone, blood cell activation 
and thrombosis through the secretion of vasoactive factors (Sandoo et al., 2010). In humans the intima 
also contains VSMCs, whereas in mice these cells are found exclusively within the medial layer (Lee et 
al., 2017a). The media itself is composed of concentric layers of VSMCs separated by layers of elastin 
known as the elastic lamina. These VSMC layers are aligned to enable modulation of vessel diameter 
and blood pressure through contraction and relaxation, processes which are responsive to vasoactive 
signals from the endothelium or adventitia, contact-dependent signalling and physical factors from the 





1.3 Vascular smooth muscle cells (VSMCs) are non-irreversibly differentiated cells capable of 
phenotypic switching for vascular repair and remodelling 
VSMCs within the media of healthy vessels exist in a differentiated state, characterised by an elongated 
morphology and the expression of contractile markers such as SMMHC (MYH11) and aSMA (ACTA2). 
These contractile VSMCs are quiescent and largely do not proliferate, with a half-life of 270-400 days 
(Neese et al., 2002). However, VSMCs are non-irreversibly differentiated and possess the ability to re-
activate, causing them to de-differentiate and re-enter the cell cycle (Owens et al., 2004). This 
activation is known as phenotypic switching and transforms a VSMC into a proliferative, migratory 
and/or synthetic cell, producing new cells and extracellular matrix components needed for vascular 
repair or remodelling (Figure 1.2). 
 
 
Figure 1.2 - VSMCs can phenotypically switch between contractile and synthetic states. 
VSMCs within the vessel medial layer are generally in a contractile state (left), which are quiescent, 
rhomboid in shape and marked by the expression of contractile proteins, which enable them to 
maintain blood pressure and vascular tone. However, upon inflammatory or mitogenic stimulus, 
VSMCs can phenotypically switch to a synthetic state (right), taking on a more rounded shape, re-
entering the cell cycle to become proliferative and synthesising new cells and extracellular matrix 
(ECM) components for vascular repair. Figure was modified from SMART (Servier Medical Art), licensed 
under a Creative Common Attribution 3.0 Generic Licence. http://smart.servier.com/  
 
A key aspect of VSMC phenotypic switching is the downregulation of contractile protein expression, 
orchestrated by competing anti- and pro-differentiation signals (Owens et al., 2004). Many of these 
signals converge at CArG elements, which are specific DNA sequences (CC(A/T)6GG) within the 
promoters of contractile genes, such as MY11, TAGLN, ACTA2 and CNN1. CArG elements are bound by 
multi-protein complexes including the transcription factor Serum response factor (SRF) and its co-
activator Myocardin, which promote contractile gene transcription in VSMCs. A potent inducer of 
VSMC phenotypic switching is platelet-derived growth factor isoform BB (PDGF-BB), a mitogen 
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released at sites of vascular injury (Andrae et al., 2008). Upon interaction with PDGF receptor (PDGFR) 
on the VSMC surface, PDGF triggers a cascade of protein kinases culminating in phosphorylation of the 
ternary complex factor ELK1, which can disrupt SRF-Myocardin interactions (Wang et al., 2004). As a 
result, PDGF causes rapid and sustained downregulation of contractile marker expression, in addition 
to activation of VSMC proliferation and migration via other protein kinase pathways (including PI3K, 
AKT, ERK1/2) and insulin receptor substrates (IRS1/2) (Blank and Owens, 1990; Zhao et al., 2011). 
Moreover, PDGF also induces Kruppel-like factor 4 (KLF4), a pluripotency associated transcription 
factor, which further reduces contractile gene expression through reduced Myocardin transcription 
and inhibition of SRF/Myocardin complex formation (Deaton et al., 2009; Liu et al., 2005).  
 
In opposition to PDGF, the cytokine Transforming growth factor β (TGFβ) is also released at sites of 
vascular injury and acts to promote a differentiated and quiescent phenotype in VSMCs. TGFβ induces 
contractile gene expression by increased SRF transcription and stimulation of SRF binding to CArG 
elements (Hautmann et al., 1997; Mack, 2011). Interestingly, TGFβ signalling also causes upregulation 
and phosphorylation of KLF4 via SMAD2/3 and p38 MAPK. Subsequent activity of the SMAD2/KLF4 
complex increases expression of the TGFβ receptor TGFβR1, with the cumulative effect of cell cycle 
inhibition and induction of differentiation in VSMCs (Li et al., 2010). Such opposing effects from the 
same factor highlight the context-dependent nature of each stimulus’ effect, requiring precise 
integration of signals within each VSMC to elicit an appropriate response. Other notable factors with 
an influence on VSMC phenotypic switching include: mitogen Fibroblast growth factor 2 (FGF2), which 
induces VSMC proliferation without contractile marker downregulation (Owens et al., 2004); Bone 
morphogenetic proteins (BMPs) 2, 4 and 6, that inhibit Myocardin-dependent contractile gene 
expression (Hayashi et al., 2006) and Angiotensin II (ANGII), which increases contractile gene 
expression via SRF-interacting transcription factor PRX1/MHOX, but also induces VSMC proliferation, 
migration and inflammatory gene expression (Das et al., 2017; Mack, 2011; Yoshida et al., 2004). 
 
Finally, VSMCs are also influenced by their surrounding extracellular matrix (ECM), sensed by 
interaction with integrins linked to the VSMC actin cytoskeleton (Clyman et al., 1990; Moiseeva, 2001). 
Different ECM components can affect VSMC phenotype; for example, laminin and collagen IV within 
the vessel basement membrane maintain a contractile phenotype in VSMCs (Thyberg and Hultgårdh-
Nilsson, 1994) and type I collagen fibrils also found in the vessel ECM promote growth arrest in G1 
(Ichii Takuya et al., 2001). In contrast, monomeric collagen and fibronectin activate VSMC proliferation 
and a synthetic phenotype (Hedin et al., 1988). Such influences are another input to the process of 





1.4 VSMC contributions to vascular disease 
Although beneficial during vascular development and the remodelling of collateral vessels for 
revascularisation (Risau, 1997; Rzucidlo et al., 2007), VSMC phenotypic switching is also implicated in 
vascular disease. The most common manifestation of unrestrained phenotypic switching is in 
atherosclerosis (Figure 1.3), a complex disease characterised by the production of a lipid- and cell-rich 
plaque in the vessel lumen, causing impaired blood flow and subsequent tissue ischaemia. 
 
The early stages of atherosclerosis are still unclear, but are thought to begin with EC activation due to 
high levels of circulating blood lipids, high blood pressure, disturbed blood flow or other inflammatory 
stimulus (Libby et al., 2011). Resulting EC damage or altered permeability allows the deposition of lipid 
in the vessel wall, causing further pro-inflammatory activation of ECs and infiltration of monocytes 
(Mundi et al., 2018). Subsequent differentiation of these monocytes into macrophages and attempts 
to phagocytose and process the deposited lipid result in the formation of cholesterol-rich foam cells, 
which are characteristic of atherosclerotic plaques (Schrijvers et al., 2007). The presence of pro-
inflammatory mediators and oxidised phospholipids are thought to cause VSMC phenotypic switching, 
activating proliferation, migration into the intima and synthesis of ECM (Cherepanova et al., 2009; 
Libby et al., 2011). Ultimately, amplification of these responses and cell apoptosis or necrosis due to 
high levels of oxidative stress cause the plaque to develop an inflammatory, necrotic ‘core’ filled with 
lipids and foam cells in various stages of phagocytosis, proliferation and death, along with cell and ECM 
debris (Martinet et al., 2011). Surrounding this, an organised fibrous ‘cap’ region of contractile VSMCs 
and ECM develops. This cap separates the many thrombotic elements in the plaque from the blood in 
the vessel lumen (Libby, 2009) and plaques which fail to develop this cap or suffer cap deterioration 
become vulnerable to rupture (Lafont, 2003). The fate of advanced plaques is therefore determined 
by stabilising factors such as ECM secretion and VSMC proliferation in the fibrous cap, balanced with 
ECM degradation, VSMC senescence or apoptosis and growth of the detrimental necrotic core 
(Alexander and Owens, 2012; Bennett et al., 1995; Newby and Zaltsman, 1999). As such, plaques can 
exist in a stable state for prolonged periods and the majority do not result in acute vascular events 






Figure 1.3 - Development of 
atherosclerosis in the vessel wall. 
a) Cross-sectional view of a healthy 
blood vessel. b) Early atherosclerosis 
shown by infiltration of lipid into the 
vessel wall, followed by monocytes 
which differentiate into macrophages. 
c) Advanced atherosclerotic plaque 
showing a large necrotic core, 
containing lipid-filled foam cells 
derived from macrophages and medial 
VSMCs, apoptotic and necrotic cells, 
and a fibrous cap rich in ECM and 
VSMCs expressing contractile 
markers. Figure was modified from 
SMART (Servier Medical Art), licensed 
under a Creative Common Attribution 





















As a major component of the fibrous cap, VSMCs are considered critical to prevent plaque rupture and 
potentially fatal thrombosis (van der Wal et al., 1994). As a result, VSMCs were traditionally seen as a 
beneficial cell type within atherosclerosis, acting to seal or encapsulate the plaque in a healing manner 
(Schwartz et al., 2000). Although VSMCs were identified in the plaque core, they were found in very 
low numbers and deemed a minimal contributor (Davies et al., 1993). However, this assumption relied 
on the identification of VSMCs by contractile protein markers, which are generally not expressed by 
phenotypically altered VSMCs. With the advent of genetic lineage tracing, a much larger role for VSMCs 
in atherosclerosis development has become appreciated (Feil et al., 2014; Shankman et al., 2015), also 
identifying VSMCs that have activated expression of macrophage associated markers, which may have 
previously been identified as macrophage cells (Chappell et al., 2016; Feil et al., 2014). Subsequent 
work has demonstrated that the majority of cells resident in advanced plaques in mouse models of 
atherosclerosis are VSMC-derived (Chappell et al., 2016; Shankman et al., 2015), including around 70% 
of foam cells, previously thought to be produced from leukocytes (Y. Wang et al., 2019). VSMC-derived 
foam cells express lower levels of the cholesterol efflux protein ABCA1 than their leukocyte-derived 
counterparts, which is a possible mechanism for impaired cholesterol processing and subsequent foam 
cell formation (Y. Wang et al., 2019). Importantly, the VSMC contributions to foam cells in animal 
models of atherosclerosis can be translated to human plaques, given that aSMA expression had been 
demonstrated in approximately 50% of foam cells from sections of human coronary artery plaques, 
which also showed activated CD68 and reduced ABCA1 expression when compared to aSMA- foam 
cells (Allahverdian et al., 2014). Moreover a further 34% of these foam cells were CD68+CD45-, 
suggestive of a non-myeloid origin (Allahverdian et al., 2014). Therefore, VSMCs are thought to play 
both protective and detrimental roles within atherosclerosis development and further work is required 
to understand the processes involved in production of each VSMC-derived plaque cell type. 
 
In addition to atherosclerosis, excessive VSMC phenotypic switching as a result of injury during vessel 
angioplasty or atherectomy leads to their accumulation within the intima, causing vessel occlusion. 
Thus, attempts to relieve a blocked vessel can actually cause a further obstruction, termed restenosis 
or recurrent occlusion, which usually occurs within 6 months after the procedure (Dangas George and 
Kuepper Frank, 2002). More complex, lipid-filled plaques can also develop within the stented intima in 
a manner akin to atherosclerosis development, termed neoatherosclerosis (Buccheri et al., 2016). 
Another complex disorder involving VSMC expansion is aortic aneurysm, whereby vascular injury 
causes the infiltration of leukocytes into the vessel wall, leading to dilation and remodelling, often 
resulting in aortic tears or rupture (Sakalihasan et al., 2018). Aneurysms occur most commonly within 
the abdominal or thoracic aorta and result in significant mortality, causing death in up to 85% of 
patients who suffer an aortic rupture (Jana et al., 2019). Although poorly understood, the processes 
underlying aneurysm development involve chronic inflammation and structural breakdown of the 
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vessel ECM (primarily through protease release by macrophages, fibroblasts and VSMCs (Quintana and 
Taylor, 2019)), along with VSMC apoptosis, which reduces the synthesis of new ECM components for 
repair (Ailawadi et al., 2009). VSMC phenotypic switching is an early event in aneurysm formation, 
proposed to be a healing response, and results in large regions of VSMC expansion, both in the medial 
layer and infiltrating the adventitia (Clément et al., 2019). Finally, there is recent evidence that VSMC 
phenotypic switching plays a role in neoplastic metastasis, particularly to sites in the lung (Murgai et 
al., 2017). In this work, Murgai et al. demonstrated increased phenotypic switching of VSMCs within 
the lungs of mice injected with melanoma cells at a distant site. These VSMCs demonstrated 
downregulation of contractile markers and activation of proliferation, migration and ECM synthesis, 
thought to be a result of inflammatory cytokines released by the injected tumour cells. Moreover, 
disruption of these responses by VSMC-specific Klf4 deletion resulted in a significant decrease in 
tumour cell metastasis, causing a reduction of their numbers found within the lung (Murgai et al., 
2017). Thus, further understanding of the processes involved in VSMC phenotypic switching could 





1.5  Models of vascular disease used to study VSMC phenotypic switching 
Cell culture is a fundamental tool for researchers to investigate cell behaviour in vitro, providing a 
means to perform experiments which would be more laborious, time-consuming and expensive to 
conduct in vivo. Cell lines used in culture are often derived from a single clone to ensure homogeneity, 
and reproducibility in experimental repeats, which means that they do not capture the heterogeneity 
of cells in vivo. Furthermore, cell lines can be immortalised to provide a renewable source, but this 
means that they are inherently proliferative, often in an unnatural manner. Isolation of primary cells 
for in vitro culture circumvents these issues, with the added benefit that culture of contractile, 
quiescent primary VSMCs causes spontaneous phenotypic switching to a proliferative and synthetic 
phenotype after 5-7 days of culture (Chamley et al., 1974). This convenient model has produced many 
valuable insights into VSMC phenotypic switching, including its stimulation by PDGF and activation of 
low density lipoprotein (LDL) metabolism, type I collagen synthesis and expression of the leukocyte 
adhesion factor ICAM-1 (Campbell and Campbell, 2012). However, this ex vivo phenotypic switch 
remains unnatural, with an absence of complex cell-cell and cell-ECM interactions, which can greatly 
influence VSMC phenotype and atherosclerosis development (Ramel et al., 2019; Stegemann et al., 
2005). Moreover, it is difficult to follow clonal expansion of VSMCs in this way, due to their migration 
during 2D culture.  
 
In order to replicate the complex processes that occur in human disease, researchers can turn to 
animal models. Most commonly used are mice, due to their physiological similarity to humans, well 
characterised genetics and short lifespan (Getz and Reardon, 2012). Wildtype-mice are, however, 
largely resistant to atherosclerosis development, in part due to a more efficient reverse cholesterol 
transport pathway than humans (Oppi et al., 2019). This efficiency is caused by a lack of the cholesteryl 
ester transfer protein (CETP) in mice, preventing cholesterol transfer from high-density lipoproteins 
(HDL) to very low-density lipoproteins (VLDL) (Oppi et al., 2019). As a result, plasma cholesterol in mice 
is predominantly carried by HDL particles, which transport it to the liver for excretion (Ouimet et al., 
2019), resulting in low concentrations of circulating lipid and athero-resistance. To side-step this 
limitation, researchers have developed mice carrying genetic modifications to remove components of 
lipid handling and the most frequently used carries a knock-out of the apolipoprotein E gene (ApoE-/-). 
ApoE is a lipoprotein ligand for the cell surface low density lipoprotein receptor (LDLR) and, as such, 
its knock-out causes reduced lipoprotein clearance and increased levels of circulating cholesterol 
(Hinder et al., 2013). ApoE-/- animals develop complex atherosclerotic plaques analogous to those seen 
in human disease, particularly when using the C57BL/6 background, which are more susceptible to 
plaque formation than other strains (Teupser et al., 2003). Development of plaques in these mice also 
proceeds in a similar manner to those in humans, beginning with monocyte attachment to ECs at 6 
weeks old, followed by the development of foam cell lesions at 8 weeks (Nakashima et al., 1994). After 
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15-20 weeks, more advanced lesions containing VSMCs and a fibrous cap are evident, which become 
more fibrous and calcified over time (Nakashima et al., 1994). Plaque development can be accelerated 
by feeding mice with a high fat diet (HFD) containing a high fat and cholesterol content, which doubles 
the level of plasma cholesterol in ApoE-/- mice (Emini Veseli et al., 2017). HFD-induced plaques develop 
faster than those from animals fed a normal ‘chow’ diet and have a higher content of foam cells and 
lipid (Getz and Reardon, 2012). The ApoE-/- mouse and other mice models of impaired lipid handling 
(such as LDLR-/-) have provided valuable insight into lipid-based mechanisms of atherosclerosis 
development, which have been translated into lipid-lowering therapies with benefits in atherosclerosis 
reduction (Daugherty Alan et al., 2017). However, there are some major distinctions between plaque 
development in mice and humans, including the aforementioned differences in lipid handling, which 
should be appreciated in interpreting the results from mouse models (Perlman, 2016). Another key 
difference is that mouse plaques are resistant to rupture and subsequent thrombosis, potentially due 
to the small vessel diameter and resulting high surface tension in mice (Jawień et al., 2004). Mouse 
atherosclerosis models also display higher vascular inflammation and less plaque calcification than in 
human disease and develop at different sites in the vasculature (Daugherty Alan et al., 2017). In 
humans, plaques are often found in the coronary arteries, carotids and peripheral vessels, whereas 
they develop predominantly in the aortic root, brachiocephalic artery and aortic arch in mice (Getz and 
Reardon, 2012). 
 
An alternative to diet-induced atherosclerosis is the use of vascular injury to induce neointimal 
formation. Frequently used is the ligation of the left common carotid artery near its bifurcation (Figure 
1.4, carotid ligation or CL), which causes a complete cessation of blood flow and extensive vascular 
remodelling, reducing the vessel luminal diameter to 80% of its original size by 28 days post-injury 
(Kumar and Lindner, 1997). This acute response occurs in a fast and reproducible manner and is 
predominantly VSMC-driven, with VSMCs shown to contribute an average of 80% of cells to the 
neointima (Herring et al., 2014). Changes in VSMC gene expression are seen as early as day 3, showing 
decreases in contractile genes and increased inflammatory cytokines, such as Spp1, Il-1, Ccl2/3 and 
Cxcl3 (Herring 2017). Proliferation of VSMCs has been observed from day 5 after injury, peaking after 
2 weeks, by which point a neointima has been formed, and significantly reduced at day 28 (Kumar and 
Lindner, 1997). Although rapid, VSMC phenotypic switching in response to CL injury results in more 
aSMA+ neointimal VSMCs than in HFD-induced atherosclerosis (Chappell et al., 2016). Moreover, more 
de-differentiated aSMA- and Mac3+ VSMCs are fewer in number in CL-induced neointima and do not 
show a specific localisation, unlike aSMA-Mac3+ HFD-induced plaque VSMCs found mainly within the 
plaque necrotic core (Chappell et al., 2016). In this way, CL-induced neointima is more analogous to 
human restenosis by VSMCs following angioplasty or atherectomy, perhaps owing to the lack of a lipid 
component to drive foam cell and necrotic core formation (Wang and Paigen, 2002). Other vascular 
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injury models include the use of wire (Lindner et al., 1993) or balloon injury  (Matter et al., 2006) to 
denude the vessel wall of ECs and stimulate VSMC proliferation. Both injuries cause a higher 
inflammatory response than CL, involving the recruitment of circulating leukocytes prior to intimal 
hyperplasia, and balloon injury also causes high levels of VSMC medial death (Matter et al., 2006; 
Roque et al., 2000). Vein grafting can also be used to mimic the atherosclerosis caused by vascular 
grafting during bypass surgery (Cooley, 2004; Zou et al., 1998), which involves a high level of local cell 
death and a substantial contribution to the neointima from bone-marrow-derived or endothelial cells, 
depending on the nature of the surgery (Cooley, 2004; Xu, 2004). Grafts also show a reduced 
contribution of VSMCs to the neointima, when compared to other vascular injuries (Roostalu et al., 
2018). It is therefore important to understand the distinctions between each of these models and their 
resemblance to human disease before using them to infer disease pathology in humans. It is also 
pertinent to note that these animal models involve prolonged and often complicated procedures and 
raise ethical considerations, invoking a responsibility for researchers to use them sensibly and as 
sparingly as possible. 
 
Figure 1.4 – The carotid ligation surgery model of vascular injury. 
Schematic demonstrating the position of the mouse aorta, showing the aortic arch (AA) descending 
thoracic aorta (DT) and right or left common carotid arteries (RCA/LCA). In the carotid ligation (CL) 
surgery model of vascular injury, the LCA is ligated near to its bifurcation (shown in black), causing 
cessation of the blood flow at this part of the vessel. Figure was modified from (Shiota, 2012) and 





1.6  Evidence from genetic lineage tracing for VSMC clonal expansion in a range of vascular 
diseases 
Although atherosclerosis and other vascular disease are often characterised by large expansions of 
VSMCs, there is compelling evidence that these regions arise from proliferation of only single or a few 
individual VSMCs (Chappell et al., 2016; Feil et al., 2014; Jacobsen et al., 2017b). Such a clonal origin 
was suggested early on in the literature by Benditt and Benditt, who found identical X-inactivation in 
cells of human atherosclerotic lesions, despite the underlying media showing a mixed pattern (Benditt 
and Benditt, 1973). However, the limit of only two possible X-inactivation states, along with 
demonstration of similar patches of identical X-inactivation in the aortic media (Chung et al., 1998; 
Murry et al., 1997) meant that this monoclonality was subject to less attention until recent advances 
using lineage tracing at a single-cell resolution (Schwartz et al., 2018).  
 
Early methods to label cells in vivo involved the introduction of dyes, radioactive or chemically 
modified components into a cell, before tracking its fate over time. Improvements were achieved 
through the use of modified retrovirus or fluorescent plasmid transfection, however these systems 
were still limited by labelling efficiency, label persistence over time and a lack of selectivity 
(Woodworth et al., 2017). These issues were largely circumvented with the advent of genetic 
engineering, allowing the incorporation of specific genetic recombinases from bacteria or yeast into 
cells, which can excise DNA between specific recognition sites (Wang et al., 2011). Further modifying 
these cells with a reporter transgene, which is initially not expressed due to the insertion of a stop 
codon flanked by recognition sites for the recombinase, allows for the reporter to be switched on in 
any cell expressing the recombinase. Placing the recombinase under the control of a cell-specific 
promoter enables labelling of just the cell type where the promoter is active and use of a ligand-
responsive recombinase allows for time-restricted cell labelling upon the ligand application. One such 
recombinase is the CreERt2, a tamoxifen-inducible recombinase developed by fusing it to a mutated 
hormone-binding domain of the estrogen receptor, which excises DNA between ‘loxP’ sequences (Feil 
et al., 2009). Importantly, because the DNA between recognition sites is permanently excised from any 
cell where the recombinase is active, subsequent progeny of labelled cells do not possess the excised 
DNA and retain the lineage label. In the case of CreER, any cells labelled under tamoxifen application 
retain the label and pass it onto their progeny, even after the tamoxifen has been removed. In the 
context of atherosclerosis, this functionality allowed for researchers to label healthy cells, using a 
wash-out period to allow for tamoxifen removal, before HFD feeding to trace their behaviour and 




Figure 1.5 – Schematic of VSMC-specific Confetti lineage tracing. 
a) Schematic of the modified Cre recombinase (CreERt2) linked to the Myh11 promoter for VSMC 
specificity (upper) and the Confetti reporter (lower). The Confetti reporter is linked to the strong CAG 
promoter at the Rosa26 locus and preceded by a loxP-flanked stop codon, such that, when the Myh11-
driven CreERt2 is expressed by a VSMC, the stop codon is excised allowing for expression of the 
downstream fluorescent proteins. Furthermore, loxP flanking of the fluorescent proteins and their 
opposite-inverted design means that only one of the four will be expressed in each cell, depending on 
stochastic recombination at loxP sites by the CreERt2. Fluorescent proteins in the Confetti reporter are 
nuclear GFP, cytoplasmic YFP or RFP and membrane associated CFP. b) Schematic of the Confetti 
labelling process: tamoxifen application to VSMCs carrying the Confetti reporter causes recombination 
so that each cell expresses one of the four fluorescent proteins. As the recombination is permanent, 
cell progeny retain the same fluorescent protein expressed by their originating cell, even in absence of 
Myh11 expression following phenotypic modulation. Figure taken from Chappell et al., 2016. 
 
In this way, Feil et al. labelled healthy medial VSMCs using an SM22a-linked CreERt2 at a low frequency 
and were able to demonstrate large reporter positive plaque regions following HFD, indicative of a 
monoclonal origin (Feil et al., 2014). This work was extended by Chappell et al. and others, who used 
Myh11-CreERt2 (Wirth et al., 2008) and exploited a multi-colour ‘Confetti’ reporter (Romagnani et al., 
2015; Snippert et al., 2010a), to stochastically label VSMCs with one of four fluorescent labels (Figure 
1.5) (Chappell et al., 2016; Jacobsen et al., 2017b; Misra et al., 2018). Subsequent HFD feeding 
produced largely single-colour plaques, despite presence of a mosaic-patterned medial layer in all four 
colours, again indicative of a monoclonal origin (Figure 1.6a). Chappell et al. estimated that an average 
of 70% of plaque cells were VSMC-derived (a range of 40-90%), with no significant difference in VSMC 
contributions in the cap, core or shoulder regions (Chappell et al., 2016). Staining of plaque VSMCs 
showed some to express macrophage markers Mac2 and Mac3, the latter of which had been previously 
noted by Shankman et al, 2015 and others, who also saw CD68 expression in plaque VSMCs (Albarrán-
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Juárez et al., 2016; Shankman et al., 2015). These observations suggested that VSMCs expressing 
contractile markers in the plaque cap and de-differentiated or trans-differentiated VSMC-derived cells 
in the plaque core originate from the same individual cell, which was able to modulate its phenotype. 
Subsequent observations of VSMC-lineage labelled cells in plaques at different stages/time-points 
have suggested that VSMC clones expressing contractile markers first form the fibrous cap and then 
de-differentiate within the lesion core, but this is yet to be validated (Misra et al., 2018). Conversely, 
Chappell et al found Mac3+aSMA- VSMCs in medial regions underlying a plaque and in cells expressing 
reporter colours differing from the plaque clone, which may indicate that de-differentiation and 
acquisition of an alternative expression profile could precede proliferation and intimal expansion 
(Chappell et al., 2016).  
 
The translation of VSMC-specific multi-colour lineage tracing to a model of vascular injury also 
demonstrated a clonal response after CL (Figure 1.6b), estimating that neointimal VSMCs originate 
from less than 0.1% of the medial cell population (Chappell et al., 2016). Subsequent work has 
extended these observations to models of abdominal aortic aneurysm (Clément et al., 2019) and 
pulmonary arterial hypertension (Sheikh et al., 2018, 2015), inferring that clonality may be a common 














Figure 1.6 - VSMC clonality in models of vascular disease, demonstrated by VSMC-specific Confetti 
lineage tracing. 
a) Cross-section of an aorta from an Myh11-CreERt2/Rosa26-Confetti/ApoE-/- animal labelled with 
tamoxifen before being fed a HFD for 18 weeks, showing medial expression of Confetti reporter 
proteins RFP (red), YFP (yellow), CFP (blue) and GFP (green) and a large, RFP+ atherosclerotic plaque. 
b-c) Whole-mounted control RCA (upper) and ligated LCA (lower) from an Myh11-CreERt2/Rosa26-
Confetti animal at 28 days post-CL surgery, showing Confetti reporters as in (a). (b) shows a maximum 
projection and (c) shows a single z-scan, with a large CFP neointima boxed in white. Images adapted 






1.7 Mechanisms of VSMC clonal expansion 
Although a clonal origin for VSMCs in atherosclerosis has been confirmed by multiple groups, the 
mechanism by which this occurs is unresolved. Indeed, a key criticism of the lineage tracing studies 
used to identify clonal VSMC expansion is that they relied on observations in advanced atherosclerosis 
and did not interrogate the earlier processes of plaque development (Gomez and Owens, 2016). In 
other words, the observation of clonally derived VSMCs in advanced plaques cannot resolve whether 
they arose from limited proliferation by such clones or competition between many proliferating clones, 
of which one became the ‘winner’ or dominant source of plaque cells. In the absence of definitive 
evidence for one mechanism or another, several hypotheses exist as to the source of clonal plaque 
VSMCs: 
 
Firstly, there have been many reports of vascular progenitors, proposed to contribute to 
atherosclerotic plaque development. The existence of such a distinct cell population would explain 
their propensity to clonally expand over differentiated, non-progenitor cells. Several of these 
progenitors have been found in the adventitia and demonstrated to express VSMC contractile markers 
in vitro when cultured in media containing PDGF-BB (Chen et al., 2013; Hu et al., 2004; Yu et al., 2016). 
In addition to VSMC-differentiation potential, many of these adventitial progenitors express the stem 
cell marker Sca1 and can contribute to the neointima in vascular injury (Chen et al., 2013; Hu et al., 
2004; Yu et al., 2016). It is, however, unlikely that such adventitial cells are the source of VSMC-derived 
plaques in work by Chappell et al., due to the lack of lineage-labelled cells in the adventitia (Chappell 
et al., 2016). Inconsistencies in these studies may be due to the nature of vascular injury used in each, 
as the plaques containing adventitial cells were a result of vein grafting or wire injury, which cause 
widespread damage and recruitment of immune cells (Matter et al., 2006; Roque et al., 2000). In 
contrast, HFD or CL-induced plaques preserve the presence of VSMCs, causing them to be the main 
neointimal cell source (Chappell et al., 2016). As such, another study showed that, although CD34+ 
adventitial cells could express VSMC markers in vitro, they did not contribute to neointima formation 
in CL-injury (Shen et al., 2016).  
 
Within the media itself, several progenitor populations have been isolated, including Sca1+ side 
population cells which were largely negative for contractile markers (Sainz et al., 2006). Such Sca1+ 
medial cells raise the possibility that there may be a transfer of progenitors between the media and 
adventitia, strengthened by localisation of Sca1+ adventitial cells at the media/adventitia interface 
(Passman et al., 2008). Recent work by Majesky et al., 2017 validated this hypothesis, demonstrating 
that VSMC-lineage labelled cells contribute to Sca1+ cells in the adventitia (Majesky et al., 2017). 
Furthermore, these VSMC-derived Sca1+ adventitial cells contributed to adventitial expansion in 
carotid ligation (Majesky et al., 2017). Thus, the adventitial Sca1+ progenitors shown to differentiate 
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into VSMCs in vitro and produce neointimal cells in severe injury may have originated from medial 
VSMCs, although this is yet to be shown experimentally. Other markers for VSMC progenitors include 
CD146 (Roostalu et al., 2018), Gli1 (Kramann et al., 2016) and Sox17 (Tang et al., 2012), but the 
relationship between each population remains unresolved. 
 
An alternative hypothesis is that all VSMCs have the ability to phenotypically switch, yet this only 
occurs in rare cells which have undergone a prior priming process in order to overcome any barriers 
to activation. Such priming has been hypothesised to create a spectrum of plasticity within the vascular 
wall, with each cell being restricted in ability to modulate its phenotype (Shanahan and Weissberg, 
1998). One mechanism for this priming could be by location, whereby each individual cell is in contact 
with unique environmental factors such as shear stress, soluble factors, ECM components and other 
cells (Rensen et al., 2007). Indeed, there is evidence for local EC inhibition of VSMCs at fenestrations 
in the elastic lamina, which is overcome in response to disrupted blood flow following CL (Lu et al., 
2017), and an influence of bone marrow-derived macrophages on individual VSMC responses in 
atherosclerosis (Misra et al., 2018). Another cause of priming may be the origin of individual VSMCs, 
as the aorta is made up of cells originating from many developmental regions, including the neural 
crest, mesoderm and proepicardium (Majesky, 2007). Interestingly, aortic arch (AA) VSMCs from the 
neural crest are atherosclerosis-prone, whereas those within the descending thoracic aorta (DT) are 
mesodermal and display higher plaque resistance (Cheung et al., 2012; Jiang et al., 2000; Wasteson et 
al., 2008). Such differences are manifested as changes in phenotypic switching, in that chick ectoderm-
derived cells become proliferative in response to TGFβ whilst those of a mesoderm origin are growth 
inhibited (Topouzis and Majesky, 1996), and in the expression of pro-inflammatory genes, which are 
lower in the DT (Trigueros-Motos et al., 2013). There is evidence that athero-susceptibility can be cell 
intrinsic, using transplantation of athero-resistant DT aortic segments into the more atherogenic 
abdominal aorta (Haimovici and Maier, 1964). In these experiments the grafted DT regions did not 
display atherosclerosis development after months of high cholesterol feeding, despite neointimal 
formation in the surrounding abdominal tissue (Haimovici and Maier, 1964). This cell-intrinsic effect 
could also be a result of prior environmental priming, distinct from developmental identity and 
maintained within each VSMC, but the precise mechanism for these observations are undetermined. 
Finally, the presence of somatic mutations may also be a priming event or trigger for proliferation in a 
similar mechanism to cancer development (Benditt and Benditt, 1973; DiRenzo et al., 2017), although 
there is no specific evidence for this argument in VSMCs. 
 
Finally, there is a possibility that clonally expanded VSMCs in vascular disease are not pre-determined 
or primed, but instead outcompete other proliferating cells. Mechanisms of cell competition are 
complex and only partially understood, but can involve the sequestering of survival signals by 
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dominating clones, the induction of apoptosis in those deemed less fit, both in a contact-dependent 
and -independent manner, and even phagocytosis of neighbours (Amoyel and Bach, 2014). It may also 
be that the hostile plaque environment itself poses a competitive barrier, permitting only a rare 
number VSMCs to survive and proliferate. Using tritiated thymidine incorporation to label cell 
replication, it has previously been suggested that a large number of VSMCs migrate into the neointima 
without proliferating (Clowes and Schwartz, 1985), although a VSMC identity was assumed for these 
cells without validation. Such single, migrating VSMCs have not been found by lineage tracing at 
advanced stages of neointima (Chappell et al., 2016); however, it could be that such single cells 
underwent cell death at an earlier timepoint and were no longer detectable.  
 
Of course, VSMC clonal expansion could also be produced by a combination of the above hypotheses, 
necessitating careful consideration of the evidence for or against each. The use of multi-colour lineage 
tracing to distinguish individual cell types and clones provides a valuable tool to study cell behaviour; 
however, the heterogeneity and complexity of atherosclerotic plaques means that further high-





1.8 Single cell RNA sequencing to study population heterogeneity 
A major advancement in the investigation of cell heterogeneity was the development of single cell 
RNA-sequencing (scRNA-seq), first implemented in 2009 (Tang et al., 2009). Prior to this, genome-wide 
transcriptome studies were limited to bulk populations of thousands of cells or more (Picelli, 2016). In 
contrast, scRNA-seq allows for profiling of individual cells within a population. The basic principle of 
scRNA-seq relies on isolation and lysis of single cells, obtaining the cellular RNA and transcribing it to 
cDNA using a reverse transcriptase (RT). The cDNA produced is then amplified using an oligo-dT primer, 
to select for poly(A)-tailed mRNA and avoid amplification of tRNA and rRNA which predominate cellular 
RNA species (He et al., 2010), before amplification and high-throughput ‘next-generation’ DNA 
sequencing (Goodwin et al., 2016). In this work I use two complementary methods of scRNA-seq, the 
Smart-seq2 and 10X Chromium systems, and also describe preliminary analysis by others in the lab 
using the Fluidigm C1 system (see chapter 3). 
 
Smart-seq2 is a sensitive and high-coverage manual protocol to produce cDNA for sequencing from 
single cells, which I isolated by fluorescence-activated cell sorting (FACS). Smart-seq2 uses SMART 
technology (switching mechanism at the 5’ end of the RNA transcript) to amplify full-length cDNA 
transcripts, reducing the 3’ coverage bias associated with incomplete reverse transcription (Picelli et 
al., 2013). SMART technology utilises the reverse transcriptase (RT) from the Molony murine leukaemia 
virus (MMLV), which adds a few additional nucleotides to the end of each newly synthesised cDNA 
strand, mainly consisting of deoxycytidine (Luo and Taylor, 1990). Binding of these nucleotides by a 
specially-designed ‘template-switching oligo’ (TSO) causes the RT to switch templates from the original 
cDNA to the TSO, allowing it to continue transcription to the 5’ end of the TSO (Figure 1.7, Zhu et al., 
2001, Picelli et al., 2014). As such, the full 5’ end of the original cDNA template is incorporated into any 
amplified cDNA. The Smart-seq2 protocol also offers improvements in efficiency and reduced cost than 
prior versions of scRNA-seq (Picelli et al., 2014, 2013). Furthermore, the use of FACS for single cell 
isolation and subsequent processing of cells in individual reaction wells means that they can be 
individually barcoded using two unique oligonucleotide tags per well (Kircher et al., 2012). In this way, 
subsequent RNA transcripts can be mapped back to the cell it was derived from, and therefore its FACS 
profile, providing an additional layer of information. It should be noted, however, that this additional 






Figure 1.7 - Preparation of RNA for scRNA-seq using the Smart-seq2 protocol. 
a) Schematic of the Smart-seq2 protocol taken from Picelli et al., 2014. Single cells are lysed in a 
solution containing ribonuclease inhibitor and oligo(dT) primers linked to a 5’ anchor sequence, before 
addition of free dNTPs, M-MLV reverse transcriptase (RT) and template switching oligo (TSO) linked to 
another 5’ anchor sequence. During reverse transcription, once at the 5’ end of each RNA template, 
M-MLV RT adds additional 2-5 cytosines to the 3’ end of the cDNA. These are bound by the guanine-
containing TSO, allowing for template switching of the RT onto the TSO, which continues extending 
the newly synthesised cDNA strand, capturing the full 5’ end of the original cDNA template and adding 
the 5’ anchor sequence. ISPCR primers complementary to this anchor sequence are used for cDNA 
amplification, which is subsequently fragmented using a Tn5 transposase, adding new 5’ and 3’ primers 
to the cDNA. These primers are used to add Illumina primers (P5 and P7) for sequencing and index 
sequences (i5 and i7) to allow for transcript mapping back to individual cells post-sequencing. b-c) 
Example Agilent bioanalyzer traces showing cDNA signal intensity (fluorescence units (FU), y axis) 
against sample size (bp, x axis). Individual traces in (b) show cDNA samples from individual sorted 
VSMCs post-PCR clean-up (i-ii), no sample control (iii) and size ladder (iv) and traces in (c) show pooled 





In contrast, the Fluidigm C1 and 10X Chromium systems are largely automated, using microfluidic 
channels to isolate single cells and perform subsequent reactions. Fluidigm C1 captures cells within an 
‘integrated fluidic circuit’ (IFC) chip and uses SMART sequencing technology for cDNA reverse 
transcription and amplification. IFC chips can hold 96 or 800 individual cells, also being optimised to 
capture only those within a specified size range, which limits their functionality (See et al., 2018). The 
10X does not suffer this limitation, using emulsified gel beads (GEMs) in a droplet-based system, which 
can sort tens of thousands of cells at a time (Figure 1.8, Zheng et al., 2017). These GEMs each carry all 
the reagents necessary for cell lysis, cDNA transcription, barcoding and amplification and then perform 
library construction and sequencing all within the 10X Chromium machine. However, this very high-
throughput nature comes at the expense of sensitivity and results in a much lower sequencing depth 
per cell. A recent direct comparison demonstrated detection of 500-1500 genes per cell using the 10X 
Chromium system, compared to 300-7000 with Fluidigm C1 and 4000-7000 using cells isolated by FACS 
and processed using Smart-Seq2 (See et al., 2018). 
 
The differences between each scRNA-seq method means that an understanding of their limitations is 
critical in determining which to use and how to interpret the data obtained. Key considerations include 
the possibility for multiplets to be isolated instead of single cells, the introduction of technical variation 
by RT or amplification bias and dropout events leading to under-representation of lowly expressed 
genes. To reduce amplification bias, the 10X system uses random oligonucleotide tags within the initial 
sequencing primer (unique molecular identifiers or UMIs) to mark each individual molecule during 
reverse transcription. Amplification bias can therefore be removed post-sequencing by counting each 
UMI only once (Grün and van Oudenaarden, 2015). Currently, UMIs are incompatible with full-length 
sequencing methods such as Smart-seq2 (Bacher and Kendziorski, 2016). In order to normalise for 
technical variability in Smart-seq2, additional DNA sequences are incorporated into each cell well 
(‘ERCC spike-ins’ developed by the External RNA Controls Consortium) at an identical concentration, 
therefore variability can be inferred from their relative amplification, normalising between individual 
cells (Lee et al., 2016; Lun et al., 2017). Ultimately, scRNA-seq must be used in parallel to additional 
investigations, in particular to validate that changes in gene expression have functional consequences 
at the protein level (Kolodziejczyk et al., 2015). Moreover, scRNA-seq of isolated cells loses any 
information as to the spatial positioning of a cell within a tissue and may suffer artefacts from 
dissociated gene expression changes (Brink et al., 2017). The former of these issues has been 
circumvented by the development of laser-capture microdissection and spatial transcriptomics 
technology, which is beginning to provide additional insight into cell heterogeneity (Nichterwitz et al., 






Figure 1.8 - Schematic of 10X Chromium workflow for high-throughput scRNA-seq. 
a) Within the 10X Chromium machine, a microfluidic chip is used to combine oil, dissociated single cells 
with all the reagents required for reverse transcription and gel beads functionalised with barcoded 
oligonucleotides. This produces an emulsion droplet known as a GEM. Cells are delivered at a limiting 
dilution, such that each GEM contains either no cells or a single cell, with a multiplet rate of 1.6% 
(Zheng et al., 2017). Each GEM then encapsulates cell lysis and reverse transcription (RT) reactions, 
after which cDNAs, barcoded by the GEM and therefore the cell they originated from, are pooled and 
undergo parallel amplification, library construction and sequencing. b) Inside the microfluidic chip, 
functionalised gel beads are mixed with cells and RT reagents then mixed with an oil-surfactant 
solution at a microfluidic junction to produce single-cell GEMs, which are collected for subsequent 
processing. c) Schematic of barcoded oligonucleotides, which are made up of Illumina adapters for 
sequencing, 14 bp 10X barcodes, 10 bp unique molecular identifiers (UMIs) and oligo(dT) primers 
((T)30VN where V=A/C/G and N=A/G/C/T) for RT priming from poly-adenylated (poly(A)) RNAs. d) 
Schematic of library cDNAs consisting of Illumina adapters and sample indices, which were either 
included on the barcoded oligonucleotides or added during library construction, allowing for their 




1.9  Project Aims & Hypothesis 
Atherosclerosis is a complex condition which contributes significantly to the pathogenesis of CVD. 
VSMCs are a non-reversibly differentiated vascular cell type, with the ability to switch their phenotype 
and reactivate proliferation, subsequently contributing a large proportion of cells to atherosclerosis 
and other vascular diseases in both humans and mice. However, recent lineage tracing of VSMCs in 
animal models of disease has demonstrated that this process is limited to only a few individual VSMCs 
from the wider population, which clonally expand in a notable manner. The process behind this 
selective expansion could arise from prior selection or priming of these reactive cells within the healthy 
population; however, the underlying mechanism remains unclear and current in vitro culture models 
are limited in their ability to model this selective response. Thus, the experiments performed in this 
thesis aim to investigate transcriptional heterogeneity within healthy VSMCs and its relevance to 
disease associated VSMC gene expression patterns. Moreover, these transcriptional patterns will be 
examined for markers of VSMCs which have activated phenotypic switching and an in vitro model will 
be developed to guide further investigations into their influence on VSMC phenotype. 
 
Hypothesis-1: The rare VSMCs which expand clonally in disease will have distinct transcriptional 
signatures from the rest of the VSMC population in the healthy aorta. 
 
Hypothesis-2: Differentially expressed genes/pathways within these rare VSMCs enable them to 
proliferate (preferentially to the rest of the VSMC population). 
 
Aims: 
1. Determine heterogeneity in healthy VSMC single-cell transcriptomes by combining VSMC-
specific lineage tracing and single-cell RNA-sequencing. 
2. Select candidate genes which show a distinct expression profile and validate their 
upregulation during VSMC phenotypic switching. 
3. Profile single-cell transcriptomes of VSMCs following carotid ligation injury using RNA 
sequencing. 
4. Develop a lineage traced in vitro model of VSMC proliferation to replicate clonal expansion 
seen in animal models of disease. 
5. Select candidate genes or pathways enriched in injury associated signatures and test their 





Chapter 2 Materials and methods. 
 
2.1 Animal work 
2.1.1 Animal lines 
Mouse lines used in this work were as follows: 
• Myh11-CreERt2/Rosa26-EYFP animals were used for animal experiments requiring VSMC-
specific single-colour lineage tracing. This mouse line was constructed from Myh11-CreETt2 
(Wirth et al., 2008) and Rosa26-EYFP animals (Srinivas et al., 2001), obtained from The Jackson 
Laboratory. 
• Myh11-CreERt2/Rosa26-Confetti animals were used for animal experiments requiring VSMC-
specific multi-colour lineage tracing, including scRNA-seq of Sca1+ VSMCs from healthy aorta. 
This mouse line was constructed from Myh11-CreERt2 (Wirth et al., 2008) and Rosa26-Confetti, 
also known as Rosa26-Brainbow2.1 (Snippert et al., 2010b) animals, obtained from The 
Jackson Laboratory. 
• Myh11-CreERt2/Rosa26-Confetti/ApoE-/- animals were used in experiments using the HFD 
model of atherosclerosis, including for scRNA-seq of VSMCs following HFD. This mouse line 
was constructed using a cross of Myh11-CreERt2/Rosa26-Confetti (above) and ApoE-/- animals 
(Piedrahita et al., 1992), obtained from the Charles River Laboratories. 
• Myh11-CreERt2/Rosa26-EYFP/Ki67-RFP animals were used for scRNA-seq of VSMCs after CL 
injury. This mouse line was constructed using a cross of Myh11-CreERt2/Rosa26-EYFP (above) 
and Ki67-RFP animals, kindly supplied by the Clevers lab (Basak et al., 2014). 
• Ly6a-GFP reporter animals were used to trace Sca1 expression in aortic cryosections and 
during in vitro culture. This mouse line was kindly supplied by the Dzierzak lab (Ma et al., 2002). 
 
All animals were of the C57BL/6 background and all experiments used male animals, as the Myh11-
CreERt2 transgene is linked to the Y chromosome. Wildtype C57BL/6 mice, originally purchased from 
the Charles River Laboratories, were used for RNA extraction to compare levels of gene expression 
between AA and DT aortic regions and also for explant optimisation experiments which didn’t require 
VSMC-specific lineage tracing. 
 
All animal experiments were approved by the UK Home Office (PPL 70/7565 to 11th June 2018 and then 






2.1.2 Animal labelling for VSMC lineage 
Activation of VSMC-specific lineage labelling in Myh11-CreERt2/Rosa26-EYFP and Myh11-
CreERt2/Rosa26-Confetti animals was performed using tamoxifen in corn oil. For high-density labelling, 
tamoxifen was prepared at 10 mg/ml in corn oil with 10% (v/v) Ethanol, heated to 55°C in a water bath 
to dissolve and aliquoted as 1.5 ml aliquots into individual Eppendorf tubes. Each aliquot was sonicated 
for 20 seconds three times at 60% amplitude (Vibra-Cell sonicator from Sonics & Materials, Inc) and 
cooled on ice between each round of sonication. Aliquots were stored at -20°C and vortexed before 
use for injection. Animals received 10 daily intraperitoneal injections of 1 mg of tamoxifen (100 µl of 
10 mg/ml solution, given for 10 days across a 2-week period). For low-density labelling, tamoxifen was 
prepared at 20% of the high-density concentration (2 mg/ml) and injected at the same volume and 
frequency. All experiments used animals labelled between 6-8 weeks of age, except for the time course 
analysis in Chapter 3.5, where animals were labelled between 9-55 weeks of age. 
2.1.3 Animal models of vascular disease 
Carotid ligation surgeries were performed by Dr Kirsty Foote, Dr Joel Chappell and Allie Finigan, on 
animals labelled for VSMC-lineage with tamoxifen at 6-8 weeks of age and given at least a 1-week 
washout period. Briefly, animals were anaesthetised using inhalation of 2.5-3% isoflurane and given 
~0.1 mg/kg pre-operative buprenorphine analgesic subcutaneously (Temgesic). The LCA was ligated 
below its bifurcation by tying it using a silk suture. Post-surgery animals were placed in a 30°C incubator 
to recover for a few hours and then fed a mashed chow diet and monitored twice daily until sacrifice. 
Monitoring including weighing the animals and assessing their surgery-site and general behaviour; any 
animals who approached a 15% loss of bodyweight from their starting value were culled for welfare. 
Animals of the same age were used for no surgery controls, taken from the same litter wherever 
possible. 
 
For the high fat diet model, animals labelled for VSMC-lineage with tamoxifen at 6-8 weeks of age were 
given a 1-week washout period. From 9 weeks of age they were fed a high fat diet containing 21% fat 





2.2 Tissue processing and cell culture 
2.2.1 Animal and tissue dissection 
For tissue extraction, mice were culled using CO2 asphyxiation before harvesting of blood vessels or 
control tissues in 1X Phosphate-buffered saline (PBS). For isolation of the carotid arteries following 
ligation surgery, the vasculature was perfused with 10 ml 1X PBS prior to tissue harvesting, to enable 
clearing of blood from the carotid arteries. To isolate the aorta, surrounding connective tissue and fat 
were removed using dissection spring scissors and forceps under an inverted light microscope in 1X 
PBS. If the AA, DT or carotid arteries were needed, they were dissected free from the rest of the aorta, 
discarding any intervening tissue.  
2.2.2 Preparation of tissue cryosections 
For cryosectioning, tissue was fixed in 4% (w/v) paraformaldehyde (Sigma-Aldrich) in 1X PBS for 20 
minutes at room temperature, washed in 1X PBS for 10 minutes and incubated in cryoprotectant 
solution (30% (w/v) sucrose in 1X PBS) at 4°C overnight. After overnight cryoprotection, tissues were 
incubated in a 50:50 mixture of cryoprotectant solution and O.C.T compound (Tissue-Tek, VWR) for 1 
hour at room temperature, then transferred to 100% O.C.T compound for 1 hour until freezing. All 
steps were performed on a tube roller to ensure even perfusion of the tissue. For freezing, the tissues 
were placed into 100% O.C.T in a plastic mould and frozen by placing onto dry ice at room temperature, 
being transferred to -80°C for storage once the O.C.T had solidified within the tissue. Cryosectioning 
was performed using a cryomicrotome, cutting serial sections of 12 µm thickness onto Superfrost Plus 
microscope slides (Thermo Scientific), and slides were stored at -80°C. 
2.2.3 Tissue processing for primary cell isolation 
For aortic VSMC isolation, the aorta was cut open longitudinally following tissue dissection and 
endothelial cells removed using a sterile cotton bud. Aorta were then incubated in 1 mg/ml collagenase 
IV (Gibco) and 1 U/ml elastase (Worthington Biochemical) dissolved in Dulbecco’s Modified Eagle 
Medium (DMEM, Sigma-Aldrich) in a 12-well plate for 8-10 mins at 37°C with 5% CO2. This pre-digest 
allowed for manual removal of the adventitial cell layer using forceps. Aortic media were digested in 
2.5 mg/ml collagenase IV and 2.5 U/ml elastase in DMEM at 37°C with 5% CO2 with disruption using 
pipetting with a P1000 pipette every 20 minutes until a single cell solution was achieved (~2 hours). 
Single VSMCs were collected from the 12-well plates, rinsing each well with 1X PBS to enable cell 
collection, and washed twice in DMEM using centrifugation at 1200 rpm for 3 minutes to collect the 




For experiments requiring primary adventitial cells, the adventitial layer removed following the pre-
digest step was retained and digested to a single cell solution in the same manner as the VSMCs (or 
not removed and the whole tissue digested together for a whole aorta sample). For experiments 
requiring primary endothelial cells, the aorta was not cut longitudinally before pre-digestion to ensure 
endothelial cell retention and a mixture of single endothelial and VSMCs obtained following digestion 
for subsequent separation by immunostaining and FACS. Cells from the spleen, liver and leukocytes 
were also used for immunostaining controls. Cells harvested from the spleen and liver were obtained 
by manual disruption of the tissue and passing through a 40 µm cell strainer in 1X PBS, before washing 
in DMEM and centrifugal collection in the same manner as isolated VSMCs. Leukocytes were isolated 
from the whole blood by incubation in 55 mM NH4Cl, 10 mM KHCO3 and 0.1 mM EDTA (pH 7.3) for 10 
minutes for red blood cell lysis, before cell washing in DMEM and centrifugal collection in the same 
manner as isolated VSMCs.  
2.2.4 Cell culture 
To determine Sca1 expression in culture, primary VSMCs and adventitial cells from Sca1-GFP animals 
were isolated by FACS and cultured in DMEM supplemented with 10% (v/v) Fetal bovine serum (FBS), 
100 U/ml penicillin, 100 mg/ml streptomycin and 2 mM glutamine. Cells were observed daily, and 
media changed every 3 days, before fixation and immunostaining after 11 days of culture (see section 
2.3.1). 
 
To compare the influence of VSMC Sca1 expression on endothelial characteristics, primary VSMCs were 
isolated from Myh11-CreERt2/Rosa26-EYFP animals by FACs in parallel to a commercial mouse EC line, 
used at passage 3 (C57BL/6 mouse primary aortic ECs, Cell Biologics). Prior to use, commercially 
sourced ECs were cultured on gelatin-coated culture flasks in complete mouse EC media (Cell 
Biologics), with the media changed every 2 days and split 1:2 at ~90% confluence as follows: cells 
washed in 1X PBS then incubated for 5 minutes in Trypsin-EDTA (Sigma Aldrich) before collection in 1X 
PBS and centrifugation for 5 minutes at 120 g. Lineage-labelled (EYFP+) VSMCs and control ECs 
negative for Zombie viability dye were sorted into individual well of an 18-well µ-chamber slide (Ibidi, 
see section 2.4.1 for Zombie staining) and cultured in EC conditions (on a gelatin-coated well in 
complete mouse EC media) for 7 days before fixation, immunostaining for CD31 and mounting for 
imaging (see section 2.3.1). In parallel, VSMCs and commercial ECs also sorted into 18-well µ-chamber 
slides were assessed for uptake for acetylated LDL (Ac-LDL), a characteristic of endothelial cells and 
macrophages (Voyta et al., 1984). Sorted cells were serum starved overnight in EC media and incubated 
with 20 µg/ml DiI-conjugated Ac-LDL overnight. Cells were then rinsed 3x with 1X PBS, before fixation 




2.3 Immunostaining and imaging 
2.3.1 Antibody immunostaining of mouse cryosections and cultured cells 
For immunostaining of mouse cryosections, tissue cryosections stored at -80°C storage were thawed 
at room temperature for 30 mins. Sections were then rinsed in 1X PBS and permeabilised for 20 
minutes in 0.5% (v/v) Triton X-100 (Sigma Aldrich) in 1X PBS, before 2x 5-minute washes in 1X PBS, all 
at room temperature. Sections were then blocked for 1 hour at room temperature in blocking buffer 
containing 1% (w/v) bovine serum albumin (BSA) and 10% (v/v) of the serum in which the secondary 
antibody was raised (normal goat serum (Dako), or normal donkey serum (Abcam)) in 1X PBS. Staining 
with primary antibodies or isotype controls, diluted in blocking buffer, was performed overnight at 
4°C, before 3x 5-minute washes in 1X PBS and incubation with secondary antibodies in blocking buffer, 
if required, for 1 hr at room temperature. Sections were again washed for 3x 5 minutes in 1X PBS and 
nuclei stained with 1 µg/mL DAPI in 1X PBS for 10 minutes at room temperature, before rinsing in 1X 
PBS and mounting in RapiClear 1.52 mounting media (Sunjinlab) using a glass coverslip. 
 
To stain cells cultured in chamber slides, cell culture media was removed and cells washed in 1X PBS 
before fixation in 4% (w/v) paraformaldehyde for 10 minutes at room temperature. Cells were then 
washed, permeabilised and stained in the same manner as cryosections above, except that the wells 
were removed from the coverslide after the final wash step and ProLong Diamond antifade media 
(Thermo Fisher) used for mounting with a glass coverslip. Mounted sections or cells were stored at 
4°C until imaging, for antibodies and concentrations used, see appendix 1. All immunostainings used 
secondary antibody only and isotype staining controls. 
2.3.2 Human paraffin section immunostaining 
Immunostaining of human aortic paraffin sections were performed by Nikki Figg. Antibodies used are 
listed in appendix 1. For antigen retrieval, sections were dewaxed in Xylene, rinsed in water and placed 
into a Citrate-based Antigen Retrieval Solution (pH6, Vector Labs), heated in the Aptum 2100 Retriever 
Pressure Cooker for 30 minutes and then cooled to room temperature.  
 
For single stains, a Horseradish peroxidase (HRP)/DAB detection immunohistochemistry kit (Abcam) 
was used as follows (all reagents in capitals supplied by Abcam): sections were incubated with 
Hydrogen Peroxide Block for 10 minutes at room temperature then washed 2x in 1X PBS and blocked 
in Protein Block for 5 minutes at room temperature, before another 1X PBS wash. Staining with primary 
or isotype control antibody in Antibody Diluent was performed overnight at 4°C before 4x washes in 
1X PBS, incubation with Secondary Antibody for 10 minutes at room temperature and another 4x 
washes in 1X PBS. Secondary antibody was visualised by incubation in Streptavidin Peroxidase for 10 
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minutes at room temperature, before 4x washes in 1X PBS and incubation in a 1:5 mixture of DAB 
Chromogen and DAB Substrate for 10 minutes at room temperature. Finally, sections were washed 
again x4 in 1X PBS and incubated in Haematoxylin for 1 minute, before 7x rinses in water and mounting 
in Mounting Medium. 
 
For co-staining with aSMA, antigen retrieval was performed as for single stains and sections were then 
blocked for 10 minutes in Peroxidase Blocking Solution (Abcam), before 3x 5-minute washes in 1X PBS 
and blocking in antibody diluent (SignalStain) for 10 minutes. Staining with candidate primary or 
isotype control antibody was performed in antibody diluent overnight at 4°C, followed by 3x washes 
in 1X PBS and secondary HRP-conjugated antibody incubation in antibody diluent for 30 minutes at 
room temperature. Sections were then washed 3x with 1X PBS and HRP visualised using DAB 
peroxidase substrate (SignalStain). After washing in water, staining with aSMA primary antibody was 
performed in Superblock diluent (Thermo Fisher) for 1 hour at room temperature, followed by 3x 
washes in 1X PBS and incubation in a biotin-coupled secondary antibody in Superblock diluent for 30 
minutes at room temperature. Sections were then washed 3x with 1X PBS and secondary antibody 
visualised using incubation in a Vectastain avidin-coupled alkaline phosphatase (AP) reagent for 30 
minutes, before a 1X PBS wash and incubation with a Blue AP substrate solution for 20 minutes, both 
at room temperature (both Vector Labs). Finally, sections were washed once in 1X PBS and mounted 
in VectaMount mounting media (Vector Labs). 
2.3.3 Imaging and analysis 
Epifluorescence imaging of cultured cells and explants was performed on an Olympus IX71 microscope 
with a 10x or 20x objective within a single z plane. This microscope was used to capture images of 
outgrowing cells from explants of different sizes, from which individual outgrowing VSMCs were 
counted manually using fluorescence from the Confetti lineage proteins. Outgrowing ECs, imaged 
using the light microscope, were too numerous to count individually, instead each edge of the explant 
was given a score of 0 (no outgrowing ECs), 1 (<5 individual outgrowing ECs), 2 (>5 outgrowing cells 
but whole edge not covered) or 3 (whole explant edge filled with outgrowing cells), for a maximum 
total score of 12. This microscope was also used to analyse the efficiency of lentiviral transduction with 
different transduction adjuvants, using FIJI software to automatically count individual GFP+ cells in 
each image, with blinding to each condition. A Zeiss 700 confocal microscope and 20x objective was 
used to image Sca1-GFP+ cells following cell culture and FIJI software again used to automatically count 
GFP+ cells in maximum projections created from images containing z-stacks of 1 µm slices, again with 
blinding as to the identity of each. Immunostained human cryosections were imaged on an Olympus 




Imaging of immunostained cryosections and whole explants was performed using a Leica SP8 confocal 
microscope, using a 20x, 40x or 63x objective, a white light laser and z-stacks of 1 µm (cryosections) or 
5 µm (explants) slices. The microscope settings were optimised to run sequential laser scans for 
maximal sensitivity without DAPI spectral overlap (Chappell et al., 2016) and used image tiling to stitch 
multiple images over a larger region. For analysis of aSMA expression in sorted Sca1-GFP VSMCs and 
adventitial cells, FIJI software was used to determine staining intensities in each cell from maximum 
projections of each image taken. FIJI software was also used to automatically count the number of 
GFP+ VSMCs in whole-mount explants transduced with lentivirus carrying GFP expression and pCAG-
Eco or pMD2.G envelope proteins across individual 5 µm z-slices. Imaris software was used to analyse 
other explant images, including using the spot-counting function to analyse the number of EdU+, GFP+ 
or DAPI+ nuclei in explant whole-mount images. For Confetti patch analysis, the surface rendering 
function of Imaris software was used to model the surface of individual patches, using the default 
setting for surface area detail level and enabling background subtraction (see Figure 5.13 for a 
comparison of this Imaris model to original explant images). The produced surfaces were then used to 





2.4 Flow cytometry and FACS 
2.4.1 Immunostaining for flow cytometry and FACS 
For cell immunostaining for flow cytometry, single cell suspensions (see section 2.2.3 for tissue 
processing), were washed twice in FACS buffer (0.5% (w/v) BSA in 1X PBS) and centrifuged at 1200 rpm 
for 3 minutes to pellet cells. Cells were then resuspended in TruStain FcX anti-mouse CD16/32 antibody 
(Biolegend), diluted 1:100 in FACS buffer and incubated for 10 minutes on ice to block antibody binding 
by the Fc receptor. Cells were then split into tubes as required and stained in primary or isotype control 
antibody for 15 minutes at 4°C, before washing twice in FACS buffer. Where secondary antibodies were 
used, cells were next incubated with secondary antibody in FACS buffer for 15 minutes at room 
temperature and washed twice in FACS buffer. Finally, cells resuspended in 250 µl FACS buffer, filtered 
through a 40 µm strainer and then kept on ice until analysis and/or sorting. See appendix 1 for 
antibodies and concentrations used. 
 
Where Zombie cell viability dye was used, cells were pre-stained with this dye before any antibody 
staining, as the dye is sensitive to BSA used in the FACS buffer. Therefore, cells were washed twice with 
DMEM and then once with 1X PBS after digestion and then incubated with Zombie-NIR, (Biolegend, 
diluted 1:100 in 1X PBS) for 30 minutes at room temperature. Cells were then washed once in FACS 
buffer and immunostaining continued as above. 
2.4.2 Poly(L)-lysine coating for cell collection 
For improved capture of cells isolated for immunostaining by FACS, chamber slides were coated in 
poly-l-lysine solution as follows: surfaces were washed with 70% (v/v) ethanol for 15 minutes at room 
temperature with shaking and then rinsed with distilled water and left to dry. Surfaces were then 
incubated in 0.02% (w/v) poly-l-lysine (Thermo Fisher) for 30 minutes at room temperature, before 
rinsing with distilled water and being left to dry overnight. If required, drying steps were accelerated 
using incubation at 37°C. Cells were then sorted directly onto the poly-l-lysine coated chamber slides 
before fixation and immunostaining. 
 
2.4.3 FACS and flow cytometry analysis 
Immunostained cells were analysed using a Fortessa or Accuri C6 flow cytometry analyser or index-
sorted on an Aria-fusion flow cytometry assisted cell sorter (all BD Bioscience) into 96-well plates, 
chamber slides or FACS tubes with assistance from the NIHR Cambridge BRC Cell Phenotyping Hub. 
Positive and negative controls were used to set the sorting gates (see section 2.6.2 for further details) 
and a multi-part gating strategy was used to isolate VSMCs positive for only a single Confetti colour 
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(see Figure 3.2). Isolation of singly coloured cells was verified by sorting Myh11-CreERt2/Rosa26-
Confetti cells directly into a poly-L-Lysine coated chamber slide followed by cell fixation, DAPI staining 
and analysis by confocal microscopy. FlowJo software was used to analyse the raw data and determine 





2.5 RNA extraction and RT-qPCR 
 
RNA was extracted from aortic tissue or cultured VSMCs by lysis in TRIzol reagent (Thermo Fisher) then 
chloroform extraction and isopropanol precipitation, using 20 ng of glycogen per sample to improve 
RNA recovery. RNA pellets were washed twice in 70% (v/v) ethanol and resuspended in dH2O before 
quantification using a Nanodrop (Thermo Fisher). To generate cDNA, reverse transcription of 1 µg RNA 
was done using the Quantitect® RT kit (Qiagen). Briefly, genomic DNA was removed using gDNA 
elimination buffer and incubation at 42 °C for 2 minutes, before reverse transcription at 42 °C for 15 
minutes and enzyme inactivation at 95 °C for 3 minutes. Resulting cDNA was diluted 1:5 in dH2O for 
SYBR® Green qPCR analysis on a Rotor-Gene cycler (Qiagen); 10 µl reactions contained 2 µL of diluted 
cDNA (or dH2O no template control), 5 µL SYBR® Green 2X master mix (Thermo Fisher) and 1 µM of 
each primer (Sigma Aldrich, primers were designed to span exon-exon junctions of splice mRNA, for 
sequences used see appendix 2). Samples were analysed in duplicate, alongside serially diluted ex vivo 
whole aorta cDNA as a standard, using the following thermocycling conditions: 5 minutes at 95°C then 
40 cycles of 5 seconds at 95°C and 10 seconds at 60 °C (SYBR green fluorescence measured at 497 nm 
at 60 °C), with subsequent dissociation melts from 60-94°C in 1°C steps to evaluate product number. 
Quantification used the standard curve method and target expression was normalised to the weighted 









2.6 Preparation of RNA sequencing data 
2.6.1 Preliminary RNA sequencing performed prior to thesis work 
Initial conventional RNA-seq and scRNA-seq of non-lineage traced VSMCs from the AA and DT were 
performed by Dr Helle Jørgensen and Dr Mikhail Spivakov. To extract RNA for conventional RNA-seq 
analysis, dissected aortas were immediately transferred to RNAlater followed by isolation of AA and 
DT segments before manual removal of the adventitial and endothelial cell layers. The cleaned medial 
layer from 3 to 5 animals was then lysed in Trizol (Thermo-Fisher) and RNA isolated as in section 2.5. 
The extracted RNA was cleaned on a RNeasy column (Qiagen) and quality assessed on a Bioanalyzer 
(Agilent). Sequencing libraries were made from 550 ng total RNA using the TruSeq Stranded mRNA 
Library Prep kit (Illumina) and sequenced using HiSeq (Illumina). For single cell sequencing, single cell 
suspensions of medial AA and DT regions were generated from wild type C57BL/6 males as in section 
2.2.3 (5-7 animals per experiment) and processed using a Fluidigm C1 system (Fluidigm). Cell 
suspensions (100 cells/μl) were loaded onto medium-sized (17–25 μm) Auto Prep Arrays (Fluidigm) 
and processed according to the manufacturer’s instructions. The loaded arrays were visually assessed 
under an inverted microscope to select capture sites containing a single cell, yielding a 40–70% capture 
efficiency. Cells included in the analysis were from two independent experiments for each aortic 
region. Cells were processed using the SMARTer® Ultra™ Low RNA kit (Clontech) and amplified cDNA 
was isolated from the arrays. Sequencing libraries were prepared from amplified cDNA using the 
Nextera library prep kit (Illumina, see library preparation in section 2.6.2 for more information) and 
analysed by paired-end sequencing on a HiSeq 2500 system (Illumina). 
2.6.2 Single cell RNA sequencing of lineage traced VSMCs using the SmartSeq2 protocol 
For the analysis of the Sca1+ medial population, single cell suspensions of the medial layer from 
Myh11-CreERt2/Rosa26-Confetti lineage-labelled animals were prepared and stained with 
Allophycocyanin (APC)-coupled anti-Sca1 antibody or IgG control, as described in section 2.4.1 (n=4, 
n=5 and n=11 animals in 3 experiments). Individual Sca1+ and control Sca1 negative cells expressing a 
single Confetti-lineage label (S+L+ or S-L+) or Sca1+ cells expressing no Confetti marker (S+L-) were 
sorted by FACS using an Aria-Fusion flow cytometer (BD Bioscience) into separate wells of a 96-well 
plate, containing 2.3 µl recombinant ribonuclease inhibitor at 40 U/µl (RRI, Clontech). The Confetti 
gates used were set using aortic VSMCs from Myh11-CreERt2/Rosa26-Confetti lineage-labelled 
(Confetti+) and wild-type C57BL/6 (Confetti-) animals and the APC gates were set using anti-Sca1 
stained adventitial cells (anti-Sca1+) or anti-IgG stained VSMCs from the carotid sample (anti-IgG-). 
 
For the analysis of post-CL VSMCs, single cell suspensions of the medial layer from ligated or non-
ligated LCAs of Myh11-CreERt2/Rosa26-EYFP/Ki67-RFP lineage-labelled animals were prepared, as 
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described in section 2.4.1 (n=5 and n=4 ligated, n=2 and n=1 non-ligated in 2 separate experiments). 
Individual YFP+RFP+ cells from ligated animals and YFP+RFP- cells from both ligated and non-ligated 
animals were sorted by FACS using an Aria-Fusion flow cytometer into separate wells of a 96-well plate, 
again containing 2.3 µl recombinant ribonuclease inhibitor at 40 U/µl (RRI, Clontech). The EYFP gates 
used were set using aortic VSMCs from Myh11-CreERt2/Rosa26-EYFP lineage-labelled (EYFP+) and 
wild-type C57BL/6 (EYFP-) animals and the RFP+ gates were set using spleen cells from Myh11-
CreERt2/Rosa26-EYFP/Ki67-RFP (RFP+) or wild-type C57BL/6 (RFP-) animals.  
 
After FACS, sample plates were centrifuged at 1000 rpm for 1 minute at 4°C and stored at -80°C 
overnight. Samples were then processed using the Smart-seq2 protocol described by Piscelli et al., 
2014, with minor modifications. The protocol steps used were as follows: 
 
Reverse transcription 
After thawing sample plates, 2 µl of annealing mixture (0.1 µl ERCCs (previously diluted 1:80,000,000, 
Invitrogen), 0.1 µl Oligo-dT30VN (100 µM, Biomers.net 5’-AAGCAGTGGTATCAACGCAGAGTAC(T30)VN-
3’), 1 µl dNTPs (10 mM, Life Technologies) and 0.8 µl dH2O) was added to each well, before centrifuging 
at 1000 rpm for 1 minute at 4°C. Next, samples were incubated at 72°C for 3 minutes and placed on 
ice, before addition of 5.7 µl of RT mixture (0.5 µl Primescript RT (200 U/ µl, Clontech), 0.125 µl RRI, 2 
µl 5X Primescript RT buffer (Clontech), 0.5 µl 1,4-Dithiothreitol (DDT, 100 µM, Sigma Aldrich), 2 µl 
Betaine (5 M, Sigma Aldrich), 0.06 µl MgCl2 (1 M, Invitrogen), 0.1 µl Template switching oligo (TSO, 100 
µM, Exiquon, 5’-AAGCAGTGGTATCAACGCAGAGTACATrGrG+G-3’) and 0.415 µl dH2O). Samples were 
then centrifuged as before and incubated in a SimpliAmp Thermal Cycler (Life Technologies) using the 
following conditions: 90 minutes at 42°C, 10 cycles of 2 minutes at 50°C and 2 minutes at 42°C then 15 
minutes at 70°C. Samples were held at 4°C before centrifuging as before. 
 
cDNA amplification 
After RT, 15 µl of PCR mixture was added to each well (12.5 µl KAPA Hifi Hotstart Readymix (Kapa 
Biosystems), 0.25 µl ISPCR primer (10 µM, Biomers.net, 5’-AAGCAGTGGTATCAACGCAGAGT-3’) and 
2.25 µl dH2O) and plates centrifuged as before. Samples were then incubated in the SimpliAmp 
Thermal Cycler using the following conditions: 3 minutes at 98°C, 24 cycles of 20 seconds at 98°C, 15 
seconds at 67°C and 6 minutes at 72°C then 1 minute at 72°C. Samples were held at 4°C before 
centrifuging as before. 
 
Bead-based cDNA clean-up 
Next, cDNA was isolated using Ampure XP beads (Agencourt) as follows: beads were equilibrated at 
room temperature for 15 minutes and vortexed, before adding 25 µl to each well. Plates were vortexed 
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slowly and incubated at room temperature for 8 minutes before being placed onto a magnetic stand 
(Thermo Fisher) for 5 minutes. The supernatant was removed from each well and beads then washed 
for 2x 30 seconds with 200 µl 80% (v/v) ethanol whilst still on the magnetic stand. Plates were then 
centrifuged as before and any remaining ethanol removed, before air drying for 5 minutes and addition 
of 20 µl elution buffer (Qiagen), mixed by vortexting. The plate was then placed onto the magnetic 
stand for 2 minutes and 15 µl of supernatant (containing eluted cDNA) collected into a new 96 well 
plate. 
 
Quality control and quantification of cDNA 
Next, 9 samples from each cDNA plate were assessed for quality using the Agilent Bioanalyzer chip-
based electrophoresis system and a High Sensitivity DNA Chip (both Agilent Technologies), according 
to the manufacturer’s instructions. Example traces from the Bioanalyzer are shown in Figure 1.7b, 
demonstrating the presence of cDNA without contaminating peaks. All cDNA was then quantified using 
the Quant-IT PicoGreen kit (Thermo Fisher) as follows: 49 µl of 1X TE buffer (Sigma Aldrich) and 50 µl 
of PicoGreen (diluted 1:200 in TE buffer) were added to each well of a U-bottom well plate 
(PerkinElmer), along with 1 µl of sample cDNA, Lambda DNA control (25 ng, 10 ng, 2ng, 0.4 ng, 0.08 ng 
or 0.016 ng per well) or dH2O control. The plate was then centrifuged as before and incubated for 5 
minutes at room temperature in the dark before the Picogreen fluorescence (representative of cDNA 
concentration) was read on a Synergy HT plate reader (BioTek Instruments). After quantification of 
cDNA concentration, using the Lambda DNA standard curve, each sample was diluted to ~5 ng/µl with 
dH2O. 
 
Library preparation and clean-up 
After quantification, libraries were prepared from the cDNA samples using the Nextera XT library prep 
kit (Illumina), as follows: Tagmentation buffer and Amplicon tagment mixture were mixed in a ratio of 
2:1 and 3.75 µl added to each well of a new well plate, before addition of 1.25 µl of sample cDNA 
(~6.25 ng) and centrifugation at 2000 rpm for 1 minute at room temperature. Samples were then 
incubated at 55°C for 5 minutes in a SimpliAmp Thermal Cycler, before addition of 1.25 µl NT buffer, 
3.75 µl Nextera PCR mix, 1.25 µl index primer 1 and 1.25 µl index primer 2. Index primers were added 
to each well in different combinations to enable cell identification post-sequencing. The plates were 
then centrifuged as before and incubated in the SimpliAmp Thermal Cycler using the following 
conditions: 3 minutes at 72°C, 30 seconds at 95°C then 12 cycles of 10 seconds at 95°C, 30 seconds at 
55°C and 60 seconds at 72°C then 5 minutes at 72°C. Next, libraries were cleaned using Ampure XP 
beads, as follows:  
Beads were equilibrated at room temperature for 15 minutes and vortexed, before adding 1 µl of each 
sample cDNA to a single Eppendorf tube, to create a single cDNA library, along with 87 µl of beads 
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(volume for 96 samples, adjusted according to number of samples in each library). This tube was 
vortexed slowly and incubated at room temperature for 5 minutes before being held onto the 
magnetic stand for 2 minutes. The supernatant was removed from the library tube and beads washed 
for 2x 30 seconds with 180 µl 80% (v/v) ethanol whilst still held onto the magnetic stand. The tube was 
then centrifuged briefly, and any remaining ethanol removed, before air drying for 5 minutes and the 
addition of 43.5 µl elution buffer, mixed by vortexing. The library tube was next incubated at room 
temperature for 2 minutes and then held onto the magnet for 2 minutes, before transfer of the 
supernatant to a new tube and storage at -20°C. 
 
Quality control and library quantification 
The cleaned library sample was assessed for quality using the Agilent Bioanalyzer chip-based 
electrophoresis system and a High Sensitivity DNA Chip as above (example traces shown in Figure 1.7c). 
The library was then quantified using the KAPA library quantification kit (Kapa Biosystems), using 8 µl 
of Kapa Sybr Fast qPCR master mix and 2 µl of library sample (diluted 1:1000 and 1:100,000) or 
standard control (20 pM, 2 pM, 0.2 pM, 0.02 pM, 0.002 pM or 0.0002 pM), analysed in triplicate. These 
samples were incubated in a Rotor-Gene cycler with the following conditions: 5 minutes at 95°C, 35 
cycles of 30 seconds at 95°C and 45 seconds at 60°C then 5 minutes at 60°C, before quantification of 
the library compared to the standard curve. Plates were stored at -20°C before sequencing by paired-
end sequencing on a HiSeq 2500 system (Illumina). 
2.6.3 Single cell RNA sequencing of lineage traced VSMCs using the 10X Chromium system 
For the analysis of healthy aortic cell populations, a single suspension was produced from the whole 
aorta of Myh11-CreERt2/Rosa26-Confetti animals (n=3), as in section 2.2.3, and stained with Zombie-
NIR viability dye, as in section 2.4.1. Individual Zombie- cells were sorted into a single Eppendorf tube 
using an Aria-Fusion flow cytometer, containing 1 ml 0.1% (w/v) BSA and 5 µl RRI. The Zombie gate 
was set using a small sample of unstained whole aorta cells (Zombie-) and wild-type C57/BL6 cells 
stained with Zombie-NIR (Zombie+). 
 
For the analysis of VSMCs following CL injury, samples were prepared and gates set as for the 
SmartSeq2 post-CL experiment in section 2.6.2, but without any non-ligated control cells (n=5 ligated 
animals). To enrich the sample for Ki67+, proliferating VSMCs, a total of 20,000 EYFP+ VSMCs were 
first sorted regardless of RFP expression and then EYFP+RFP+ VSMCs sorted from the remainder of the 
sample. VSMCs were sorted into an Eppendorf tube as above. 
 
Collection of cells for scRNA-seq analysis of VSMCs from atherosclerotic animals was performed by Dr 
Helle Jørgensen and Dr Lina Dobnikar, who manually isolated plaques by dissection from Myh11-
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CreERt2/Rosa26-Confetti/ApoE-/- lineage-labelled animals which had been fed a HFD for 14 or 18 weeks 
(n=2 and n=3). Cells were sorted for expression of a single Confetti-lineage label, gated using a wild-
type C57BL/6 negative control, into an Eppendorf tube as above. 
 
Sorted cells were pelleted by centrifugation at 1000 rpm for 3 minutes at 4°C, supernatant removed 
and cells resuspended in 35 µl PBS per 20,000 cells with 0.05% (w/v) BSA and loaded onto a 10X 





2.7 Analysis of RNA sequencing data 
2.7.1 Preliminary RNA sequencing analysis performed prior to thesis work 
Conventional or bulk RNA-seq and Fluidigm C1 scRNA-seq of non-lineage traced VSMCs from the AA 
and DT were performed by Dr Helle Jørgensen, Dr Mikhail Spivakov and Dr Lina Dobnikar. Briefly, 
Tophat (Trapnell et al., 2009) was used to align reads to the GRCm38 mouse genome and reads per 
gene were counted using Seqmonk (bulk) or htseq-count (Anders et al., 2015) (Fluidigm C1). For bulk 
RNA-seq data, Bioconductor R package DESeq2 (Love et al., 2014) was used to perform differential 
gene expression analysis, classifying differential expression as genes with log2 fold-change >1 and fdr-
adjusted p-value <0.01. For Fluidigm C1 data, quality control (QC) was performed on single-cell 
transcriptomes, removing cells with <1 million or >3.5 million read pairs, <5,000 or >9,500 genes 
detected, <80% of reads mapping to genes, <50% of reads mapping to exons and >20% mitochondrial 
reads. Read counts from cells which passed QC were normalised using the computeSumFactors 
function from the Bioconductor R package scran (Lun et al., 2016). 
2.7.2 Processing of SmartSeq2 data and highly variable gene analysis. 
SmartSeq2 data analysis in this section was performed by Dr Lina Dobnikar. QC and normalisation of 
SmartSeq2 data was performed as in section 2.7.1, including cells with >200,000 total reads, >1,000 
genes detected and <30% of ERCC controls and removing genes with mean expression <1. For the 
analysis of variable genes in AA and DT or S+L+ VSMCs sequenced by SmartSeq2, variance 
decomposition was used to separate log-transformed and normalised expression counts into technical 
variance, estimated using ERCC spike-in controls, and biological variance, using the trendVar and 
decomposeVar functions in the Bioconductor R package scran (Lun et al., 2016). Highly variable genes 
(HVGs) were defined as those with biological variance significantly >0 and the analysis was repeated 
1,000 times using 90% of the profiled cells, taking genes with a p value <0.05 to be truly highly variable.  
Functional annotation of the 147 HVGs identified in AA and DT VSMCs was performed by Annabel 
Taylor and based on NCBI PubMed citations listed under the entry for the Mus musculus reference 
sequence for each HVG in the NCBI Gene database (https://www.ncbi.nlm.nih.gov). The identified 
citations were manually examined for experimental evidence of direct regulation of VSMC function, 
cell proliferation, cell migration, inflammation, stem cell properties and/or development of 
cardiovascular disease. For co-expression analysis of HVGs in S+L+ VSMCs, weighted correlation 
network analysis was implemented using the R package WGCNA (Langfelder and Horvath, 2012, 2008), 
creating a network where nodes are genes and edges are defined by similarity in expression patterns, 
identifying a module of co-expressed contractile genes termed the ‘cVSMC network’. Expression of this 
network was defined as a ‘cVSMC score’, produced using assignment of positive and negative signs to 
each principal component to positively correlate with the mean expression values of the respective 
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gene sets across cells. Genes which significantly correlated with cVSMCscore (p<0.05) were termed 
‘cVSMCpos’ (positively correlated) and ‘cVSMCneg’ (negatively correlated). For integration of post-CL 
scRNA-seq data produced by SmartSeq2 and 10X Chromium see section 2.7.3. 
2.7.3 Processing of 10X Chromium scRNA-seq data and analysis of single cell expression patterns 
The 10X Genomics cellranger pipeline was used to align raw sequencing reads to the GRCm38 mouse 
genome and count those aligned with each gene. Subsequent QC, normalisation and gene expression 
analysis was performed using the CRAN R package Seurat (Butler et al., 2018; Stuart et al., 2019). QC 
parameters differed by dataset as follows:  
- HFD VSMCs, removal of cells with <5,000 or >20,000 UMI counts, <1,000 or >5,000 genes 
detected and >9% mitochondrial reads. 
- Whole aorta or healthy Confetti+ VSMCs, cells removed which had <1,000 or >8,000 UMI 
counts, <500 or >2,500 genes detected and >8% mitochondrial reads. 
- Post-CL VSMCs, cells removed which had <5,000 UMI counts, <2,000 genes detected and >5% 
mitochondrial reads. 
Human atherosclerotic VSMC scRNA-seq data from Wirka et al., 2019 was downloaded from the Gene 
Expression Omnibus (GEO) repository (accession number GSE131778) and QC performed using the 
parameters listed in the paper (cells removed which had <500 or >3,500 genes detected and >7.5% 
mitochondrial reads). Read counts from cells which passed QC were normalised using the 
NormalizeData (scale.factor = 10,000) and ScaleData functions before linear dimensional reduction by 
principle component analysis (PCA) using the 2,000 most variable genes and cell clustering based on 
their expression of 5 principle components (FindVariableFeatures, RunPCA, FindNeighbours and 
FindClusters functions). Cell clustering and gene expression was visualised using non-linear 
dimensional reduction by t-distributed Stochastic Neighbour Embedding (t-SNE, RunTSNE function). 
Datasets were integrated by creation of a reference assembly and transfer learning as described by 
Stuart et al., 2019. In this method, canonical correlation analysis (CCA) is used on a merge of two or 
more datasets to find linear correlations in expression between them. These correlation vectors are 
then normalised and cell pairs which are mutual nearest neighbours identified in this shared space, 
termed ‘anchors’ (FindIntegrationAnchors function). Anchors are scored based on the overlap in 
mutual neighbourhoods of each cell in the pair. These anchors are then used as a reference to 
transform the whole dataset into an integrated space, using correction vectors from each pair, 
weighted by their score (IntegrateData function). 
2.7.4 Trajectory analysis and candidate filtering 
Trajectory analysis was performed on the post-CL VSMC scRNA-seq data from 10X Chromium using the 
Bioconductor R package Monocle version 2.8.0 (Trapnell et al., 2014). Cells were first filtered using the 
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QC parameters listed in section 2.7.3 and normalisation performed via the estimateSizeFactors 
function. The top 1,000 differentially expressed genes were then selected to construct a trajectory in 
an unsupervised manner, using the differentialGeneTest function, and reversed graph embedding (Qiu 
et al., 2017) used to reduce the data dimensionality into a trajectory and order cells in pseudotime 
using manifold learning (reduceDimension and orderCells functions). Genes which showed variable 
expression across the pseudotime were identified using the differentialGeneTest function and then 
clustered and plotted by expression level on heatmaps over pseudotime using the 
plot_pseudotime_heatmap function. Genes showing co-expression in pseudotime with Sca1 and Ki67 
were selected manually and prioritised according to comparisons in expression between the CL, 
healthy and HFD VSMC scRNA-seq datasets (merged as in section 2.7.3) and association in the 
literature with VSMC phenotypic switching and/or cardiovascular disease. 
2.7.5 Pathway analysis of cVSMCpos and cVSMCneg genes and genes with pseudotime 
associated expression. 
Gene ontology (GO) term enrichment or ‘pathway’ analysis of cVSMCpos and cVSMCneg genes and 
genes with pseudotime associated expression were performed using the Bioconductor R packages 
clusterProfiler version 3.10.0 (Yu et al., 2012) and RDAVIDWebService version 1.20.0. Genes were 
analysed for expression of biological process (BP) terms defined by the Gene Ontology consortium 
(Ashburner et al., 2000) using DAVID - The Database for Annotation, Visualisation and Integrated 
Discovery (Huang et al., 2009) and the KEGG pathway database (Kanehisa et al., 2010) and selected 
pathways visualised using the ggplot2 R package. 
2.7.6 Data availability 
Raw and processed bulk and scRNA-seq data is available in the Gene Expression Omnibus (GEO) 
repository under accession number GSE117963, with the exception of post-CL scRNA-seq data (both 





2.8 Aortic tissue explant model 
2.8.1 Preparation and culture of aortic tissue explants 
Aortic tissue for explanting was collected and dissected as in section 2.2.3, but using OptiMEM media 
instead of 1X PBS for tissue transport, dissection and digestion for adventitial removal. After adventitial 
removal, aortic media were serum starved overnight in OptiMEM media. The next day, prior to further 
tissue dissection, 150 µl Matrigel matrix (Corning) was pipetted into the 4 central wells of an 8-well 
chamber slide (Ibidi, one well per sample) and set by incubation at 37°C. Matrigel wells then had 400 
µl of OptiMEM reduced serum media with GlutaMAX supplement (Gibco, Thermo Fisher) added and 
were stored at 37°C until explant tissue embedding. Next, tissue pieces with dimensions of approx. 1 
mm x 1 mm were cut from the serum-starved aortic media using a sterile scalpel and transferred onto 
pre-set layers of Matrigel matrix with the OptiMEM media removed (Corning) within an 8-well 
chamber slide (Ibidi). Each transfer was made using dissection tweezers, holding each explant in a 
central position to create an internal injury site whilst moving onto the Matrigel layer in each well. 
Explants were then immediately covered with 150 µl Matrigel, which was set at 37°C for 6-8 minutes 
before addition of 400 µl OptiMEM media pre-warmed to 37°C and supplemented with 10% (v/v) FBS, 
100 U/ml penicillin, 100 mg/ml streptomycin and 20 ng/mL PDGF. Explants were embedded and set 
individually and then cultured at 37°C and 5% CO2, with media changed every 2-3 days. 
 
To block vascular endothelial growth factor receptor 2 (VEGFR2) signalling, inhibitors SU5419 or 
AAL993 were added to the explant culture media (SU5419 at 500 nM, 1 µM or 2 µM and AAL993 at 
100 nM, 500 nM or 1 µM) daily for 8 days before explant fixation. For labelling with 5-ethynyl-2’-
deoxyuridine (EdU), explant culture media was supplemented with 10 µM EdU (Click-iT Alexa Fluor 647 
Imaging kit, Thermo Fisher) 24 hours prior to fixation. For testing of siRNA transfection, explants were 
cut from the aortic media on the day of dissection prior to serum starvation. Next, siGLO siRNA 
targeting mouse Lamin A/C and labelled with DY-547 (Dharmacon) at 50 nM, 100 nM or 200 nM were 
mixed with 0.5 µl DharmaFECT in 50 µl serum-free OptiMEM media and incubated for 20 minutes at 
room temperature, before adding to explants during overnight serum starvation. For explant 
transduction with lentivirus see section 2.9.2. 
2.8.2 Explant processing and imaging 
For optimal explant fixation to retain VSMC fluorescence, chambers were washed briefly in 1X PBS 
before incubation in fixation solution (2% (w/v) methanol-free paraformaldehyde (glass ampoules 
from Thermo Fisher) and 0.5% (w/v) glutaraldehyde (Sigma Aldrich) in 1x PBS) for 30 minutes at 4 °C. 
Explants were then washed twice for 20 minutes in 1X PBS before removal of the culture wells from 
the coverslide and mounting using RapiClear 1.47 (Sunjinlab) and a 0.55 mm iSpacer. For explant 
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cryosectioning and immunostaining, the procedures in sections 2.2.2 and 2.3.1 were followed, 
carefully lifting the Matrigel containing the explant tissue into an O.C.T-filled plastic mould after 
removing the culture wells from the coverslide. To detect EdU labelling, the Click-iT® Plus Alexa Fluor® 
647 imaging kit (Life Technologies) was used according to the manufacturer’s instructions, extending 
the wash steps to 2x 20 minutes and reaction to 1 hour for explant detection, also using DAPI nuclear 





2.9 Lentivirus production and transduction 
2.9.1 Cloning of a lentivirus plasmid to express GFP and Klf4 
In order to express both GFP and Klf4 within transduced cells, a bicistronic vector was created encoding 
expression of both proteins separated by the T2A peptide. T2A is a member of the ‘self-cleaving’ 2A 
peptide family which cause a ribosomal ‘skip’ at their C-terminal end, producing two separate proteins 
(Donnelly et al., 2001). Importantly, 2A peptides are 18 amino acids in length, reducing any loss of 
function effects when added to another protein. Systematic comparison of gene expression using 
different 2A peptides attributed the highest level of ‘skipping’ and expression of the second position 
gene when using T2A (Liu et al., 2017). Gibson assembly (Gibson et al., 2009) was used to produce this 
bicistronic vector, using the NEBuilder HiFi DNA Assembly kit (New England BioLabs) according to the 
manufacturer’s instructions. In brief, a pLenti-CMV-GFP-Puro plasmid was cleaved with SalI and XbaI 
restriction enzymes (Promega) to remove GFP and then gel purified using the QIAquick gel extraction 
kit (Qiagen). Overlapping inserts encoding GFP-T2A(1-27) (GT) and T2A(28-54)-Klf4 (TK) were amplified 
by PCR using pLenti-CMV-GFP-Puro, pCX-Klf4 and T2A oligo (Sigma Aldrich, for primers used see 
appendix 3). Plasmids were kindly provided by Barak Cohen (pCX-Klf4, Addgene plasmid #66656) and 
Eric Campeau & Paul Kaufman (pLenti-CMV-GFP-Puro, Addgene plasmid #17448). PCR insert products 
(GT and TK) were also gel purified and subsequently used in the assembly reaction containing a 5’ 
exonuclease, DNA polymerase and DNA ligase (Figure 2.1a), incubated at 50°C for 15 minutes. 
Following the reaction, 50 µl of XL10 Gold ultracompetent cells (Agilent) were transformed with 2 µl 
of assembly product or no insert negative control reaction using heat shock at 42°C for 30 seconds 
followed by incubation on ice for 2 minutes, addition of 950 µl SOC media and then incubation with 
shaking at 37°C for 1 hour. Bacterial samples were plated onto LB-Agar containing 100 µg/ml Ampicillin 
at 37°C overnight and tested for GTK incorporation by colony PCR. Plasmids were purified using the 
QIAprep spin miniprep kit (Qiagen) and further tested by restriction digest and Sanger sequencing, 
using GT and TK construction primers as well as primers spanning the pLenti-GT and TK-pLenti 




Figure 2.1 - Production of a GFP and Klf4 expressing transfer plasmid for single-cell Klf4 
overexpression using lentivirus. 
a) Schematic of the NEBuilder Gibson assembly protocol, in which donor plasmid (pLenti-CMV-GFP-
Puro) was cleaved to single-strands with restriction enzymes XbaI and SalI. Oligonucleotides were 
produced containing Klf4 and GFP expression cassettes, connected by a T2A cleavage site and flanked 
by sticky ends corresponding to the those of the donor plasmid. A mixture of 5’ exonuclease, DNA 
polymerase and DNA ligase were used to join the donor plasmid and oligonucleotides, creating one 
single plasmid expressing GFP-T2A-Klf4, which was amplified by bacteria following heat-shock 
transformation. b) Agarose gels showing DNA products from each stage of Gibson assembly. Expected 
products are labelled below each lane and size marking shows NEB 2-log ladder band positions. i) Uncut 
pLenti-CMV-GFP-Puro vector or cut with SalI and XbaI restriction enzymes. ii) Products of PCR 
amplification of Gibson GFP-T2A or T2A-Klf4 oligonucleotides. iii) Correct product of Gibson reaction 
cut with SalI and XbaI to release GFP-T2A-Klf4. c) Snapgene software alignment of expected pLenti-
GFP-T2A-Klf4 plasmid with Sanger sequencing traces from the correct Gibson product. 
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2.9.2 Lentivirus production and explant transduction 
In order to produce lentivirus expressing pLenti-GTK, human embryonic kidney (HEK293FT) cells were 
transfected with the pLenti-GTK plasmid, along with the third-generation helper and envelope 
plasmids required to produce virus particles (see Figure 2.1 for schematic). One day before transfection 
(day 0), HEK293FT cells were plated at a density of 6x106 cells per T175 flask in DMEM supplemented 
with 10% (v/v) FBS, 100 U/ml penicillin, 100 mg/ml streptomycin and 2 mM glutamine. The following 
morning (day 1) HEK293FT cells were transferred to antibiotic-free DMEM for transfection that 
afternoon. For transfection, 52 µl of TransIT-X2 transfection reagent (Mirus Bio) was added to 6 µg 
pMDLg/pRRE helper plasmid, 2 µg pRSV-Rev helper plasmid, 3 µg pCag-Eco envelope plasmid (pMD2.G 
or pCag-Eco) and 15 µg pLenti-GTK or pLenti-GFP control in 3.5 mL of OptiMEM media (amounts given 
per flask). Plasmids were kindly provided by Didier Trono (pMDLg/pRRE and pRSV-Rev, Addgene 
plasmids # 12251 and 12253) and Arthur Nienhuis & Patrick Salmon (pCag-Eco, Addgene plasmid # 
35617). The transfection mixture was incubated for 30 minutes at room temperature before adding 
dropwise into each flask and incubating the cells at 37°C/5% CO2 overnight. The next day (day 2), GFP 
expression was examined to check transfection efficiency then cells were gently washed with 1X PBS, 
followed by feeding with DMEM media containing antibiotics (as above). Lentivirus was collected on 
day 3 by harvesting the DMEM containing lentivirus and adding 5 U/mL DNase I (Thermo Fisher) and 1 
mM MgCl2 to degrade any contaminating DNA. After incubation for 20 minutes at room temperature, 
contaminating cells were pelleted by centrifugation at 500 g for 10 minutes and the supernatant 
filtered through a 0.45 µm filter. Lentivirus was then concentrated by adding Lenti-X Concentrator 
solution (Clontech) at a 1:3 volume (solution: supernatant), incubated overnight at 4°C. Finally, on day 
4, this mixture was centrifuged at 1500 g for 45 minutes at 4°C and lentiviral pellets gently resuspended 
at 1/100th of the original volume in OptiMEM. Lentivirus was then immediately aliquoted and stored 
at -80°C before use. Each batch of lentivirus was titrated after one round of freeze thaw using a 
Lentivirus titration kit (Applied Biological Materials Inc) according to the manufacturer’s instructions. 
For explant transduction, 1.04x108 IU/mL pLenti-GTK or pLenti-GFP was added to 0.5 mg/mL 
Poloxamer 407 (Sigma Aldrich) in OptiMEM and added to explants or cultured cells after overnight 
serum starvation. After overnight incubation the explants were embedded in Matrigel and cultured as 






Figure 2.2 - Lentivirus particle production and explant transduction. 
Schematic of lentivirus production via HEK293FT transformation with envelope, transfer and packaging 
plasmids using TransX-IT transduction reagent. Virus was collected from HEK239FT cells after 48 hours 
of incubation and lentivirus particles concentrated using LentiX reagent. Explant transduction was 
performed using lentivirus and polybrene or poloxamer adjuvants. 
2.9.3 Western blotting 
Cells transduced with lentivirus were collected from their culture wells by treatment with Trypsin as in 
section 2.2.4. Cell pellets were frozen at -20°C overnight before lysis by incubation at 98°C for 5 
minutes in 2X Laemmli sample buffer (20% (v/v) glycerol, 4% (w/v) SDS, 200 mM DTT, 100 mM Tris HCl 
pH 6.8) and then sonication for 1 minute at medium intensity (Bioruptor, Diagenode). Total protein 
(30 µg/sample) was run on a 12% Bis-Tris polyacrylamide NUPAGE gel in 1X MES SDS buffer (both 
Thermo Fisher) at 165 V for 35 minutes. Proteins were wet-transferred to PVDF membranes in Bjerrum 
Schafer-Nielsen buffer (48 mM Tris, 39 mM glycine, 20% (v/v) methanol, 0.0375% (w/v) SDS) in a Mini 
Trans-Blot cell (Bio-Rad Laboratories) at 100 V for 1 hour at 4°C. Membranes were incubated in 
blocking buffer (5% (w/v) milk power (Marvel) in 1X Tris buffered saline (TBS) (150 mM NaCl, 50 mM 
Tris-HCl pH 7.5) for 1 hour at room temperature, before incubation with primary antibodies in blocking 
buffer overnight at 4°C. Membranes were then washed for 3x 5 minutes in 1X TBS and incubated in 
HRP-conjugated secondary antibody in blocking buffer for 10-30 minutes at room temperature, before 
another 3x 5-minute washes in 1X TBS. Proteins were detected using the ECL system (GE Healthcare), 
following the manufacturer’s instructions and developed on X-ray film manually. For antibodies and 
concentrations used see appendix 1. 
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Chapter 3  Sca1 as a candidate marker for phenotypically switching VSMCs 
within healthy and diseased blood vessels. 
 
3.1 Introduction:  
The clonal nature of neointimal or plaque-resident VSMCs in vascular injury (Chappell et al., 2016; 
Clément et al., 2019; Jacobsen et al., 2017a) may be due to a limited, selective response from the 
medial VSMC population or a general proliferative response followed by clonal selection (Gomez and 
Owens, 2016). Under the hypothesis that the responding VSMCs are primed for activation, these cells 
would possess a distinct transcriptional signature compared to the non-responding VSMCs prior to 
injury stimulus. For example, responding VSMCs could express genes which confer an increased 
capacity to activate proliferation. Preliminary work in our group had used Fluidigm C1 technology to 
assess VSMC heterogeneity. Profiling of 143 single cells from the aortic arch (AA) and descending 
thoracic (DT) aorta demonstrated that VSMCs from arteries of young healthy animals are largely 
homogeneous, but also suggested that some variation in expression patterns could be distinguished 
using this method. I therefore pursued further scRNA-seq of VSMCs from healthy animals to investigate 
the existence of any discrete subpopulations and their relation to VSMCs which clonally expand. 
 
The Fluidigm scRNA-seq analysis identified Ly6a as an interesting candidate, herein referred to by its 
protein name stem cell antigen-1 (Sca1 gene and Sca1 protein). Sca1 is a surface protein belonging to 
the Ly6 gene family, which are GPI-anchored proteins with a diverse range of cellular functions 
(Loughner et al., 2016). The functional importance of this protein is not clear, but its expression is used 
as a marker of progenitor populations, including haematopoietic stem cells (Spangrude et al., 1988) 
and mesenchymal stem cells (Morikawa et al., 2009). Sca1+ ‘side-population’ (SP) cells have also been 
isolated from the aortic media using Hoechst dye efflux, a method which exploits Abcg1 expression to 
identify progenitor cells (Scharenberg et al., 2002), and were demonstrated to be capable of both EC 
and VSMC differentiation in vitro (Sainz et al., 2006). Although this study did not use lineage tracing to 
determine a VSMC origin for the SP cells, more recent work has demonstrated that Myh11-lineage 
traced VSMCs within HFD-induced plaques also express Sca1 (Shankman et al., 2015). Therefore, it may 
be possible that a Sca1+ VSMC progenitor population exists within the healthy media, capable of 
producing neointimal cells in HFD. Of note, Sca1 expression was detected in only one of the 143 VSMCs 
analysed, matching the expectation that a potential primed population would constitute a small 
fraction of all VSMCs. However, Sca1 is also expressed by adventitial cells and ECs which sit adjacent 
to the medial VSMC layer and this scRNA-seq experiment was performed without VSMC lineage 
tracing. Thus, Sca1 was nominated as a candidate gene for further investigation, but subject to 
validation of its expression in VSMCs from healthy animals and ruling out of contamination from other 
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cell types. This chapter details the investigation of Sca1 expression in VSMCs; further investigation into 
alternative markers of potentially primed VSMC subpopulations are detailed in Chapter 5. 
 
Aims: 
1. Assess the sensitivity of scRNA-seq analysis to detect distinct VSMC expression patterns 
2. Validate Sca1 expression in VSMCs from healthy animals using Myh11-lineage tracing and a 
larger sample size for scRNA-seq. If Sca1 expression is due to contamination, investigate gene 
expression patterns in this dataset, to identify any distinct subpopulations. 
3. Investigate the association of VSMC subpopulations from healthy animals with phenotypic 
switching. 
4. Compare the profiles of VSMC subpopulations from healthy animals with those in vascular 
disease, using scRNA-seq of HFD-induced plaques. 
 
This results chapter is based on a collaboration between the groups of Dr Helle Jørgensen and Dr 
Mikhail Spivakov. Initial conventional and scRNA-seq of AA and DT-derived non-lineage traced VSMCs 
were performed by Dr Helle Jørgensen and Dr Mikhail Spivakov and collection of HFD VSMCs for scRNA-
seq was performed by Dr Helle Jørgensen and Dr Lina Dobnikar. Data analyses presented in Figures 
3.1b, Figures 3.1d-e and Figures 3.6a-c were performed by Dr Lina Dobnikar, as well as the 
identification of cVSMCpos and cVSMCneg signatures in section 3.4. Data analyses shown in Figure 
3.86 and Figure 3.9 were performed by Dr Mikhail Spivakov. The remaining experiments and analyses 
were performed by Annabel Taylor.  
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3.2 VSMCs from healthy animals show inter- and intra-regional heterogeneity in gene 
expression, profiled by scRNA-seq. 
VSMCs derived from the AA and DT regions (Figure 3.1a) were used as an initial model to dissect 
disease-relevant transcriptional patterns, owing to their different susceptibility to atherosclerotic 
plaque formation (Cheung et al., 2012) which may be related to their differing embryonic origin (the 
AA from neural-crest and DT of mesodermal lineage (Majesky, 2007)).  Using microarray and RT-qPCR 
analysis, it has previously been shown that VSMCs from the AA and DT aortic regions of healthy animals 
express different levels of a number of disease associated genes (Assche et al., 2011; Trigueros-Motos 
et al., 2013). However, it was unclear if this could be detected within individual cells by scRNA-seq. 
 
Conventional or ‘bulk’ RNA-seq of VSMCs from the two regions identified 386 genes which were 
increased in AA VSMCs and 56 in DT VSMCs (Figure 3.1b-c). DT-enriched genes included many involved 
in developmental patterning (e.g. Hoxa7), in line with prior observations (Assche et al., 2011; 
Trigueros-Motos et al., 2013). Genes enriched in the AA contained extracellular matrix components 
(e.g. Dcn and Lum) and genes associated with synthetic VSMCs (Spp1, Pde1c), which is consistent with 
the increased propensity for phenotypic switching and plaque development by AA VSMCs. Expanding 
this investigation using scRNA-seq of a small number of AA and DT VSMCs demonstrated that the 
differential expression patterns observed arose from both inter- and intra-regional heterogeneity 
(Figure 3.1d). Namely, many of the genes upregulated in one region showed exclusive expression in 
cells from that region (inter-regional variation); however, others were expressed in both regions, but 
in different numbers of cells from each (intra-regional variation). The identification of intra-regional 
VSMC transcriptional heterogeneity suggests that differential gene expression can arise independently 
of VSMC embryonic origin and regional location. Indeed, many of the genes with intra-regional 
variation were associated with VSMC phenotype or cardiovascular disease (see functional annotation 
in appendix. 4 and section 3.7.2 for details); for example, Tnc is highly expressed in inflammation and 
atherosclerosis and causes enhanced VSMC proliferation and migration in response to PDGF (Golledge 
et al., 2011; Imanaka-Yoshida et al., 2014; Ishigaki et al., 2011). Moreover, the heterogeneous 
expression of such genes was observed in individual VSMCs from the AA and DT, indicating that this 
phenomenon was independent of embryological origin or general flow dynamics in each region and 
may occur by a shared mechanism. Consistent with this hypothesis, clonal expansion has been 






Figure 3.1 - Conventional and single cell RNA-sequencing of aorta arch (AA)- and descending 
thoracic aorta (DT)-derived VSMCs demonstrated inter- and intra-regional heterogeneity in gene 
expression. 
a) Schematic of the aorta, showing the location of the AA (boxed in red) and DT (boxed in yellow) 
regions. b) Volcano plot from conventional RNA-seq data of AA and DT-derived VSMCs (n=3 each) 
showing the significance (-log10 p-value) of genes and their differential expression between regions 
(log2 fold change DT/AA). Each dot shows a single gene and genes with significance above p<0.01 and 
log2 fold change>1 are coloured (AA in red to left, DT in yellow to right). c) Relative expression of 
candidate AA- or DT-enriched genes (log2 fold change DT/AA) in dissociated AA- or DT-derived VSMCs 
(black, paired samples from n=4 animals) by RT-qPCR and bulk RNA-seq (grey, paired samples from 
n=5 animals pooled). Each dot represents a single sample and error bars show SEM. Rik* = 
3632451O06Rik. d) Boxplots from single cell RNA sequencing showing log expression of genes 
differentially expressed between AA (red) and DT (yellow) VSMCs. Top panel shows genes with inter-
regional variation and lower panel shows those with intra-regional variation. Each dot represents a 
single cell and the box shows first and third quartiles (box bounds) and median (central line) levels of 
expression. Figure adapted from Dobnikar, Taylor et al., 2019.   
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3.3 Validation of Sca1 expression in a rare population of VSMCs from healthy animals, which 
are distinct from Sca1+ adventitial cells and ECs. 
 
One such gene displaying intra-regional variation was Sca1, prompting further investigation into its 
expression in VSMCs. To examine the expression of Sca1 at the protein level in VSMCs, flow cytometry 
analysis was performed using dissociated medial VSMCs from Myh11-CreERt2/Rosa26-Confetti lineage 
traced animals labelled with tamoxifen.  Cells were stained with anti-Sca1 or isotype control antibody 
and a gating strategy was used to ensure that analysed cells were positive for only a single Confetti 
lineage colour to further exclude events representing cell doublets (Figure 3.3). Singlet status was also 
verified by microscopy of sorted Confetti+ VSMCs. This experiment demonstrated the presence of 
Sca1+Confetti+ medial cells at a frequency of 0.1% of all singly-coloured Confetti cells, aligning with 
predictions from Chappell et al. of the number of clonally expanding VSMCs in atherosclerosis 










To further investigate the identity of Sca1+ medial cells, scRNA-seq data was collected from adventitial 
cells, VSMCs and ECs, representing all three layers of the vascular wall. For this, the whole aorta was 
dissected free of surrounding fat and connective tissue and then digested to a single cell suspension 
without manual removal of the adventitia or ECs. Live cells were then collected using a viability dye 
and sequenced using the high-throughput 10X Chromium platform (Zheng et al., 2017) (see section 
1.8 and figure 1.10), to maximise the number of Sca1+ medial cells analysed, given that they represent 
such a rare population. The resulting whole aorta dataset encompassed 2846 cells post-QC, which fell 
into 4 clusters (Figure 3.3a-b, see methods section for details). These clusters could be designated as 
VSMCs (cluster 0 and 1), adventitial cells (cluster 2) and ECs (cluster 3) by their expression of the 
Figure 3.2 - Flow cytometry of lineage traced 
dissociated aortic media demonstrated the 
existence of Confetti+Sca1+ cells. 
Gating strategy for the analysis of Sca1 expression 
in tamoxifen labelled Myh11-CreERt2/Confetti 
animals. Events were gated as cells using forward 
and side scatter (a, FSC and SSC) and as single cells 
using forward scatter area and width (b, FSC-A 
and FSC-W). Single-coloured Confetti-labelled 
cells were then isolated from single cells using 
negative gating for two Confetti proteins (c-d) and 
positive gating of these double negative 
populations for the third Confetti protein (e-f). 
Using a Boolean “OR” gate, single Confetti 
positive cells from (e) and (f) were combined and 
analysed for Sca1 expression by anti-Sca1-APC 
staining (g). VSMCs from wild type animals were 
used to define Confetti negative gates, anti-IgG-
APC stained Confetti cells for the APC negative 
gate (h) and anti-Sca1-APC stained adventitial 
cells were used as APC positive cells. Gating 
strategy here uses gating for just two single 
Confetti proteins (RFP+ and GFP/YFP+); however 
subsequent sorting experiments for sequencing 
also used GFP/YFP-RFP-CFP+ cells. Note that 
GFP/YFP signals are inseparable. 
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markers Myh11, Pdgfra and Cdh5 respectively (Figure 3.3c-e). Interestingly, this dataset did show 
some Myh11 expression in adventitial cluster 2, despite its designation as a VSMC-specific marker, 
although at a lower level than seen in the VSMC clusters 0 and 1. Sca1 was expressed at a high level in 
both endothelial and adventitial cell clusters; and importantly, there were also Sca1+ cells within the 
VSMC clusters 0 and 1 (Figure 3.3f). These VSMCs expressed Sca1 at a lower level than the other two 
cell types but at a frequency of 3% of VSMCs, which is higher than previous estimates of Sca1+Confetti+ 
VSMCs. Considering the high level of Confetti lineage labelling in medial VSMCs (70-95%) and the low 
frequency of Confetti+ adventitial cells or ECs, it is likely that the observed Sca1+Confetti+ cells are 
indeed VSMC-derived. Furthermore, Sca1+ cells in the VSMC cluster expressed other VSMC markers 
such as Acta2, Tagln and Cnn1 and lacked expression of Pdgfra and Cdh5, similarly to the single Sca1+ 
VSMC detected in the earlier Fluidigm C1 experiment. This expression pattern supported the 






Figure 3.3 - RNA-seq of dissociated cells from the whole aorta confirmed the presence of Sca1+ 
cells with a VSMC transcription profile. 
tSNE (a and i in c-f) and violin plot (b and ii in c-f) visualisations of QC-filtered clusters in 10X Chromium 
scRNA-seq data from dissociated whole aorta cells, showing each cell as an individual dot. Cell 
clustering is shown in (a) and (b) shows key QC parameters: number of genes (i), number of UMI (ii) 
and percentage of mitochondrial reads for each cluster (iii). (c-e) show expression of markers used to 
identify each cell population: Myh11 for VSMCs (c), Pdgfra for adventitial cells (d) and Cdh5 for ECs (e) 






Although Myh11 is thought to be the most specific SMC marker and the Myh11-CreERt2 used here (Feil 
et al., 1997) has widely been demonstrated to be specific for SMCs in the blood vessels (Chakraborty 
Raja et al., 2019), given the Myh11 expression in the adventitial cluster of the 10X scRNA-seq, there 
remained a risk of contamination by a very rare population of Sca1+Confetti+ adventitial cells. To 
assess this possibility, cryosections from the AA, DT and carotid arteries of tamoxifen labelled Myh11-
CrERt2/Rosa26-Confetti animals were examined for Confetti expression outside of the medial layer. In 
total 72 cryosections were analysed, using six animals either at 1- or 16-weeks post-tamoxifen labelling 
(three per timepoint) and four sections from two parts of each of the three aortic regions. In the 
examined sections, 7 adventitial cells and 1 EC expressed Confetti fluorescent proteins, which 
corresponded to 0.02% of estimated total cell numbers analysed. This frequency was lower than the 
observed percentage of Sca1+ VSMCs in the AA/DT scRNA-seq data (0.7%, 35x lower) and flow 
cytometry analysis (0.1%, 5x lower). No difference in frequency was observed between the two 
labelling timepoints. 
 
Sca1GFP reporter animals were next utilised to assess Sca1 promoter activity within the vessel wall. 
These animals express a pLAG transgene containing GFP within a Ly6a expression cassette (Ma et al., 
2002), which contains 3’ control elements necessary for IFNγ-mediated induction of Sca1 expression 
in vitro and drives GFP expression in HSCs among other cell types (Ma et al., 2001). Within aortic 
cryosections from these animals, abundant GFP expression were observed in both adventitial cells and 
ECs (Figure 3.4), and also in 2 individual medial cells (Figure 3.4b-c). Interestingly, these GFP+ medial 
cells were located within layers of the elastic lamina (EL) around which no EL breaks could be observed, 
suggesting that Sca1+ medial cells were not adventitial or endothelial cells which had recently migrated 
into the medial layer. Additionally, anti-aSMA antibody staining was performed on one of these 






Figure 3.4 - Confirmation of GFP expression in medial using aortic cryosections from Sca1-GFP 
transgenic animals. 
Confocal microscope images of aortic cryosections from Sca1GFP animals. Images are single z scans 
showing GFP signal (green) and DAPI nuclear stain (white). (b) Images show signals for GFP only (i), 
DAPI only (ii) and a merge of the two channels (iii). A yellow arrowhead points to a medial GFP+ cell. 
(c) Images show signals for GFP only (i), DAPI only (ii), anti-aSMA antibody staining (magenta, iii) and a 
merge of all three channels (iv). Yellow arrows point to a single GFP+aSMA+ medial cell. Scale bars are 
10 µm (a-b) or 5 µm (c). Adventitial (Adv) and luminal (Lum) sides of the aorta are indicated. 
 
To assess medial GFP expression in a more quantitative manner, flow cytometry analysis of GFP 
expression was conducted on dissociated medial and adventitial cells from Sca1GFP animals (Figure 
3.5a-b). In this experiment 0.2-1.6% of medial cells expressed GFP, which is in line with the frequency 
of Sca1+ VSMCs by Fluidigm C1 (0.69%) and anti-Sca1 flow cytometry (0.1-0.4%). Within the adventitial 
layer, 17% of cells were GFP+. Additionally, an average of 54% of sorted GFP+ medial cells stained 
positively with anti-aSMA antibody, in comparison to no aSMA+ sorted GFP+ adventitial cells (Figure 
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3.5c-d). These results reinforced the conclusion that Sca1+ medial cells have a VSMC phenotype and 




Figure 3.5 - Confirmation of aSMA+GFP+ medial cells using dissociated cells from Sca1GFP animals 
and anti-aSMA antibody staining. 
a) FACS plots showing forward scatter (FSC, y axis) against Sca1-driven GFP expression (Sca1GFP, x axis) 
in dissociated cells isolated from wild type (WT) medial and Sca1GFP transgenic animals (adventitial or 
medial cells). Labels state the percentage of cells which are GFP+. b) Quantification of plots in (a), 
showing the percentage of GFP+ cells from wild type media (black dots, n=1 animal), Sca1GFP adventitia 
(red squares, n=4 animals pooled) and Sca1GFP media (green triangles, n=4 animals), error bars show 
SEM. c) Confocal images showing GFP+ cells from Sca1GFP media (i) or adventitia (ii) and control GFP- 
cells from WT media (iii). Images are single z scans, identical across each sample row, showing DAPI 
nuclear stain (white, far left column), GFP (green, mid left column), signal from anti-aSMA antibody (i-
ii) or isotype control (iii) antibody staining (magenta mid right column) and a merge of all three 
channels (far right column). Scale bars show 10 µm. d) Quantification of the percentage of cells which 
stained aSMA- and aSMA+ sorted from Sca1GFP adventitia (red squares, n=4 animals pooled and n=30 
GFP+ cells) or media (green triangles, n=4 animals, n=18-38 GFP+ cells), error bars show SEM. Figure 
adapted from Dobnikar, Taylor et al., 2018.  
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3.4 Profiling of healthy Sca1+ VSMC expression patterns using Smart-seq2 scRNA-seq 
demonstrated their expression of a non-contractile, activated transcriptional signature. 
 
To directly profile Sca1+ VSMCs in comparison to other cells, further scRNA-seq data was generated 
from dissociated VSMCs from the aorta of healthy animals. Cells were sorted for a single Confetti 
lineage colour (as in Figure 3.2) and the sample was enriched for Sca1+ cells by anti-Sca1 staining in 
order to capture more of this rare population. Exploiting the plate-based Smart-seq2 protocol, the cells 
were index-labelled to allow their FACS profile to be tracked post-sequencing (Picelli et al., 2014). The 
final dataset included 93x Sca1+Lineage+ (S+L+), 27x Sca1+Lineage- (S+L-) and 36x Sca1-Lineage+ (S-
L+) cells (see section 2.6.2, section 1.9 and Figure 1.9 for library preparation). Sequencing data 
reflected the expected patterns of Myh11 expression in each single positive population, with the 
exception that a few S+L- cells expressed Myh11, indicating that they were VSMCs which had failed to 
recombine the Confetti locus during tamoxifen labelling. Average Myh11 expression levels were lower 
in double positive S+L+ VSMCs than the conventional S-L+ VSMCs; however, this was still much higher 
than the S+L- cells, which showed minimal Myh11 expression (Figure 3.6a, left dot plots). Sca1 
transcripts were absent in some of the cells identified as Sca1+ by antibody staining, which may be due 
to sequencing dropouts or differences in protein and transcript stability. S+L+ cells positive for Sca1 
transcript showed a range of expression levels, but appeared to be Sca1-high in comparison to S-L+ 
cells (Figure 3.6a right violin plots).  
 
Principle component analysis (PCA) based on the 500 genes with the highest variable expression across 
all cells demonstrated segregation of S+L- and S-L+ cells (excepting the aforementioned Myh11+ S-L+ 
cells) across principal component 2 (PC2). The S+L+ cells were more heterogeneous in PC2 expression 
and spanned the space between the two single positive cell populations in this dimension (Figure 3.6b). 
The spread of S+L+ cells indicated that Sca1+ VSMCs are not only distinct from Sca1+ adventitial cells 
and ECs (section 3.3), but that a subpopulation is also distinct from Sca1- VSMCs, positioned towards 
S+L- cells in the PCA plot. 
 
Further analysis of the variance in gene expression within S+L+ population identified 52 highly variable 
genes, containing a network of 24 contractile VSMC markers found to be co-expressed by weighted 
gene co-expression network analysis (“cVSMC network”). As expected, the cVSMC network was highly 
expressed in S-L+ cells and those S+L+/S+L- cells which co-localised with S-L+ in the PCA plot, with 
reduced expression in all other S+L+ and S+L- cells (Figure 3.6c). There were 312 genes which were 
positively associated with this cVSMC network in S+L+ cells (“cVSMCpos”), for which pathway analysis 
demonstrated an enrichment for VSMC-specific terms such as muscle contraction, muscle cell 
differentiation and negative regulation of SMC proliferation (Figure 3.6d left bubble plot). In contrast, 
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the 303 genes identified to be negatively associated with the cVSMC network (“cVSMCneg”) showed 
enrichment for terms associated with disease-relevant signalling pathways, including those involving 
small GTPases, ERK cascades, TGFβ and PI3K (Figure 3.6d right bubble plot). Genes associated with the 
VSMC synthetic phenotype (e.g. Spp1 and Col8a1), migration, angiogenesis and cell growth (e.g. Nrp1, 
Flt1 and Smad3) were also enriched in the cVSMCneg signature, suggesting that the S+L+ cells may 
have acquired an alternate, activated phenotype. 
 
Prompted by the observation of EC genes in cVSMCneg (e.g. Flt1, Cd34 and Srpx2), Sca1+ VSMCs were 
assessed for EC characteristics by comparison to Sca1- VSMCs and commercial primary mouse ECs as 
a positive control. VSMCs were sorted by FACS for VSMC lineage and Sca1 expression using anti-Sca1 
antibody and cultured in EC-specific media; however, neither Sca1+ nor Sca1- VSMCs were able to 
adhere to the culture surface and survive. Sorted cells were also stained for EC marker CD31 (Figure 
3.7a) and assessed for acetylated-LDL uptake (ac-LDL, Figure 3.7b), for which ECs show enhanced 
capability than VSMCs (Voyta et al., 1984). In both assays, VSMCs showed no positive response, 
whereas the primary ECs expressed CD31 expression and showed ac-LDL uptake. Therefore, in these 







Figure 3.6 - Further investigation of Sca1+ VSMC transcriptional signatures demonstrated down-
regulation of the contractile phenotype and activation of a responsive gene signature. 
a) Box plots showing log expression of Myh11 and Sca1 in Sca1- lineage label+ (S-L+, magenta, n=36), 
Sca1+ lineage label+ (S+L+, yellow, n=93) and Sca1+ lineage label- (S+L-, cyan, n=27) cells, each dot 
representing a single cell. b-c) PCA plots based on the expression of the top 500 variably expressed 
genes in S-L+ (squares), S+L+ (triangles) and S+L- (circles) cells. Cell colours in (b) indicate cell type 
(given in a) and cells in c are colour-coded by expression of the cVSMC network on a scale from blue 
to red. d) Bubble plot of selected GO terms from those enriched in genes from cVSMCpos (left) and 
cVSMCneg (right). Dot colour shows adjusted p value on a scale from blue to red and size shows the 





Figure 3.7 - Isolated Sca1+ VSMCs did not show EC characteristics when compared to Sca1- VSMCs 
by CD31 immunostaining or ac-LDL uptake. 
Confocal images of cultured (i) or sorted (ii) commercial primary mouse ECs and sorted Sca1+ lineage 
label+ (S+L+, iii) or Sca1- lineage label+ (S-L+, iv) medial cells. Images are single scans showing DAPI 
nuclear stain (white) and anti-CD31 antibody staining (a, magenta) or DiI signal after overnight 
incubation with 20 µg/mL DiI-conjugated Ac-LDL (b, magenta). Scale bars are 20 µm. Images are 




3.5 VSMCs in healthy vessels upregulate Sca1 expression during phenotypic switching in vitro 
and over time in vivo. 
 
The hypothesis that reduced cVSMCpos and increased cVSMCneg expression in Sca1+ VSMCs may 
represent an altered phenotypic state prompted an investigation into Sca1 expression during VSMC 
phenotypic switching. For this, dissociated aortic VSMCs were placed into in vitro culture, which causes 
them to lose expression of contractile markers and activate proliferation (Chamley et al., 1974). When 
compared to freshly isolated ‘ex-vivo’ dissociated VSMCs, cultured cells showed an increase in Sca1 
expression by RT-qPCR, concurrent with a downregulation of the contractile marker Myh11 (Figure 
3.8a). Although an increase in Sca1 in culture was suggestive of activation during phenotypic switching, 
RT-qPCR is a measurement of expression in the bulk population. Therefore, this result may also be due 
to selective expansion of a small number of Sca1+ cells, rather than Sca1 activation by previously Sca1- 
VSMCs. 
 
To better resolve the increase in Sca1 expression, dissociated aortic VSMCs from Sca1GFP animals were 
placed into culture, providing a means to report Sca1 expression at an individual cell level. Specifically, 
GFP- medial VSMCs were sorted into culture, along with GFP+ or GFP- adventitial cells and control 
VSMCs from the media of wild type animals. At day 3 of culture, the cells maintained the GFP 
expression patterns seen at the time of sorting (Figure 3.8b, top panels); however, by day 10 a subset 
of both GFP- VSMCs and GFP- adventitial cells became GFP+, indicating increased activity of the Sca1 
promoter. Control GFP+ adventitial cells stayed GFP+ and wild type VSMCs remained GFP- at day 10 
(Figure 3.8b, lower panels). This evidence for Sca1 promoter activation in VSMCs in culture suggested 
that Sca1 may not be a permanent marker of a VSMC subpopulation and could be acquired during 
phenotypic switching. Interestingly, there was heterogeneity in this activation, producing GFP 
expression in 15-28% of VSMCs at day 11, comparable to the frequency seen in adventitial cells (Figure 
3.8c). 
 
To assess if Sca1 activation occurs in VSMCs from healthy animals in vivo, Sca1 expression at different 
timepoints post-tamoxifen labelling was determined using anti-Sca1 antibody staining and flow 
cytometric analysis of aortic VSMCs from Myh11-CreERt2/Rosa26-EYFP animals. Although high 
variability was seen between animals, linear regression showed a small but significant trend towards 
increased numbers of Sca1+ VSMCs over time which is not linked to animal age (Figure 3.9, p=0.0164, 
R2=0.34). This suggests that VSMCs from healthy animals can become Sca1+ over time in vivo and 
indicates that the S+L+ phenotype does not represent an intermediate state in the conversion from a 




Figure 3.8 - VSMCs increase Sca1 expression during in vitro culture-induced phenotypic switching. 
a) Relative expression of Myh11 and Sca1 in ex vivo (black dots, n=3 animals) and cultured mouse 
VSMCs at passage 4-5 (red squares, n=3 animals) by RT-qPCR, normalised to the expression of 
housekeeping gene Hmbs. For differences in Myh11 p=0.00098 and Sca1 p=5.1e-10 by t-test and error 
bars show SEM. b) GFP- medial (left panels) and GFP+ adventitial (middle panels) cells from Sca1-GFP 
animals and WT GFP- medial cell controls (right panels) were sorted and cultured for 11 days. Panels 
show epifluorescence images of GFP expression (white) after 3 (top) or 10 (bottom) days of culture 
and scale bars show 100 µm. c) Quantification of the number of GFP+ cells as a percentage of total 
DAPI+ cells after 11 days of culture. Samples are WT medial cells (black dots, n=1 animal, 202 cells 
analysed), Sca1-GFP adventitial cells sorted as GFP- (blue squares, n=4 animals pooled, 527 cells 
analysed) or GFP+ (red squares, n=4 animals pooled, 464 cells analysed) and Sca1-GFP medial cells 
sorted as GFP- (green triangles, n=4 animals, 127-242 cells analysed per animal). Error bars show SEM. 





Figure 3.9 - Sca1-expressing VSMCs increase in number with increased time post-tamoxifen 
labelling in vivo. 
Frequency of Sca1+ lineage label+ (S+L+) cells shown as a percentage of total lineage label+ cells in 
aortic media of Myh11-CreERt2/EYFP animals analysed at different timepoints post tamoxifen-
mediated lineage labelling. Values for each individual animal are shown by single dots and dot colour 
represents animal age from 9-55 weeks on a scale from light grey to black. Linear regression was used 






3.6 Phenotypically modulated Sca1+ VSMCs exist in high-fat diet-induced atherosclerotic 
plaques and share expression of the activated transcriptional signature identified in VSMC 
subpopulations from healthy animals.  
 
As mentioned, VSMC-derived Sca1+ cells have been identified in HFD-induced plaques from ApoE-/- 
animals (Shankman et al., 2015). To determine the relevance of healthy Sca1+ VSMCs to the population 
seen in disease, scRNA-seq was used to compare the transcriptional profiles of plaque-derived and 
healthy Sca1+ VSMCs. For this, dissociated plaques and their underlying media from Myh11-
CreERt2/Rosa26-Confetti/ApoE-/- animals fed a HFD for 14 or 18 weeks were sorted for single Confetti 
lineage expression (as in Figure 3.2). In order to capture the diversity of VSMCs within atherosclerotic 
plaques, the high-throughput 10X Chromium platform was used for scRNA-seq, producing sequencing 
data for 1600 and 1906 VSMCs post-QC from 14 and 18 weeks of HFD respectively. Plaque-derived 
VSMCs showed high heterogeneity, producing 11 clusters post-QC (Figure 3.10a). Of these, the 
majority were Myh11-high, excluding three distinct clusters (clusters 8-10) which showed 
downregulation of contractile VSMC markers Myh11, Acta2, Cnn1 and Tagln (Figure 3.10b-d). These 
three clusters also had higher UMI counts and lower mitochondrial gene expression as a percentage 
of total reads, which could represent a higher level of transcription when compared to quiescent cells. 
In addition to a loss of VSMC contractile markers, cluster 10 expressed macrophage-like markers 
(Cd68+ and Lyz2+), cluster 8 expressed chondrocyte-like genes (Sox9+ and Ibsp+) and cluster 9 
expressed Sca1 (Figure 3.10e-h). As Sca1 was associated with phenotypic switching in vitro, these S+L+ 
plaque cells which are low in contractile marker expression may represent an expansion of 
phenotypically switched Sca1+ VSMCs from healthy animals or activation of Sca1 in previously Sca1- 
VSMC, as seen in vitro. The S+L+ clusters also showed activation of genes associated with VSMC 
phenotypic switching (Spp1, Timp1, Mmp2 and Col1a1, Figure 3.10i), loss of cVSMCpos and enrichment 
of cVSMCneg (Figure 3.10j-k). Therefore, both plaque derived and healthy Sca1+ VSMCs share a loss 
of the VSMC contractile network and expression of an activated transcriptional signature, with features 
of VSMC phenotypic switching. Interestingly, clusters 8 and 9 also showed high cVSMCneg and low 
cVSMCpos expression despite being Sca1-. As these two clusters are positive for markers of 
macrophages and chondrocytes, it possible that they represent populations which have begun to take 
on alternative cellular phenotypes, which are not Sca1+. 
 
To determine if Sca1+ and Sca1- plaque VSMCs represent distinct VSMC clones, Sca1 expression in 
plaque VSMCs was characterised by anti-Sca1 immunostaining performed on aortic cryosections taken 
from Myh11-CreERt2/Rosa26-Confetti/ApoE-/- animals after 18-30 weeks of HFD. Consistent with the 
lack of contractile gene expression in VSMCs positive for Sca1 transcripts, Sca1+ VSMCs were observed 
within the core region of the plaque and not the contractile, fibrous cap region. Moreover, this 
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expression pattern was noted in plaques where both cap and core regions were derived from VSMCs 
of the same Confetti lineage colour (Figure 3.11), a further indication that single VSMCs may be able 
to modulate their expression of Sca1 in vivo. 
 
 
Figure 3.10 - Plaque-resident Sca1+ VSMCs show reduced expression of contractile markers and 
increased synthetic marker expression, indicative of phenotypic switching, and share 
transcriptional profiles with Sca1+ VSMCs detected in healthy animals. 
tSNE (a and i in e-l) and violin plot (b-d and ii in e-l) visualisations of clusters of QC-filtered cells in 10X 
Chromium scRNA-seq data from dissociated single Confetti lineage label+ VSMCs from HFD-induced 
plaques and their underlying media. Each cell is represented by an individual dot. Cell clusters are 
shown in (a) and (b-d) show key QC parameters: number of genes (b), number of UMIs (c) and 
percentage of mitochondrial reads (d). (e-l) show expression of markers for contractile VSMCs (Myh11, 
e), macrophages (Cd68, f) or chondrocytes (Sox9, g) and Sca1 (h). (i-l) show expression of synthetic 
VSMC marker Spp1 (j), transcriptional profiles defined using healthy Sca1+ VSMCs cVSMCpos, k and 




Figure 3.11 – Plaque associated VSMCs expressing the same colour lineage reporter can be both 
Sca1- and Sca1+, the latter of which localise to the plaque core and not the contractile fibrous cap. 
a-b) Confocal images of an aortic cryosection from an Myh11-CreERt2/Confetti animal after 30 weeks 
of HFD, stained with anti-Sca1 (a) or isotype control (b) antibody. Images are maximum projections of 
whole cryosections, showing Confetti signal, DAPI nuclear stain (white) and antibody staining 
(magenta). Scale bars are 20 (a) or 15 (b) µm. c) Magnifications of the image in (a) showing a maximum 
projection (i) or a single scan (ii-iv). Images show DAPI nuclear stain (white) with (i-iii) or without (iv) 
Confetti signal and with (i-ii, iv) or without (iii) anti-Sca1 antibody signal (magenta). Orange arrows 
point to Sca1+RFP+ VSMCs and scale bars are 40 (i) or 15 (ii-iv) µm. Figure adapted from Dobnikar, 




3.7 Summary and discussion of findings from chapter 3. 
3.7.1 Identification of Sca1+ VSMCs within the healthy aortic media and their distinction from 
previously identified Sca1+ adventitial cells. 
This work sought to investigate the transcriptional profile of VSMCs from healthy animals, to 
determine the presence of any subpopulations which could be candidates for cells primed to clonally 
expand in disease. During pilot experiments to test the ability of scRNA-seq to detect differences 
between VSMCs from healthy animals, Sca1 expression was identified in one medial cell. This Sca1+ 
cell was intriguing, as Sca1 expression is commonly associated with stem cells (Spangrude et al., 1988; 
Yutoku et al., 1974), including those involved in the repair of the adult heart (Uchida et al., 2013) and 
skeletal muscle (Lee et al., 2000). Sca1 has proposed roles in cell-cell interactions and the modulation 
of lipid raft signalling, particularly in the context of tissue stress or injury (Holmes and Stanford, 2007). 
Knockout mice for Sca1 appear normal, yet present defects in progenitor cell populations, such as 
osteoporosis due to impaired mesenchymal progenitor renewal (Bonyadi et al., 2003). The 
involvement of Sca1 in the function of mesenchymal progenitors, which are capable of producing 
SMCs, may also indicate that Sca1+ SMCs are more progenitor-like. Although the function of Sca1 is 
not resolved, it has been used successfully as a marker to trace and isolate specific cell populations. 
Therefore, I explored its use as a maker for activated VSMCs. 
 
One caveat to the initial observation of a Sca1+ VSMC was that adventitial cells and ECs also express 
Sca1. Indeed, the identification of Confetti+ cells of both types in aortic cryosections here 
substantiated that they may present a potential contaminating source of Sca1+Confetti+ cells, 
although observed at a much lower frequency. Subsequent scRNA-seq analysis demonstrated Sca1 
expression in cells of each three identities (Figure 3.3) and cryosections from Sca1-GFP transgenic 
animals showed medially located Sca1+ cells (Figure 3.4) enclosed by an intact elastic lamina. These 
observations are suggestive of a VSMC-identity for Sca1+ medial cells, reinforced by contractile marker 
expression by both scRNA-seq and Sca1-GFP immunostaining (Figures 3.4-3.5). The possibility remains 
that Sca1+ medial cells could have been derived from adventitial cells or ECs prior to Confetti lineage 
labelling, though the increase in Sca1+ lineage positive cells over time in Figure 3.9 suggests that these 
cells are VSMC-derived. The extent of plasticity between each vascular layer in absence of disease in 
unknown. Differentiation of adventitial-resident Sca1 cells into VSMCs has been demonstrated in vitro 
and in in vivo disease models (Hu et al., 2004; Kramann et al., 2016; Passman et al., 2008; Yu et al., 
2016), though the Sca1+ medial cells identified here do not express alternative Sca1+ adventitial cell 
markers identified in these papers (Shh, Gli1). Additionally, these reports use severe aortic injury 
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models, which have been demonstrated to cause VSMC death allowing adventitial access to the lumen 
for neointima formation (Roostalu et al., 2018), and it may be that there is redundancy in Sca1+ cells 
from each layer in order to react to mild or severe injury. Moreover, VSMCs have recently been 
demonstrated to contribute to progenitors in the adventitia, so there may be more plasticity between 
these two layers than previously appreciated (Majesky et al., 2017). 
 
Concerning ECs, trans-differentiation from an EC to VSMC phenotype (or EndMT) has been 
demonstrated in atherosclerosis, though its prevalence in healthy vessels is not determined (Souilhol 
et al., 2018). Despite expression of multiple EC markers, Sca1+ VSMCs did not possess an enhanced 
endothelial phenotype in vitro (Figure 3.7). This data is in contrast to in vitro differentiation of 
adventitial Sca1+ progenitors to an EC lineage by Passman et al., using 10 ng/mL VEGF-A in DMEM 
media (Passman et al., 2008), and similar experiments by Sainz et al. on their ‘side population’ 
progenitor cells, using 10 ng/mL VEGF in commercial EC media (Sainz et al., 2006). Although mouse 
VEGF was used at an equivalent concentration here, there may be differences in the commercial media 
used, and the adventitial Sca1+ cells used may have distinct capabilities to medial Sca1+ cells. There 
were also significant challenges in the isolation and culture of rare Sca1+ VSMCs and it may be that 
they would perform better in a more confluent environment. Finally, EC gene expression may just be 
an indicator of increased plasticity or de-differentiation of Sca1+ VSMCs, as VSMCs and ECs can be 
formed from a common progenitor (Yamashita et al., 2000). Similarly, VSMC-derived MSC-like plaque 
cells isolated by Shankman et al. were unable to trans-differentiate to adipocytes or osteoblasts in 
vitro, despite expressing MSC markers Sca1 and Cd105 (Shankman et al., 2015).  
3.7.2 Healthy, Sca1+ VSMCs as a source of Sca1+ HFD-induced plaque cells. 
The rare occurrence of healthy, Sca1+ VSMCs, the link between Sca1-expression and progenitor state 
and the prior observation of Sca1+ VSMCs in HFD-induced plaques (Shankman et al., 2015) implicated 
them as candidate markers of cells undergoing selective clonal expansion in vascular disease models. 
In support of this association, in-depth analysis of Sca1+ VSMC profiles using index-sorted cells and 
Smart-seq2 scRNA-seq showed a loss of contractile marker expression and acquisition of the 
responsive, activated cVSMCneg transcriptional signature (Figures 3.6). The non-rhomboid shape of 
Sca1-GFP+ medial cells (Figure 3.4) also implied a less contractile phenotype (Rensen et al., 2007). The 
expression of an activated signature by Sca1+ VSMCs may represent their priming for responsiveness 
to immune or injury stimuli. Similar Sca1 expression under activation is seen in T-cells, where 
precursors turn on Sca1 during activation (Yang et al., 2005), and in HSCs and epithelial cells, which 
induce Sca1 in response to inflammation (Bujanover et al., 2018; Flanagan et al., 2008). Interestingly, 
cVSMCneg was also enriched in genes involved in vascular development (e.g. Runx1), which, along with 
their low Myh11 expression, may suggest that Sca1+ VSMCs represent a less differentiated state than 
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Myh11-high, Sca1- VSMCs. The extent of reactivation of developmental processes during phenotypic 
switching is not resolved; however, developmental signalling is a common feature of other cellular 
responses to injury, regeneration and chronic disease (Chanda et al., 2016; Fabian and Humphreys, 
2012; Uygur and Lee, 2016). 
 
Activation of Sca1 was also demonstrated in VSMCs in the culture-induced model of phenotypic 
switching (Figure 3.8). Flow cytometry of dissociated VSMCs at different timepoints post-tamoxifen 
lineage labelling (Figure 3.9) was also consistent with Sca1 activation in previously Sca1- VSMCs, along 
with demonstration of the modulation of Sca1 expression by individual VSMCs by immunostaining of 
HFD-induced plaques (Figure 3.11). Activation of Sca1 in culture was notably limited, demonstrating 
non-uniformity in the capacity or propensity of individual VSMCs to activate Sca1, similar to the rarity 
of its expression in vivo. ScRNA-seq of plaque-resident VSMCs from animals fed a HFD identified a 
Sca1+ VSMC population, likely analogous to those seen by Shankman et al. (Shankman et al., 2015).  
Importantly, Sca1+ plaque VSMCs shared a loss of cVSMCpos and gain of cVSMCneg transcriptional 
signatures with the healthy Sca1+ VSMCs (Figure 3.10), further implicating the healthy counterparts in 
disease expansion. The lack of a contractile phenotype in Sca1+ VSMCs was also evident through 
plaque localisation in aortic cryosections, being associated with the non-contractile plaque core and 
not the contractile fibrous cap (Figure 3.11). Taken together, these experiments identify Sca1+ medial 
cells that are VSMC-derived, but lack a conventional, contractile VSMC phenotype. The analysis also 
suggests that Sca1 expression is a feature of VSMC phenotypic switching and demonstrate that healthy 
Sca1+ cells express an activated profile shared by disease associated Sca1+ VSMCs. Although definitive 
evidence for healthy Sca1+ VSMC expansion in disease and plaque investment would require dual 
lineage labelling strategies which were not employed here, this work strongly suggests that healthy 






Chapter 4 Identification of candidate regulators of selective VSMC 




The dissection of early events in the selective VSMC activation seen in atherosclerosis is difficult due 
to the complex cellular composition and diverse phenotypes within a plaque (Babaev et al., 1990). 
There is also significant heterogeneity in plaque development, which is dependent on vessel location 
and the atherosclerotic mouse model used (Getz and Reardon, 2012; Nakashima et al., 1994). 
Knowledge of the process by which VSMCs invest in a plaque is limited, largely hindered by the 
underestimation of their contribution to plaque-derived cells until the implementation of VSMC-
specific lineage tracing (Gomez et al., 2013; Shankman et al., 2015). An alternative to traditional diet-
induced models of atherosclerotic plaque formation is the use of vascular injury to produce neointimal 
growth analogous to human VSMC restenosis following angioplasty (see section 1.5). In this model, 
VSMCs downregulate contractile markers, activating proliferation and the expression of inflammatory 
genes, similar to their behaviour in atherosclerosis development, but in a much faster and more 
reproducible manner than in HFD models (Herring et al., 2014; Kumar and Lindner, 1997). VSMC 
phenotypic switching in carotid ligation is transient and a higher proportion of aSMA+ and less Mac3+ 
neointimal cells are observed at 28 days post-injury (Chappell et al., 2016; Kumar and Lindner, 1997). 
Furthermore, neointimal VSMCs in the carotid ligation model have been shown to arise by clonal 
expansion, similarly to those in HFD plaques (Chappell et al., 2016), illustrating that this selective 
response is not dependent on an altered lipid profile. Therefore, this model provides a good system to 
test the early changes in gene expression associated with selective VSMC activation.  
 
Overall Aim: identification of candidate regulators of selective activation of VSMC proliferation. 
  
Specific Objectives:  
- Characterisation of VSMC activation and proliferation after injury  
- Generation of scRNA-seq datasets at a timepoint of early VSMC activation. 
- Identification of candidate regulators using scRNA-seq datasets. 
- Validation of identified candidates using immunostaining of plaque cryosections. 
 
Carotid ligation surgeries in this chapter were completed by Dr Kirsty Foote, Dr Joel Chappell and Allie 
Finigan. Data shown in Figure 4.2, was collected by Dr Jenny Harman, with figures produced by Annabel 
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Taylor. ScRNA-seq samples were generated in collaboration with Dr Joel Chappell and processing in 
the 10X Chromium system performed by the CRUK genomics core facility. Sequencing, read mapping 
and generation of counts matrices were performed by the Babraham Institute sequencing facility and 
data analysis conducted by Annabel Taylor, excepting the quality control filtering of Smart-seq2 data, 
performed by Dr Lina Dobnikar. Immunostaining of human plaque samples was performed by Nikki 
Figg, with images taken and quantification carried out by Annabel Taylor. The remaining experiments 
and analyses were performed by Annabel Taylor.  
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4.2  Sca1 is upregulated in response to vascular injury and associated with VSMC proliferation. 
In order to collect transcriptional data relevant to early VSMC phenotypic switching and clonal 
expansion, a suitable time point post-CL needed to be chosen, when VSMCs had begun to respond to 
injury stimulus and proliferating cells could be distinguished. The first report of the CL technique 
identified proliferation from day 2 post-injury by BrdU incorporation, but this was not attributed 
specifically to VSMCs (Kumar and Lindner, 1997). More recent work using Myh11-CreERt2 lineage 
tracing showed a decrease in RNA transcripts for VSMC contractile markers at day 3, but not at the 
protein level until day 7, concomitant with neointimal formation by day 14 (Herring et al., 2017, 2014). 
Thus, the activation of VSMC responses begins between days 3 and 7 post-injury, with the majority of 
VSMC proliferation and expansion into the neointima occurring between days 7 and 14.  
 
To more directly assess VSMC proliferation, Ki67-RFP reporter animals were crossed with those 
carrying the Myh11-CreERt2/Rosa26-EYFP lineage tracer. These animals carry a knock-in of the TagRFP 
protein at the C-terminus of the Ki67 gene (Basak et al., 2014), so that tamoxifen-labelled VSMCs from 
Myh11-CreERt2/Rosa26-EYFP/Ki67-RFP animals are EYFP+ and become EYFP+RFP+ when actively 
proliferating. Using flow cytometry (example gating strategy shown in Figure 4.1), dissociated VSMCs 
from ligated left carotids were assessed for proliferation at different time points post-injury (Figure 
4.2). In parallel we assessed the expression of Sca1, which was detected in a small subpopulation of 
VSMCs in healthy vessels (Chapter 3). This showed a clear increase in frequency of Sca1-expressing 
cells among both lineage and non-lineage labelled cells at day 8 post-injury (Figures 4.2a-c). 
Sca1+EYFP- cells are a mixture of unlabelled VSMCs, EC and adventitial cells and their large expansion 
after injury is in line with prior reports of adventitial expansion post-CL (Herring et al., 2017). The 
increase in Sca1+EYFP+ VSMCs was variable, with 2-40% of lineage label positive (or EFYP+) cells 
expressing Sca1 (Figure 4.2c). In contrast, 3-4% of VSMCs expressed the Ki67 proliferation reporter 
(Figure 4.2d). Up to 100% of Myh11+Ki67+ VSMCs were also Sca1+ (Figure 4.2e), demonstrating that 
Ki67+ VSMCs can indeed express Sca1, although only an average of 7% of total Sca1+ VSMCs were 
Ki67+. There were also no significant differences in the proportion of Ki67+ cells which were Sca1+ or 
vice versa in control or ligated tissue. Given the widespread activation of Sca1 expression post-injury 
and the small proportion of proliferating VSMCs, it is likely that this is due to induction of Sca1 in cells 
that were Sca1- before injury rather than entirely from expansion of cells that were Sca1+ in healthy 
vessels. To examine the overlap in Sca1 and Ki67 expression further, their expression was analysed at 
different time points post-CL from day 2 to day 13 (Figures 4.2g-h). The time course demonstrated a 
significant increase in Sca1+ cells from day 2 of injury and Ki67 from day 5, indicating that activation of 
Sca1 expression may precede proliferation. The frequency of Ki67+ cells peaked at day 8 and was 
significantly reduced again by day 13, whereas widespread/high frequency Sca1 expression persisted 
at both days 8 and 13. These results demonstrate that Sca1 and Ki67 expression are not directly 
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coupled and that Sca1 expression and proliferation may not be activated concurrently in VSMC injury. 
Using the data in Figures 4g-h, day 7 was chosen for collection of VSMC CL scRNA-seq data; a time 
point at which Myh11 downregulation has occurred in a subset of cells (Herring et al., 2017) and Sca1 
and Ki67 expression are approaching peak levels. 
 
 
Figure 4.1 - Flow cytometry gating strategy for analysis and/or isolation of proliferating and non-
proliferating post-CL VSMCs for scRNA-seq. 
FACS gates used to analyse and isolate Myh11-EYFP+Ki67-RFP+ and Myh11-EYFP+Ki67-RFP- VSMCs. 
Example gating strategy is shown where events were gated for cells using forward and side scatter (a, 
FSC and SSC) and as single cells using forward scatter area or width (b, FSC-A and FSC-W). Single cells 
were then gated for Myh11-EYFP and Ki67-RFP expression (c-d) using wild type cells (negative control) 
and Myh11-CreERt2/Rosa26-EYFP/Ki67-RFP spleen cells (Ki67-RFP positive control). (c-d) show a left 














Expression of Sca1 by 
anti-Sca1-APC and 






EYFP left carotid no 
surgery controls or 
post-CL. a-b) FACS plots showing Sca1 (Sca1-APC, y axis) against lineage label expression (Myh11-EYFP, 
x axis) in dissociated VSMCs from a no surgery control (a) or at 8 days post-CL (b). Input events for 
single cells were gated as in Figure 4.1. Myh11-EYFP gating was set using wild type control cells and 
Sca1-APC gating was set using anti-IgG-APC stained cells (negative control) and anti-Sca1-APC stained 
adventitial cells (positive control). Labels state the percentage of cells in each quadrant. c-f) Percentage 
of VSMCs which are Sca1+ (c) or Ki67+ (d), percentage of Sca1+ VSMCs which are also Ki67+ (e) and 
percentage of Ki67+ VSMCs which are also Sca1+ (f) in dissociated VSMCs from no surgery controls 
(black dots, n=5) or at day 8 post-CL (green squares, n=5). Each dot represents a single animal and error 
bars show SEM. For (c) and (d) p=0.0016 by Mann Whitney t-test. g-h) Percentage of Myh11-EYFP+ 
cells which are Sca1+ (g) or Ki67+ (h) in no surgery controls (D0, n=8) or at different timepoints post-
CL (D2-D13, n=3-5). Each dot represents a single animal and error bars show SEM. For Sca1+ VSMCs 
p=0.025 by Kruskal-Wallis test and differences between D0 to other timepoints were significant by 
Mann-Whitney u-test (p<0.02). For Ki67 VSMCs p=0.0073 by Kruskal-Wallis test and differences D0-D5 
and D8-other timepoints were significant by Mann Whitney u-test (p<0.02 for D0-D8 and p<0.05 for 
others). Figure panels (a) and (b) taken from Dobnikar, Taylor et al., 2018. 
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4.3  Generation and characterisation of scRNA-seq datasets of post-injury VSMCs. 
In order to compare the profiles of proliferating and non-proliferating VSMCs post-injury and identify 
markers of activated VSMCs, VSMCs from Myh11-CreERt2/Rosa26-EYFP/Ki67-RFP were isolated 7 days 
after carotid ligation. Both EYFP+RFP+ and EYFP+RFP- VSMCs were collected for sequencing using a 
strategy to enrich for EYFP+RFP+ VSMCs and single cell profiles for 1335 cells were generated using 
the 10X Chromium system (see methods for details). After quality control filtering to remove cells with 
<5,000 UMIs, <2,000 genes or >5% of reads mapping to mitochondrial genes, the dataset encompassed 
955 cells, with a mean of 249,241 reads and 3,349 genes per cell (Figure 4.3). However, even following 
this filtering, it was clear that the remaining cells still had a large range in numbers of UMIs and genes 
sequenced (Figure 4.3b-c), which was to be expected due to the analysis covering a mixture of 
quiescent and activated cells with lower and higher transcriptional activity respectively. Moreover, the 
10X Chromium system uses a high gel bead to cell ratio to reduce the likelihood of multiple cells being 
captured in one bead (Wang et al., 2019). In an experiment profiling a similar number of cells as used 
here (1012 cells recovered), authors Zheng et al. achieved a multiplet rate of 1.9% (Zheng et al., 2017). 
This means that we could expect a possible 21 cells to be multiplets within our data, which is much 
below the numbers of VSMCs sequenced with high numbers of UMIs and genes (Figures 4.3b-c), 
indicating that these increases are more likely to be due to VSMC activation from quiescence than 
multiplet contamination. 
 
The clusters showing high transcriptional activity (clusters 1, 4, 5 and 8, Figures 4.3a) also showed gene 
expression changes associated with the activation of VSMCs in atherosclerosis. Firstly, they showed 
reductions in contractile marker expression, such as Myh11 (Figure 4.4a) and activation of synthetic 
VSMC genes, such as Spp1 (Figure 4.4b), which increases VSMC proliferation, migration and 
atherosclerosis development (Gadeau et al., 1993; Matsui et al., 2003; Yue et al., 1994). These clusters 
also showed activation of expression of inflammatory markers, such as Ccl2 (or Mcp-1, Figure 4.4c), 
which is strongly linked to atherosclerosis development (Aiello et al., 1999). Finally, these clusters 
expressed higher levels of the cVSMCneg gene signature found in healthy Sca1+VSMCs and 
correspondingly lower levels of cVSMCpos (Figures 4.4d-e) signatures defined by Dr Lina Dobnikar, see 






Figure 4.3 - 10X scRNA-seq of VSMCs at day 7 post-CL showed a range in expression level 
parameters used for quality control. 
a) tSNE visualisation of 10X scRNA-seq data clusters of FACS-isolated VSMCs 7 days after carotid 
ligation surgery, following removal of low-quality cells (removing cells with <5,000 UMIs, <2,000 genes 
or >5% of reads mapping to mitochondrial genes). Cells from tamoxifen-labelled Myh11-
CreERt2/Rosa26-EYFP/Ki67-RFP were sorted as EYFP+RFP- and EYFP+RFP+ as in Figure 4.1 and each 
cell is shown as an individual dot. b-d) tSNE (i) or violin plot visualisations (ii) of the data from (a) 
showing the number of genes (b), number of UMIs (c) and percentage of reads mapping to 
mitochondrial genes (c) for each cell. tSNE plots in (i) show these parameters on a scale from grey to 

























































































































































































































































































































































































In addition to the activation of atherosclerosis and inflammation associated genes, clusters 1, 5 and 8 
also expressed Sca1, clusters 5 and 8 expressed early activation marker Ccnd1(Figures 4.4f-g) and 
cluster 8 expressed Ki67 (Figure 4.4h). There was an overlap in Sca1+, Ccnd1+ and Ki67+ cells (Figure 
4.5), though the frequency of these cells could not be used to reflect on their relative number in vivo 
as the dataset was specifically enriched for EYFP+RFP+ proliferating cells. Also, scRNA-seq suffers from 
a high number of dropouts, whereby mRNA transcripts are not detected due to low amounts of mRNA 
in each cell. This is particularly problematic when considering lowly expressed genes and using high-
throughput protocols with a low read depth, such as the 10X system used here (Li and Li, 2018). Despite 
these caveats, the data did identify Sca1+Myh11+ cells (Figure 4.5), indicating that Sca1 expression can 
be switched on prior to a loss of a contractile phenotype, as seen in healthy arteries (Chapter 3). There 
was also an overlap between the expression domains of Sca1+ and Ki67+ cells, indicating that Sca1 can 
be expressed during proliferation. Moreover, dropouts of Myh11 transcripts are less likely in the data, 
due to its very high transcriptional rate in contractile VSMCs, thus the presence of Sca1+Myh11-Ki67+ 
cells (Figure 4.5) suggested that Sca1 expression can persist in Myh11-, proliferating VSMCs.  
 
 
Figure 4.4 - Expression of Sca1 overlapped with cell cycle genes in CL 10X scRNA-seq data. 
Venn diagrams showing the overlap between Sca1 (green, n=121), Ccnd1 (blue, n=86) and Ki67 
(orange, n=86) cells from the CL 10X scRNA-seq dataset. Values indicate the numbers of cells in each 





To provide more information on the overlap of Sca1, Myh11 and Ki67-expressing VSMCs, two further 
scRNA-seq experiments were performed from Myh11-CreERt2/Rosa26-EYFP/Ki67-RFP animals at day 
7 post-CL using the Smart-seq2 method. This method also suffers from drop-out events, but at a lower 
rate than other scRNA-seq methods (Ziegenhain et al., 2017), including the 10X system (Wang et al., 
2019), and also provides higher read depth, full length transcript coverage and the ability to index sort 
cells to compare their transcriptional signature and flow cytometry profile. Exploiting the latter, non-
ligated EYFP+ VSMCs were also included, to provide a healthy reference VSMC population. The 
resulting sequencing data was filtered to remove cells with <200,000 total reads, <1,000 genes or >30% 
of ERCC controls (performed by Dr Lina Dobnikar), producing datasets with 83 or 81 cells, a mean of 
1.12 and 1.32 million reads and 3,879 and 3,019 genes per cell for batches 1 and 2 respectively. 
Importantly, analysis of flow cytometry parameters demonstrated similar forward scatter (indicative 
of size) of Sca1+ VSMCs and EYFP+RFP+ VSMCs from CL when compared to Sca1- or non-ligated VSMCs 
(Figure 4.6a-b), validating that these expression patterns were not due to the sorting of doublets. 
There was a small increase observed in side scatter for both Sca1+ and EYFP+RFP+ populations, which 
may reflect a higher nuclear, endoplasmic reticulum or other organelle content as a result of cell 
activation (Figure 4.6c-d). An increase in granularity has previously been observed for VSMCs in culture 













Figure 4.5 - VSMCs from proliferating and Sca1+ VSMCs at day 8 post-CL showed increased 
granularity, but no change in size, when compared to non-proliferating or Sca1- VSMCs. 
Light scattering of dissociated VSMCs isolated from tamoxifen-labelled Myh11-CreERt2/Rosa26-EYFP 
left carotid no surgery controls or at 8 days post-CL, each dot representing a single cell. Plots show 
forward scatter (a-b, area FSC-A vs width FSC-W) and side scatter (c-d, SSC) for Sca1+ (green dots in (a) 
and (c), n=64) and Sca1- (black dots in (a) and (c), n=84) VSMCs sorted as Myh11-EYFP+ (non-ligated, 
black dots in (b) and (d), n=33), Myh11-EYFP+Ki67-RFP- (CL, green dots in (b) and (d), n=37) and Myh11-
EYFP+Ki67-RFP+ (CL, red dots in (b) and (d), n=78). 
 
In this high coverage dataset a higher frequency of co-expression was observed, such that fewer cells 
expressed only Sca1 or Ccnd1 (Figure 4.7, 32% and 12% respectively vs 50% and 40% in the 10X data), 
producing a larger proportion of cells which were Sca1+Ccnd1+ (53% of total Sca1+ cells and 59% of 
total Ccnd1+ vs 21% and 30% in the 10X data). There was also an increase in the proportion of Sca1+ 
cells that were Ki67+ (21% vs 7% in the 10X data). Both observations again suggest that Sca1+ cells are 






Figure 4.6 - Expression of Sca1 overlapped with cell cycle genes in CL Smart-seq2 scRNA-seq data. 
Venn diagrams showing the overlap between Sca1 (green, n=19), Ccnd1 (blue, n=17) and Ki67 (orange, 
n=54) cells from the CL Smart-seq2 scRNA-seq dataset. Values indicate the numbers of cells in each 
population. In addition to the values shown, 2 Sca1+ cells, 1 Ccnd1+ and 5 Ki67+ cells were also 
Myh11+. 
 
To compare the expression patterns of post-CL VSMCs from both methods, the 10X and two batches 
of Smart-seq2 data were integrated (Figure 4.8) using an anchoring strategy developed by Stuart et 
al., which identifies connections between single cells in each dataset and uses these so-called ‘anchors’ 
to build a reference, providing a basis for transfer-learning to map the non-anchor cells (Raina et al., 
2007; Stein-O’Brien et al., 2019; Stuart et al., 2019). Visualising the raw number of UMI counts for 10X 
and read counts for Smart-seq2 in each dataset prior to integration showed significantly higher values 
in the Smart-seq2 data, as expected due to its higher read depth (Figure 4.8bi). These differences were 
eliminated post-integration, demonstrating normalisation of the read counts, allowing for comparison 
of their relative gene expression levels (Figure 4.8bii). The identities of VSMCs sequenced by Smart-
seq2 were then mapped back onto this merged dataset, using their flow cytometry profiles (Figure 4.9) 
to inform the interpretation of the 10X data. This analysis mapped non-ligated (NL) VSMCs exclusively 
to Myh11-high (0, 2 and 4) and Myh11-mid (5 and 6) expressing clusters, which also contained post-
CL, non-proliferating (CLNP) VSMCs. Additionally, CLNP VSMCs were found in Myh11-mid cluster 3 and 
Myh11-low cluster 1. Of post-CL, proliferating (CLP) VSMCs, the highest contribution of cells was to 
Ki67+ cluster 8, confirming that the observed Ki67 transcripts matched its protein expression. In total, 
81% of proliferating CL VSMCs mapped to Myh11-low clusters 1, 7 and 8, with the remaining 19% 
mapping to Myh11-high cluster 2 and Myh11-mid clusters 3, 5 and 6. Taken together, the Smart-seq2-
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profiled VSMCs confirmed that the Myh11-high clusters in the 10X dataset corresponded to non-





Figure 4.7 - Integration of post-CL scRNA-seq datasets from two platforms to produce a merged CL 
VSMC dataset. 
a) tSNE plot visualisation of a merged dataset showing the contribution of cells from the 10X (left) and 
the Smart-seq2 datasets (right) of day 8 post-CL VSMCs to each cluster. b) Violin plot visualisations of 
count numbers in each dataset before (i) and after (ii) integration, showing data from the 10X (left, 




























































































































































































































































































































































In order to identify genes involved in VSMC activation, I used tobit regression to identify cluster-specific 
markers in the CL scRNA-seq data (Tobin, 1958), specifying a minimum log2FC in expression between 
clusters of 0.25 and a minimum of 50% of cells in the cluster expressing the marker. However, when 
the expression of each identified marker was show in a tSNE visualisation across the whole dataset, 
each showed a lack of discrete cluster specific expression. Instead each so-called marker gene was 
expressed over a range of clusters (Figure 4.10). A heatmap of the top 20 genes positively associated 
with each cluster also showed overlapping expression patterns, with similarities between neighbouring 
clusters (Figure 4.11). These observations suggest that selective VSMC activation in CL injury is not 
reflected by discrete expression patterns in a subset of cells, but instead a spectrum of responsiveness 




Figure 4.9 - Cluster markers in the CL 10X scRNA-seq dataset showed a range in expression, 
appearing to mark cells across a number of clusters. 
tSNE visualisation of CL 10X scRNA-seq data from Figure 4.3, showing data clustering (a) and expression 
of Dstn (b), Col15a1 (c) and Mgp (d). These markers were defined as specific to clusters 2, 4 and 0 





Figure 4.10 - Cluster-specific markers in the CL 10X scRNA-seq dataset showed an overlap in 
expression between neighbouring clusters from the tSNE visualisation. 
a) tSNE visualisation as in Figure 4.10a with indication of cluster numbers. b) Heatmap showing 
expression of the top 20 genes which showed the highest positive association with each cluster as 
determined by tobit regression. Expression is shown on a scale from purple to yellow, with each row 
representing a single gene and each column a single cell. Cells are grouped by cluster, which in turn 




4.4  Identification of candidate regulators of VSMC activation following injury. 
 
Prompted by the lack of cluster-specific markers in the CL 10X scRNA-seq dataset, I next used a 
trajectory analysis to determine if the VSMCs could be aligned to show a spectrum of gene expression 
changes. Using an unsupervised algorithm designed to map differentiation trajectories (Trapnell et al., 
2014), the similarity in transcription between VSMCs was determined and used to map them in 
pseudo-time. Interestingly, despite the ability of the algorithm to map branch points and multiple cell 
fates, this produced a single trajectory, which correlated with the localisation of neighbouring clusters 
in their corresponding tSNE visualisations (Figure 4.12a-b). Interestingly, the trajectory produced 
showed Myh11 downregulation across pseudo-time, concordant with activation of Spp1, Ccl2, Ly6a, 







Figure 4.11 - Mapping of an unbiased trajectory using the CL 10X scRNA-seq dataset demonstrated 
activation of Sca1 and Ki67 over pseudo-time, concordant with Myh11 downregulation. 
a) trajectory (i) and tSNE (ii) visualisations of clusters in the CL 10X scRNA-seq dataset, defined by the 
monocle trajectory software. Each dot represents a single cell, coloured by cluster assignment. b-g) 
Relative expression level (y-axis) of contractile VSMC marker Myh11 (b), marker of phenotypic 
switching Spp1 (c), inflammatory cytokine Ccl2 (d), Sca1 (e) and proliferation markers Ccnd1 (f) and 
Ki67 (g) over the trajectory pseudo-time  
(x-axis). Each dot represents a single cell, coloured by cluster assignment and lines show the average 
level of expression across the pseudo-time. 
 
Pathway analysis of genes with significant differential expression across pseudo-time (p<0.05) was 
next conducted to determine the relevance of the constructed trajectory to VSMC activation, 
annotating the gene list for enrichment of Gene Ontology biological processes (Ashburner et al., 2000; 
Yu et al., 2012). This demonstrated significant enrichment for genes involved in muscle cell processes 
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and development, as well as regulation of ECM organisation, angiogenesis and proliferation (Figure 
4.13). Further analysis using the KEGG pathway database (Kanehisa et al., 2010) and the DAVID 
knowledgebase (Huang et al., 2009) also identified enrichment for pathways established to play a role 
in VSMC proliferation in disease, such as Foxo (Abid et al., 2005) and TNF (Davis et al., 2012) signalling 
(appendix 5). These findings indicate that the trajectory generated using a non-biased algorithm show 
meaningful gene expression changes related to VSMC activation. The upregulation of Sca1, Ccnd1 and 
Mki67 expression at the opposite end to Myh11-high cells again therefore indicates that Sca1 
expression is a feature of VSMC activation and proliferation in CL, similar to the observations made 
during in vitro phenotypic switching and HFD-induced plaque development (Figures 3.9 and 3.11). 
Furthermore, the single linear trajectory suggests that this response occurs to some extent in many 
VSMCs, not just a proliferative subset, which is in agreement with the expression of Sca1 in non-Ki67+ 
VSMCs by flow cytometry and scRNA-seq (Figures 4.2 and 4.4). 
 
 
Figure 4.12 - Pathway analysis of genes with pseudo-temporal expression showed enrichment for 
pathways relevant to VSMC activation. 
Bubble plot of selected GO terms from those enriched in genes determined to have pseudo-temporal 
expression in the CL 10X scRNA-seq trajectory. Dot colour shows adjusted p value on a scale from dark 
blue to light blue, size shows the number of genes in each term and x-axis value shows the number of 




In order to identify candidate regulators of VSMC activation, the list of genes with pseudo-temporal 
expression patterns was filtered to select those most closely associated with Sca1 and Ki67 expression 
after injury (filtering steps shown in Figure 4.14). For this, the genes were clustered by shared pseudo-
temporal expression and heatmaps of expression across pseudo-time were inspected to manually 
identify those associated with Sca1 and Ki67 activation. In particular, those which were upregulated 
only within the 50% of the pseudotime not including Sca1 and Ki67 were removed (e.g. Ctnnd2 in 
cluster 5 of the heatmap in Figure 4.14 were removed). Next, the remaining genes were prioritised by 
Sca1/Ki67 associated expression in both the CL injury and a healthy dataset of Confetti+ VSMCs. 
Specifically, genes were ranked by the differences in average expression in Sca1- or Ki67- cells vs Sca1+ 
or Ki67+ cells in both datasets, producing a list of 41 genes with a difference >0.25. Finally, expression 
of these genes in the post-HFD VSMC scRNA-seq datasets was interrogated, in order to choose 
candidates with shared activation across the two injury models and a literature search conducted to 







Figure 4.13 - Strategy for candidate gene selection from the CL 10X scRNA-seq dataset. 
a) Filtering steps used for selection of candidate regulators. Cells in the CL 10X scRNA-seq dataset were 
assessed for transcriptional similarity and used to construct a trajectory of VSMC activation. Analysis 
of the association between each gene’s expression and the trajectory pseudo-time identified 3754 
genes with pseudo-temporal specific expression, which were enriched for VSMC-related GO terms by 
pathway analysis. Genes were clustered by shared pseudo-temporal expression patterns and heatmap 
plots used to manually include clusters with high expression and activation at a similar pseudo-time to 
Sca1 and Ki67. Genes were then prioritised according to comparisons in expression between the CL, 
healthy and HFD VSMC scRNA-seq datasets and by searching the literature for prior association with 
VSMC phenotypic switching and/or cardiovascular disease. b) Heatmap showing expression of example 
genes clustered by pseudo-temporal expression patterns. Each row represents one gene and each 





Several of the top candidates had links to cardiovascular disease; in particular I focused on four: Timp-
1, an inhibitor of metalloproteinases, which is high expressed in human plaques when compared to 
healthy controls (Orbe et al., 2003); Fbln2, which has been suggested as a biomarker for atherosclerosis 
(Liu et al., 2016), Angptl4, which has a coding variant associated with coronary artery disease (Folsom 
et al., 2008; Stitziel et al., 2016) and Gdf6 (Bmp13), a TGFβ-related protein whose CpG 
hypomethylation was shown to be associated with atherosclerosis (Yamada et al., 2018). However, 
precise roles for these genes in VSMCs and/or selective clonal proliferation are unknown. Expression 
of Angptl4, Fbln2 and Gdf6 overlapped with Myh11-low clusters in both CL and HFD scRNA-seq 
datasets; this is shown in a merged dataset of healthy, post-CL and post-HFD VSMC scRNA-seq data 
(clusters 6 and 11 in Figures 4.16-4.17, constructed using the same method as in Figure 4.8). These 
clusters were also both positive for Sca1 and Ccnd1 and cluster 11 expressed Ki67. Timp1 showed more 
widespread activation, also detected in Myh11-low Sca1+ cluster 14 and Myh11-high clusters 10 and 
12 (Figure 4.15). 
 
To further assess the relevance of the four candidate regulators in disease, their expression was 
interrogated in a recently published scRNA-seq dataset from atherosclerotic human right carotid 
arteries. In this work, the authors identified a VSMC-like modulated cell population termed 
‘fibromyocytes’, distinguishable by down-regulation of VSMC contractile marker CNN1 and up-
regulation of FN1, TNFRSF11B and LUM (Wirka et al., 2019). Using their dataset, I saw fibromyocyte 
gene expression in clusters 5, 6, 9, 13 and 15 (note that TNFRSF11B is lower in clusters 5 and 6, which 
is similar to its expression only in some fibromyocyte clusters in the Wirka et al., 2019). These clusters 
were also positive for expression of the identified candidate regulators of VSMC phenotype (Figure 
4.17) ANGPTL4 (clusters 5, 6, 13 and 15), TIMP1 (cluster 5 and 6), FBLN2 (clusters 5, 6 and 15) and 
GDF6 (clusters 5, 6, 9 and 13), indicating that these genes may be relevant to human disease. 
Therefore, these genes may provide a means to investigate mechanisms of VSMC activation in both 
















Figure 4.14 - Marker gene expression in a merged VSMC dataset, integrated from five individual 
scRNA-seq datasets. 
a) tSNE plot visualisation of a merged dataset constructed by integration of five individual scRNA-seq 
datasets using the methodology described above (see Figure 4.8). Plots show contributions from 10X 
datasets of scRNA-seq from sorted healthy VSMCs (second from left) or at day 8 post-CL (left) or ApoE-
/- animals after 14 (middle) or 18 (second from right) weeks of HFD and two batches of Smart-seq2 
scRNA-seq from sorted VSMCs at day 8 post-CL (right). b-j) tSNE (i) and violin plot (ii) visualisations of 
the merged VSMC scRNA-seq dataset. Data shows expression of contractile VSMC marker Myh11 (b), 
marker of phenotypic switching Spp1 (c), Sca1 (d), cell cycle genes Ccnd1 (e) and Mki67 (f), phagocytic 







Figure 4.15 - Expression of candidate markers of selective VSMC activation in the merged VSMC 
dataset. 
tSNE (i) and violin plot (ii) visualisations of the merged VSMC dataset showing expression of contractile 
VSMC marker Myh11 (a) and candidate markers of selective VSMC activation Timp1 (b), Fbln2 (c), 

































































































































































































































































































































































































Further relevance to disease was tested by immunostaining of atherosclerotic plaque sections from 
human and mouse to determine if the expression of candidates could be seen at the protein level in 
diseased samples. Using aortic cryosections from Myh11-CreERt2/Rosa26-EYFP lineage traced mice 
fed a HFD for 24 weeks, Fbln2+EYFP+ VSMCs were identified in a subset of VSMCs in all regions of 
atherosclerotic plaques, particularly in the core (average of 2%, 6% and 1% of total EYFP+ VSMCs in 
the cap, core and shoulder respectively, Figures 4.18, 4.19 and 4.20a). Fbln2+EYFP+ cells were also 
detected in the medial layer underlying plaques, in regions where the elastic lamina was broken and 
cells had adopted a disordered structure (Figure 4.18d). Interestingly, Fbln2+EYFP+ cells from all 
regions were negative for aSMA (Figure 4.18c-d and 4.19c), despite a large proportion of YFP+ plaque 
cells retaining aSMA expression (average of 79%, 10% and 11% of total EYFP+ VSMCs in the cap, core 
and shoulder respectively, Figure 4.20b). This fits with a loss of a contractile VSMC phenotype in 
























Figure 4.17 - Lineage traced plaque VSMCs stain positively for candidate marker Fbln2. 
Confocal images of aortic cryosections from tamoxifen-labelled Myh11-CreERt2/Rosa26-EYFP animals 
fed a HFD for 24 weeks and stained with anti-aSMA (red) and anti-Fbln2 or isotype control (magenta) 
antibodies. Scale bars are 200 µm (a-b) or 20 µm (c-d). a-b) Maximum projections of cryosections 
stained with anti-aSMA (a, red) and anti-Fbln2 (a, magenta) or anti-IgG controls (b, red and magenta). 
c-d) Single scan images showing magnifications of boxed regions in (a-b), ci-iii show white box in plaque 
cap region from (a), civ white box from (b), di-iii show blue box in medial region from (a), div blue box 
from (b). Images show Myh11-EYFP (yellow), elastic lamina autofluorescence (green) and antibody 








Figure 4.19 - Lineage traced plaque VSMCs which have lost aSMA expression stain positively for 
candidate marker Fbln2. 
Confocal images of aortic cryosections from tamoxifen-labelled Myh11-CreERt2/Rosa26-EYFP animals 
fed a HFD for 24 weeks and stained with anti-aSMA (red) and anti-Fbln2 or isotype control (magenta) 
antibodies. Scale bars are 200 µm (a-b) or 20 µm (c). a-b) Maximum projections of cryosections stained 
with anti-Fbln2 (e, magenta) or anti-IgG control (f, magenta). c) Single scan images showing 
magnifications of boxed plaque core regions in (a-b), ci-iii show blue box from (e), civ blue box from 
(b). Images show Myh11-EYFP (yellow), DAPI nuclear stain (white), elastic lamina autofluorescence (EL, 











Figure 4.20 - Percentage of Fbln2+ and aSMA+ VSMCs in HFD-induced plaques. 
Aortic cryosections from tamoxifen-labelled Myh11-CreERt2/Rosa26-EYFP animals fed a HFD for 24 
weeks were stained with anti-Fbln2 and anti-aSMA antibodies. Plots show the average percentage of 
EYFP+ cells which were Fbln2+ (a) or aSMA+ (b) in cap (left, circles), core (middle, squares) or shoulder 
(right, triangle) regions of plaques from 3 animals. Each dot represents the average percentage from 
an individual animal and 6 plaques were analysed in total, 2 from each of the AA, DT and carotid 
regions. Differences between the regions were non-significant. 
 
Using sections from human patients undergoing carotid endarterectomy or coronary artery 
bypass/valve replacement, heterogeneous expression of TIMP1, GDF6 and ANGPTL4 could be seen in 
the aortic medial layer (TIMP1 n=3/3, GDF6 n=2/3 and ANGPTL4 n=4/4 samples analysed) and carotid 
plaques (Figure 4.21, TIMP1 n=4/4, GDF6 n=4/4 and ANGPTL4 n=4/5 samples analysed). For FBLN2, 
there was much less expression within the aortic media (1/3 samples analysed), but high plaque 
expression (4/4 plaques analysed). Moreover, co-staining for aSMA identified aSMA+ANGPTL4+ aortic 
medial cells (Figure 4.22a, 2/4 samples analysed) and aSMA+FBLN2+ carotid plaque cells (Figure 4.22b, 
4/5 samples analysed). Taken together with the human scRNA-seq data, this provides further evidence 




Figure 4.21 - Human plaque cells show heterogeneous expression of candidate markers for VSMC 
activation. 
Paraffin sections of human atherosclerotic carotid tissue stained with isotype control (i), anti-Timp1 
(aii-iii) or anti-Gdf6 (bii-iii) antibody. Antibody staining is shown in brown, with nuclear staining in blue 
and images in (iii) show a magnified image of those in (ii). Images are labelled to show the medial layer 






































































































































































































































































4.5 Summary and discussion of findings from chapter 
4.5.1  Induction of Sca1 expression in VSMCs post-CL. 
This work demonstrated expression of Sca1 in VSMCs with reduced levels of contractile genes and 
expression of ‘activated’ genes, suggestive that it is induced in activated VSMCs post-CL injury (Figures 
4.2a-c), similarly to during phenotypic switching in vitro and in in vivo HFD-induced plaques (chapters 
3.4-3.5). In agreement with this, Sca1+ VSMCs in this model also showed higher transcription levels 
(Figure 4.3) and activation of genes associated with phenotypic switching and inflammation, such as 
Spp1 and Ccl2 (Figure 4.4). Similar expression patterns have been seen in VSMCs post-CL previously by 
microarray, demonstrating Spp1 and Ccl2 to be highly upregulated genes (Herring et al., 2017); 
however, this analysis was within a bulk population sample and did not identify selective upregulation 
of these genes by a subset of VSMCs.  
 
Sca1 was expressed in Ccnd1+ and Ki67+ VSMCs in both 10X and Smart-seq2 CL datasets, despite the 
likelihood of dropout events (Figures 4.5 and 4.7). The use of Smart-seq2 scRNA-seq of index-sorted 
VSMCs allowed for confirmation that Sca1+ cells also positive for Ccnd1 or Ki67 were not the result of 
doublet contamination and that detection of the Mki67 transcript correlated with expression of the 
Ki67-RFP reporter (Figures 4.6 and 4.9e/h). The higher co-expression of Sca1 and Ccnd1 than Sca1 and 
Ki67 may reflect upregulation of Sca1 in VSMCs at the onset of proliferation (marked by expression of 
the G1-S marker CyclinD1) and that Sca1 expression is downregulated at later stages of the cell cycle 
that have high Ki67 levels (Sobecki et al., 2017). The expression of other cell cycle regulators is also in 
agreement with this hypothesis. For example, both Ki67 and Ccna1 are lowly expressed during the G1 
phase of the cell cycle, becoming activated in S phase (Miller et al., 2018; Resnitzky et al., 1995), 
whereas Ccnd1 is G2 and G1 restricted, being degraded upon S phase initiation (Stacey, 2003). 
Appropriately, Ccna2 expression correlates with Ki67 and not Ccnd1 (data not shown), which is 
consistent with G1 entry by formerly quiescent cells, becoming Ccnd1+Sca1+ before proceeding to 
Ccna2+Ki67+ in S phase. Again, these conclusions carry the caveat that the low efficiency of scRNA-seq 
may mask detection of more lowly expressed genes. 
 
In addition to an association with cell activation or proliferation, the expression of Sca1 may also 
represent a distinct de-differentiated state of activated VSMCs, in line with its characterisation as a 
stem cell marker. Accordingly, Sca1 is lost in HFD clusters with high expression of phagocytic or 
chondrocytic markers Cd68 and Sox9, suggestive that these cells may have to trans-differentiated to a 




Interestingly, Sca1+ VSMCs also shared transcriptional signatures seen in healthy Sca1+ VSMCs (Figure 
4.4f-g), suggesting that the two may be analogous. It is therefore possible that these Sca1+ VSMCs 
from healthy vessels represent a partially activated or primed subset within the healthy population, 
which may be predisposed to become activated or proliferative. Indeed, Sca1 appears to be an early 
marker of VSMC activation, showing evidence of induction from day 2 post-injury (Figure 4.2e). 
Moreover, previous work by Fitzpatrick et al., 2017 has shown Sca1+ is expressed in CL-induced 
neointimal cells, however using the Sca1-GFP reporter animal and only partial CL (Fitzpatrick et al., 
2017). The authors reported Sca1+aSMA- neointimal cell populations, but the origin of these cells was 
not further resolved. It has also long been speculated that a spectrum of phenotypic plasticity may 
exist in distinct VSMC populations, in which epigenetic regulation confers a limited boundary of 
modulation in each cell (Rensen et al., 2007). As such, each cell may have a limited ability to progress 
to being Sca1+, Myh11-, proliferative and/or further phenotypically modulated. The trajectory defined 
here shows Sca1 activation prior to that of Ccnd1 and then Ki67, with the progressive loss of Myh11 
from a point before Sca1 activation (Figure 4.12). This single, linear trajectory suggests that responses 
occur to some extent in many VSMCs, but only a subset progress to proliferation. Although no 
trajectory of VSMC activation has been shown previously, a similar activation trajectory for 
atherosclerotic plaque macrophages was recently suggested using scRNA-seq of Cx3cr1-lineage traced 
macrophages at 18 weeks of HFD (Lin et al., 2019). In this work, the authors showed contiguous cell 
clusters, which could be mapped into a spectrum of activation and included a small subset which were 
proliferative. Interestingly, the trajectory also showed a significant increase in Sca1 expression with 
plaque progression (Lin et al., 2019), indicating that it may be a feature of activation of multiple cell 
types. 
4.5.2 Identification of proposed candidate regulators of VSMC activation. 
Using the trajectory defined with CL scRNA-seq data in Figure 4.12 and comparison to other scRNA-
seq datasets and published literature, four candidate regulators of VSMC activation were identified. 
Of these, Timp1 is the highest explored in the context of atherosclerosis and has been demonstrated 
to be expressed in human atherosclerotic plaques (Orbe et al., 2003).  Additionally, ApoE-/- mice 
deficient in Timp1 expression show reduced plaque VSMC numbers and decreased plaque size after 
HFD feeding (Gregoli et al., 2016). Timp1 has also been studied in the context of vein grafting, whereby 
global Timp1 over-expression caused reduced lesion size and increased VSMC content (Vries et al., 
2012). These results are in agreement with a role of Timp1 in VSMC activation and indicate that its 
expression may be beneficial to plaque stability.  
 
Fbln2 has been suggested as a biomarker for atherosclerosis (Liu et al., 2016) and has been shown to 
be differentially expressed in human acute aortic dissection when compared to healthy controls 
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(Mohamed et al., 2009). Interestingly, it is expressed by developing AA VSMCs (Tsuda et al., 2001), but 
is dispensable during mouse development  (Sicot et al., 2008), perhaps due to compensation by 
another fibulin. In agreement, a single Fbln2 knock-out did not alter neointimal formation at day 28 
post-CL, but a double knock-out with Fbln5 reduced neointimal formation significantly (Chapman et 
al., 2010). In vitro Fbln2 is induced in VSMC phenotypic switching and blocking its interaction with ECM 
component versican inhibited SMC migration (Ström et al., 2006). Thus, Fbln2 may have direct roles in 
VSMC function post-injury. In the HFD-derived scRNA-seq data, Fbln2 had limited expression, 
associated with Sca1+Ccnd1+ clusters, but not those which were Ki67+ or Sox9+ (Figures 4.15-6). The 
expression of Fbln2 in aSMA- VSMC-derived plaque cells further links Fbln2 to the non-contractile, 
activated phenotype (Figures 4.18-19). It is possible that the moderate expression observed in plaques 
is due to the late stage of analysed lesions (24 weeks of HFD), where Fbln2 might have been 
downregulated. 
 
Angptl4 is increased in lipid-loaded macrophages (Aryal et al., 2016), airway SMCs in lung injury 
(Stapleton et al., 2010) and human CD68+ plaque cells (Georgiadi et al., 2013). It is induced by hypoxia 
in human MSCs and chondrocytes (Fink et al., 2004; Murata et al., 2009) and genetic Angptl4 variants 
are associated with coronary artery disease (Folsom et al., 2008; Stitziel et al., 2016), triglyceride levels 
(van Leeuwen et al., 2016) and large artery atherosclerotic stroke (He et al., 2016). Moreover, Angptl4 
is induced in wound healing responses to interact with ECM components and ablation of Angptl4 in 
keratinocytes reduced cell migration (Goh et al., 2010). Conversely, global Angptl4 over-expression in 
ApoE*3 Leiden mice reduced total lesion area and did not alter VSMC plaque content by aSMA staining 
(Georgiadi et al., 2013). This suggests that Angptl4 may be a non-functional marker of VSMC activation; 
however, the Angptl4 over-expression also reduced macrophage plaque-investment, which may be a 
pre-requisite for VSMC infiltration. Similarly to Fbln2, Angptl4 is associated with Sca1+Ccnd1+ clusters 
in the scRNA-seq data presented here and is also expressed in Sox9+ cells (Figures 4.15-4.16). 
 
Finally, Gdf6 has been shown to be hypomethylated in atherosclerosis (Yamada et al., 2018) and 
required for EC barrier function through inhibition of VEGF (Krispin et al., 2018, p. 6). The latter study 
suggests a role in vascular quiescence; thus, it is possible that it is secreted by VSMCs to prevent further 
EC breakdown. In melanoma Gdf6 functions to repress melanocyte differentiation and Sox9 
expression, correlating with an aggressive phenotype of poor prognosis (Venkatesan et al., 2018). It is 
therefore interesting to speculate that Gdf6 may play a similar role in activated VSMCs, to prevent 
differentiation to a Sox9+ state. Accordingly, in scRNA-seq data here Gdf6 expression is absent in Sox9+ 
cells and maps strictly to Sca1+Ccnd1+ clusters (Figure 4.15-4.16). Gdf6 expression is highly Sca1-




Each candidate was expressed in clusters of activated VSMC in both HFD plaque and CL injury models, 
which implies a consistent, non-context-dependent mechanism of their activation. This is in agreement 
with the similar clonal VSMC expansion in each model (Chappell et al., 2016), which therefore may 
occur by a shared mechanism. Furthermore, expression of candidate regulators was heterogeneous 
within human and mouse plaques (Figures 4.15-4.17), showing that their activation is non-uniform in 
VSMC or plaque cell populations, and may therefore play a role in the selective VSMC response. 
Candidates were also expressed in human ’fibromyocyte’ clusters (Figure 4.17), observed in VSMC-
derived cells during atherosclerosis (Wirka et al., 2019). Mouse models of atherosclerosis differ 
significantly to human neointima and plaque formation (Lee et al., 2017b), thus the identification of 



























Chapter 5 Development of a lineage traced in vitro model to investigate 
VSMC clonal expansion. 
5.1 Introduction. 
Advances in scRNA-seq techniques have enabled generation of large transcriptomic datasets that can 
be readily queried to identify candidate genes regulating cell behaviour and disease. Validating the 
effects of these genes and dissecting their importance in cell function and behaviour, however, relies 
on extensive further experiments. To assess the impact of candidate genes on VSMC clonal expansion 
in vivo would require carotid ligation surgery or high fat diet feeding of lineage traced animals with 
and without an intervention to alter the expression of the gene. As such, screening of many 
differentially expressed genes identified by scRNA-seq in vivo cannot be justified due to resource, time 
and ethical considerations. Alternatively, a screening process may be carried out in silico, comparing 
differentially expressed gene sets to gene ontology terms, previous literature and other datasets, such 
as genome wide association studies. Much of this in silico analysis, however, is based on prior work 
and limits the ability to identify novel regulators. 
 
To address the lack of higher-throughput, more inexpensive models that allow for screening of 
candidate gene effects on VSMC clonal expansion, I sought to develop an in vitro system using lineage 
traced primary VSMCs. Conventional in vitro investigations into VSMC behaviour often use sub-
cultured cells; for example, to determine proliferation and migration rates. A limiting factor in the 
ability to assess VSMC behaviour in this way is their propensity to undergo general phenotypic 
switching, becoming non-contractile and activating proliferation after 5-7 days of in vitro culture 
(Chamley-Campbell et al., 1979b). This means that cells cultured for more than this time will allow only 
for the dissection of synthetic VSMC behaviours and not the exit from quiescence that could underlie 
the selective clonal expansion seen in vivo. Primary, enzymatically-dissociated VSMCs can overcome 
this issue, as they do undergo phenotypic switching when first placed into culture; however, this is a 
broad activation of all cells, resulting in 60% of VSMCs being in S-phase after 3-5 days post-phenotypic 
switch (Chamley-Campbell et al., 1979b).  
 
Hypothesising that this general induction of proliferation in dissociated cells is due to a loss of contact 
inhibition from interaction with either other VSMCs or the extracellular matrix (ECM), I pursued an 
explant-based in vitro model to maintain these contacts. Explants are small pieces of vascular tissue, 
often with the adventitial and endothelial layers removed, and are widely used to isolate primary 
VSMCs (Sedding and Braun-Dullaeus, 2005). Similarly to dissociated cells in culture, VSMC explants 
undergo phenotypic switching in culture and activate proliferation from day 7-8 (Kokubu and Pollak, 
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1961; McMurray et al., 1991). Aside from VSMC isolation, explants have been used to study the extent 
of proliferation of VSMCs from different vascular regions (Kikuchi et al., 2018), from models of disease 
such as diabetes (Larson and Haudenschild, 1988) and in response to different agents, such as 
heparinase and hyperlipidic serum (McMurray et al., 1991). They have not, however, been combined 
with VSMC-specific lineage tracing nor been used to study clonality in VSMC proliferation. An 
adaptation of explants are aortic rings, which comprise of ring segments of whole aortic tissue 
embedded in a matrix, and are widely used to study EC angiogenesis using supplementation with FGF 
or VEGF (Nicosia, 2009). Although the presence of smooth muscle cells in this model has been noted 
(Baker et al., 2012a), VSMC activation and proliferation in aortic rings has not been studied. Here I 
planned to use VSMC aortic explants in an in vitro system to maintain cell-cell contacts and embed 
them in matrix to maintain cell-ECM contact as in the aortic ring assay. Using Myh11-CreERt2/Rosa26-
Confetti VSMC lineage tracing, I planned to develop this model to track the behaviour of individual 
VSMCs and determine if the selective clonal expansion seen in vivo could be replicated in vitro. 
 
Aims: 
1. Develop an in vitro model of vascular injury using VSMC-specific Confetti lineage tracing to 
study the response of individual cells. The primary requirements for the model were: 
• A small-scale system, allowing multiple conditions or interventions to be tested in 
parallel. 
• Usage of VSMC-specific lineage tracing, to track proliferation of individual cells and 
verify VSMC origin 
• Usage of quiescent cells from healthy arteries and maintenance of cell-cell and cell-
ECM contacts using explants and ECM, to mimic the in vivo conditions as far as possible 
and prevent spontaneous general proliferation.  
2. Assess the ability of the model to replicate the VSMC clonal expansion seen in vivo. 
3. Optimise manipulation of single cell gene expression within the model to investigate the 
effects of candidate genes on VSMC behaviour. 






5.2 Development of a lineage traced in vitro model of VSMC proliferation and optimisation for 
cell viability and fluorescence. 
Initial experiments following published vascular explanting protocols resulted in a widespread loss of 
fluorescent protein activity in Myh11-CreERt2/Rosa26-Confetti tamoxifen-labelled VSMCs, suggestive 
of cell death. These observations led to the use of lineage traced cell fluorescence as an indicator of 
cell viability during model development. In particular, endothelial cell removal by tissue "scraping" 
greatly reduced cell viability and was avoided. Adventitial cells, which are a more proliferative cell type 
than VSMCs and may inhibit smooth muscle cell proliferation (Wolburg-Buchholz et al., 1992), were 
more easily separated from the medial layer after partial enzymatic digestion without affecting VSMC 
fluorescence. 
 
Tissue adherence to culture plates by drying also severely reduced cell viability, whereas tissue 
explants placed directly into culture maintained fluorescent reporter protein expression across the 
tissue. Although the explants could be left to grow in this ‘free-floating’ manner, which has been 
demonstrated to produce outgrowing cells (Fritz et al., 1978), we opted to include an ECM to better 
mimic the environment that VSMCs would contact in vivo. Often specific ECM coatings can induce a 
particular cellular phenotype; for example, Collagen IV can maintain VSMC contractile phenotype, 
whilst plating on monomeric Collagen I causes increased inflammatory VCAM-1 expression (Orr et al., 
2009). Such specific influences on phenotype were undesirable in our assay and instead Corning 
Matrigel, a commercial matrix secreted from mouse sarcoma cells, was chosen for its diversity in 
matrix components. Matrigel promotes a differentiated phenotype in many different cell types, but 
also contains embedded growth factors and induces improved cell outgrowth and responses in aortic 
ring and capillary tube-formation assays (Kleinman and Martin, 2005). I trialled different formats of 
explant embedding in Matrigel (tissue explanting on top of a single layer, embedding in diluted 
Matrigel). The optimal format for maintenance of cell fluorescence and explant structure was 
sandwiching the tissue between two layers of Matrigel (Figure 5.1) as suggested by Baker et al. in 2012 
for the culture of aortic rings, with successful outgrowth of endothelial and VSMC tubules using VEGF 
or FGF2 stimulus (Baker et al., 2012b). In this protocol, the authors favour the use of collagen or fibrin 
for embedding, which created more robust tubules and was more easily imaged at high resolution, but 
acknowledge that Matrigel may better mimic in vivo conditions, producing thinner, spindle-like 
projections. It has also been shown that matrix stiffness alters the phenotype of VSMCs in culture 





Figure 5.1 - Development of an in vitro, lineage traced explant model of VSMC growth. 
Schematic depicting the final format of the explant model, in which the lineage traced (4) aortic tissue 
(1) is stripped of its adventitial layer and pinched with tweezers to create an injury site (5). It is then 
embedded between two layers of Matrigel (2) within a chamber slide, with cell culture media added 
above (3). 
 
Although reporter fluorescence was best maintained in this format, there remained persistent regions 
of cell death. These could be clearly attributed to tissue handling during dissection and often 
resembled the outline of dissection tweezers (Figure 5.2aiii). Alteration to tissue dissection procedures 
minimised this damage to only the top and bottom of the aorta, yet each explant still needed to be 
individually handled (i.e. damaged) for Matrigel embedding. This requirement was exploited to create 
a defined "injury site" within the explant, into which proliferating cells could expand, in addition to the 
cut edges of the explant that also represented an injury. Further technical optimisation to the explant 
model included alteration of tissue fixation and processing. During tissue culture, live, fluorescent cells 
within each explant could be viewed using epifluorescence microscopy, however upon fixation there 
was a drastic loss of fluorescent signal. This loss was reduced by optimising explant processing 
conditions including fixation time, fixative concentration and methanol content of fixative 
formulations. Moreover, imaging was improved by clearing tissue in RapiClear 1.47 mounting media 
with mounting using iSpacers and by increasing confocal image averaging and detector gating which 
reduced Matrigel autofluorescence. The cumulative effect of these optimisations allowed for confocal 
imaging of fixed explants and outgrowing cells after tissue culture, retaining VSMC fluorescent lineage 







Figure 5.2 - Optimisation of explant processing and mounting to improve cell viability and 
fluorescence for live and confocal microscopy. 
a) Epifluorescence (i/iii) and confocal microscope (ii/iv) images of freshly embedded explants before 
(i/ii) and after (iii/iv) optimisation of tissue dissection and clearing with Rapiclear mounting media. 
Epifluorescence images show signal from YFP+ or GFP+ Confetti lineage labelled VSMCs. Confocal 
images are a single z scan (aii) and a maximum projection (aiv) showing fluorescent Confetti VSMC 
lineage label proteins (RFP in red, YFP in yellow and GFP in green) and DAPI nuclear stain (white). Scale 
bars are 50 µm. b) Confocal microscopy images of explanted tissue fixed after 9 days of culture, before 
(i/ii) and after (iii/iv) optimisation of fixation conditions, mounting procedures and microscope 
settings. Images are maximum projections showing Confetti VSMC lineage proteins (as in (a) with the 
addition of CFP in blue) with (i/iii) or without (ii/iv) DAPI nuclear stain (white). Boxed regions in (i) and 
(iii) are magnifications from the underlying images and scale bars are 100 µm.
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Immunostaining was not possible in whole mount samples due to poor antibody penetration (Figure 
5.3a). Therefore, cryosectioning (10 µm) was implemented (Figure 5.3bc), which also enabled better 
resolution of individual cells in the explant, particularly at later time-points where the explant 
morphology became more complex (Figure 5.4). 
 
Figure 5.3 - Increased antibody penetration of explant cryosections enables improved 
immunostaining. 
a) A whole-mounted, explant fixed immediately after Matrigel embedding and stained using anti-
αSMA (magenta) and DAPI nuclear stain (white). Confocal image shows a maximum projection and 
scale bar is 100 µm. b) Schematic showing the orientation of transverse cryosections cut from a frozen 
explant (injury site shown in black). c) Cryosections of an explant fixed immediately after Matrigel 
embedding and stained using anti-αSMA (i) or isotype control (ii) antibody (magenta) and DAPI nuclear 





Figure 5.4 - Explant cryosections enabled better visualisation of the explant injury site and gross 
morphology changes over time. 
a) Cryosection of a freshly injured and embedded explant, showing fluorescent Confetti signal and 
DAPI nuclear stain (white). b) An explant cryosection fixed after 8 days of culture showing Confetti 
nuclear signal with (i) and without (ii) DAPI nuclear stain (white). All images are maximum projections 










5.3 VSMCs and endothelial cells proliferate at sites of injury in the explant model and are 
inhibited by VEGFR2 small molecule inhibitors. 
To determine the behaviour of VSMCs within the model, explants were examined daily using 
epifluorescence microscopy and fixed for confocal imaging after 8 or 15 days of culture. During this 
culture period, epifluorescence imaging showed protrusions of fluorescent VSMCs from the explant 
edges into the surrounding matrix and central injury site (Figures 5.5a and 5.5bi). These protrusions 
appeared from numerous sites from day 5-7, which is consistent with the activation of VSMC 
phenotypic switching in vitro (Chamley-Campbell et al., 1979b), and formed elongated chains that 
extended over time. The response of VSMCs in the explant was non-uniform; it was not a general 
outgrowth of all cells and often produced chains of singly coloured cells. This was suggestive that there 
was a selective activation of some cells over others, as seen in vivo. In contrast to the epifluorescence 
images of outgrowing VSMC chains, brightfield images demonstrated a much wider response occurring 
in unlabelled cells (Figure 5.5bii); later identified as ECs by CD31 immunostaining (Figure 5.6). These 
ECs formed similar elongated protrusions from day 4 of culture, later developing into dense networks 
at every edge of the explant.  
 
Figure 5.5 - Outgrowth of VSMCs and non-labelled cells is evident in the explant model. 
a) Epifluorescence images of outgrowing YFP+ or GFP+ (i) and RFP+ (ii) lineage labelled VSMCs from an 
explant after 14 days of culture. Scale bars show 50 µm. b) Epifluorescence (i) and bright field 
microscopy (ii) images of RFP+ lineage labelled VSMCs (i) and non-fluorescent non-lineage labelled 




Figure 5.6 - Non-lineage labelled cells in the explant model are CD31+ endothelial cells. 
Cryosections from an explant fixed after 8 days of culture showing fluorescent Confetti signal and 
stained with anti-CD31 (ai and b, magenta) or isotype control antibody (aii, magenta) and DAPI nuclear 
stain (white). Confocal images show maximum projections and yellow boxed region in (a) is magnified 
in (b) with (i) and without (ii) DAPI nuclear stain. Scale bars are 50 µm (a) and 20 µm (b). 
 
Hypothesising that a larger piece of tissue would provide more cells at the explant edge capable of 
proliferation or migration and allow clear separation of the injury site from non-affected areas, 
different sized tissue explants were examined for VSMC and EC growth over ten days in culture. 
Individual lineage traced VSMCs were counted manually using epifluorescence (Figure 5.7a) and, EC 
networks scored from 0 (no outgrowth) to 4 (full explant edge surrounded by network) for each explant 
edge (i.e. a maximum score of 12, Figure 5.7b). EC growth was visible from day 4 in medium and large 
explants, appearing at day 5 in smaller explants; all of which reached the maximum score by day 10. 
Single VSMCs were seen from day 5 in medium and large explants, becoming longer chains and more 
numerous over time. Smaller explants were delayed behind this by two days, producing single VSMCs 
from day 7 and chains between day 8-9. Consistently across each day, both cell types showed an 
increased prevalence of outgrowth with explant size, indicating that larger explants produced more 
cell growth (proliferation and/or migration) per explant edge. Following these observations, it would 
have been ideal to standardise explant size. Usage of tissue biopsy punches was investigated for this 
reason; however, these caused excessive tissue damage. Instead, explant size was matched to scalpel 





Figure 5.7 - Outgrowth of VSMCs and endothelial cells over time is increased with explant size. 
a-b) Quantification of outgrowing cells from small (black, ~25 mm2), medium (dark grey, ~50 mm2) or 
large (light grey, ~100 mm2) over time in culture (n=3 per size). Number of individual VSMCs growing 
out of each explant was manually counted using epifluorescence microscopy (a) and endothelial cell 
outgrowth score was assigned by the extent of network formation at each side of the explant under 
light microscopy (b). Two-way ANOVA indicated increased growth with time (VSMC p<0.0001 & EC 
p<0.0001) or explant size (VSMC p=0.0161 & EC p<0.0001) and an interaction between the two 
variables (VSMC p=0.004 & EC p<0.001), error bars show SEM. 
 
Efforts to remove ECs were ineffective; manual scraping caused similar damage to the explant tissue 
as other manual handling, and partial enzymatic digestion did not sufficiently remove contaminating 
ECs. An alternative solution would be to specifically inhibit EC growth within the model, but this proved 
difficult to achieve without also affecting expansion of VSMCs. In vivo growth of ECs, or angiogenesis, 
is a complex process involving pro- and anti-angiogenic stimuli including VEGF, FGF and tumour 
necrosis factor (TNF) signalling among others. The most specific EC stimulus is vascular endothelial 
growth factor (VEGF), which promotes EC survival, proliferation and migration through interaction with 
receptors VEGFR1-3. Traditionally, ‘active’ pro-angiogenic vascular signalling is attributed to VEGFR2, 
with VEGFR1 acting as an ‘inhibitory’ decoy receptor and VEGFR3 associated with lymphangiogenesis. 
In the scRNA-seq dataset from healthy aorta there was widespread VSMC expression of ‘inhibitory’ 
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VEGFR1, but ‘active’ VEGFR2 was limited to one single VSMC; therefore, VEGFR2 was trialled to 
selectively block EC expansion. Two small molecule VEGFR inhibitors were used at three 
concentrations, above their IC50 values for VEGFR2 inhibition (Table 5.1) and were able to reduce 
unlabelled cell outgrowth from the explants (Figure 5.8). However, this also abolished VSMC growth 





Figure 5.8 - Endothelial cell outgrowth from the explants is blocked by VEGFR2 inhibitors. 
Light microscopy images of explants after 8 days in culture treated with VEGFR2 inhibitors SU5419 
(500nM-2µM, top right three panels) or AAL993 (100nM-1µM, lower right three panels) and compared 




















VEGFR1 VEGFR2 VEGFR3 PDGFR EGFR 
SU5419 
Semaxanib 
500 nM - 
2 µM 
43 nM 220 nM 50 nM 22.2 µM > 10 µM  
AAL993 
Anthranilamide 
100 nm – 
1 µM 
130 nM 23 nM 18 nM 640 nM 10.4 µM 
*Values taken from (Manley et al., 2002).  
138 
 
5.4 VSMC and EC proliferation in the explant model replicates VSMC responses seen in vivo 
and produces monoclonal patches of Confetti fluorescence, indicative of VSMC clonal 
expansion. 
As mentioned, chains of outgrowing VSMCs were often of a single colour, suggesting that VSMC 
outgrowth is associated with proliferation. This was confirmed by nucleoside analogue EdU 
incorporation in lineage-labelled VSMCs, both extending out from the explant edge and within the 
internal injury site (Figure 5.9a-b), and consistent with prior observations that VSMC migration in injury 
does not occur independently of proliferation in vivo (Chappell et al., 2016). Importantly, EdU+ VSMCs 
were not observed within the non-injured internal region of the explant, demonstrating that limited 
or selective proliferation was occurring (Figure 5.9c). Non-lineage labelled EdU+ ECs were also 












































































































































































































































































































































































































































Figure 5.10 - VSMCs and ECs proliferate at sites of injury in the explant model. 
Cryosections of explants fixed after 8 days of culture showing fluorescent Confetti signal (a-c and di), 
EdU (a-c and dii, magenta) and DAPI nuclear stain (white). Boxed injury site in (a) is magnified in (b) 
and boxed outgrowth in (c) is magnified in (d). Images show maximum projections (a-c) or a single z 
scan (d) and scale bars are 50 (a-c) or 20 µm (d). 
 
EdU incorporation was used to assess explant proliferation at day 8 of culture in response to PDGF-BB 
(Figure 5.11a), a growth factor that stimulates VSMC growth both in vitro (Kenagy et al., 1997; Parenti 
et al., 2002)  and in vivo (Jawien et al., 1992). I observed a marked variability in the responses of 
individual explants, despite each being taken from matched regions of the descending thoracic aorta, 
but also a significant increase in proliferation of PDGF-treated samples. Furthermore, the explant 
model was also able to replicate differential responsiveness of VSMCs from neural crest or mesoderm 
lineages, with increased EdU incorporation into day 8 AA-derived explants than those which were DT-
derived (Figure 5.11b). The ability of the explant model to reproduce PDGF stimulation and increased 
AA proliferation, in addition to the selective injury-site activation described above (Figure 5.9c), 
suggests that cells within the explant are not undergoing a general activation as seen during in vitro 
culture of dissociated VSMCs. This suggests that the heterogeneity in VSMC responsiveness which 
manifests as in vivo clonal expansion is retained in this model. 
 
In addition to outgrowing chains of cells, monochromatic patches (Figure 5.12b) were typically 
observed at the explant edge and within the explant injury site by day 8 and day 15 of culture (Figure 
5.12c). Along with the monochromatic nature of outgrowing VSMC chains (Figure 5.12d), these 
141 
 
patches indicated a selective VSMC response, analogous to the clonal expansion seen in in vivo disease 
models (Chappell et al., 2016; Clément et al., 2019). Furthermore, growth of the explants produced a 
gross change in morphology over time from a flat, square piece of tissue to a curled, rounded shape. 
This curling effect was caused by growth of the cells around the explant edges and they could not be 
flattened out without tearing the tissue. The morphology of such VSMCs at the explant edges was 
highly elongated, surrounding the explant edge in layers as if to seal it off from the external matrix 
(Figure 5.12a). Interestingly, such ‘onion-skin’ layers have been noted in pulmonary hypertension 
lesions produced by lung smooth muscle cells (Veyssier-Belot and Cacoub, 1999). 
 
 
Figure 5.11 - EdU+ explant cells increased in number with PDGF treatment and in explants taken 
from the aortic arch (AA) vs those from the descending thoracic aorta (DT). 
a) Number of EdU+ cells normalised by explant perimeter size (µm) in explants fixed after 8 days in 
culture with or without supplementation with 20 ng/mL PDGF (n=11 (-PDGF) and n=7 (+PDGF) from 
n=6 animals). Error bars show SEM and p=0.026 by Mann-Whitney U-test. b) Number of EdU+ cells 
normalised by explant perimeter size (µm) in AA or DT-derived explants fixed after 8 days in culture 










Figure 5.12 - Types of monochromatic growth seen within the explant model. 
a) Elongated YFP+ VSMCs at the edge of an explant fixed after 8 days of culture. Image is a maximum 
projection showing fluorescent Confetti signal and scale bar is 50 µm. b) YFP+ and CFP+ 
monochromatic VSMC patches at the edge of an explant fixed after 15 days of culture. Image is a single 
confocal z scan showing Confetti fluorescent signal and scale bar is 50 µm. c) RFP+ monochromatic 
patch within the injury site of an explant after 15 days of culture. Image is a single confocal scan 
showing fluorescent Confetti signal. The injury site is depicted by a dotted white line. Scale bar is 50 
µm. d) Outgrowing "chains" of VSMCs with a non-random reporter-colour distribution from an explant 
fixed after 15 days of culture showing fluorescent Confetti signal. Image is a maximum projection and 
scale bar is 200 µm. 
 
 
To assess the extent of monoclonal patch expansion, Imaris software was used for quantification. 
Surfaces of monochromatic VSMC patches were mapped using the surface function and the volume of 
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patches of each colour quantified in explants fixed freshly after embedding (day 0) or after 8 and 15 
days of culture (Figure 5.13), normalised by explant perimeter size. When considering all 
monochromatic regions (Figure 5.14a) or maximum patch volume per explant (Figure 5.14b) there was 
a significant increase between day 0 and days 8 or 15 of culture. There was also a reduction in patch 
size seen between day 8 and day 15, which may be attributed to the lower level of Confetti 
fluorescence intensity seen in explants fixed at day 15 which impedes reliable surface rendering. An 
average of 15 patches per explant at day 8 and 6 at day 15 exceeded the baseline maximum patch 
volume seen in freshly embedded explants, corresponding to 0.17% (day 8) or 0.04% (day 15) of total 
regions. These threshold calculations were performed separately for each Confetti fluorescent protein 
and then pooled per explant in Figure 5.14c. Here there is again a reduction, although non-significant, 
between days 8 and 15. Again this may be attributed to loss of fluorescent Confetti signal at day 15.  
 
In addition to larger patch size, selective proliferation of a subset of VSMCs was also indicated by the 
proportion of cells which were labelled in each Confetti lineage colour. At day 0 there was a 10-17% 
variation in the proportion of cells of each colour in freshly embedded explants, which was increased 
at days 8-15, up to 35-36% (Figure 5.15). This means that there is a higher enrichment of individual 




Figure 5.13 - Imaris software representation of whole mount explant images for subsequent 
quantification of colour heterogeneity. 
Confocal images (left panels) and Imaris representations (right panels) of whole mount explants fixed 
directly after Matrigel embedding (a) or after 8 (b) or 15 (c) days of culture. Confocal images are 
maximum projections and show fluorescent Confetti signal. Imaris representations show mapped 
surfaces used for volume quantification with colours matched to the Confetti channel from which they 





Figure 5.14 - Increased size of monochromatic patches of lineage label positive VSMCs in cultured 
in cultured explants versus those fixed at day 0. 
a-b) Monochromatic Confetti fluorescent patch volume (all volumes in (a), maximum per explant in 
(b)) measured by Imaris software in explants fixed immediately after embedding or after 8 or 15 days 
of culture (n=5 (D0), n=6 (D8) and n=12 (D15) explants from n=3 animals, coloured by animal in (b)). 
Patches from each Confetti lineage colour are pooled and error bars in (b) show SEM. In (a), p<0.0001 
for all comparisons and in (b), D0-D8 p=0.0173, D8-D15 p=0.0094 and D8-D15 was non-significant, all 
by Mann-Whitney U-test. c) Number of patches per explant fixed after 8 or 15 days of culture which 
exceed the maximum patch volume of freshly embedded explants. Thresholds were calculated for each 
Confetti fluorescent protein separately and compared to volumes from the corresponding fluorescent 
protein from day 8 or 15 explants, with number of patches exceeding each threshold pooled per 
explant for visualisation. Data is coloured by animal, error bars show SEM and differences between 







Figure 5.15 - Expansion of VSMCs in the explant model caused an increased range in the proportion 
of explant volume labelled in each lineage label colour. 
a) Proportion of total explant volume labelled in each Confetti lineage colour in explants fixed 
immediately after embedding (black) or after 8 (light grey) or 15 (dark grey) days of culture (n=5 (D0), 
n=6 (D8) and n=12 (D15) explants from n=3 animals). b) Range in the proportion of total explant 
volume labelled in each Confetti lineage colour from explants in (a), showing GFP in green, RFP in red, 
CFP in blue and YFP in yellow. 
 
To verify clonal expansion of single cells, I analysed explants from animals labelled at a lower 
frequency. Based on the analysis shown in Figure 5.14c, an average of 3 patches per explant would be 
expected at 20% of the labelling frequency. Monochromatic patches were apparent in explants fixed 
after 8 days of culture (1-2 patches per explant in 4/6 explants from 3 animals) when compared to 
those fixed immediately after embedding (Figure 5.16a-b). Not every labelled VSMC was present 
within a patch, confirming selective expansion of a subset of VSMCs. Interestingly, one very large VSMC 
outgrowth could be observed in one explant, highlighting that a single VSMC can undergo extensive 




Figure 5.16 - Monochromatic VSMC patches were visible in low-density labelled explants after 8 
days of culture. 
Fluorescent Confetti signal in explants from animals labelled with 20% of the standard tamoxifen 
dosage (2 mg). Explants were fixed immediately after embedding (a) or after 8 days of culture (b-c). a) 
Single confocal z scan showing lineage labelling in a low-density labelled explant fixed immediately 
after embedding. b) Single confocal z scan showing internal RFP+ and YFP+ patches (white arrows) in 
a low-density labelled explant, scale bar is 100 µm. c) Maximum projection showing a large YFP+ 








5.5 Optimisation of gene transfer for manipulation of gene expression within the explant 
model. 
To test the influence of specific genes by manipulating their level of expression within a cell, I combined 
gene over-expression or knock-down with a cell tracer (e.g. using a fluorescent label) to measure the 
effect at a single-cell level. This would mimic the acquisition of an alternative expression pattern in a 
discrete population of cells, as has been observed in collected healthy and CL single-cell RNA 
sequencing data (chapters 3-4).  
 
Attempts to use transient transfection of synthetic siRNA into explant VSMCs were unsuccessful 
(Figure 5.17). Improved genetic transfer can be achieved using viral transduction of cells, which use 
specific envelope proteins to target the cell membrane and induce expression via integration into the 
host cell genome. For transduction of VSMC explants, lentivirus vectors derived from HIV virus were 
chosen, due to their ability to target non-proliferating, differentiated cells and maintain stable 
expression in cell progeny. Third generation lentivirus vectors were selected for their improved 
biosafety when compared to other formats (Dull et al., 1998), as the transduced explants would need 
to be handled manually for Matrigel embedding. The highest transduction efficiencies in this model 
were obtained using the MLV pCag-Eco envelope protein (Figure 5.18) and Poloxamer 407 
transduction adjuvant (Figure 5.19). 
 
 
Figure 5.17 - Transfection of siGLO control siRNA showed a lack of uptake by explant VSMCs. 
Wildtype explants transfected with 100 nM Dharmacon siGLO control siRNA targeted to mouse Lamin 
A/C and labelled with DY-547 (red). Explants were transfected overnight then fixed immediately after 
embedding and stained with DAPI nuclear stain (white). Images show maximum projections and scale 




Figure 5.18 - Explant transduction with GFP-expressing lentivirus using different envelope proteins. 
a) GFP expression (green) in whole mount wildtype BL6 explants transduced with lentivirus carrying 
expression of GFP and pCAG-Eco (i) or pMD2.G (ii) envelope proteins and fixed after 8 days of culture. 
Images show maximum projections and scale bars are 100 µm. b) Number of GFP+ cells in whole mount 
wildtype explants transduced with GFP-expressing lentivirus using pCAG-Eco or pMD2.G envelope 
proteins and fixed after 8 days of culture. Quantification used 3 explants from 1 animal, error bars 





Figure 5.19 - Explant transduction with GFP-expressing lentivirus using different transduction 
adjuvants. 
a) GFP expression (white) in confluent cultured primary mouse VSMC non-transduced control (i, NTC) 
or transduced with GFP-expressing lentivirus and 8 µg/mL polybrene (ii, Pb), 5% w/v poloxamer 407 
(iii, P1), 10% w/v poloxamer 407 (iv, P2), 0.1 mg/mL synperonic F108 (v, S1) or 0.5 mg/mL synperonic 
F108 (vi, S2). Cells were imaged by epifluorescence microscopy at 72 hours post-transduction and scale 
bars show 100 µm. b) Number of GFP+ cells in confluent VSMC cultures transduced with GFP-





5.6 Lentivirus-mediated explant transduction and Klf4 overexpression in single explant VSMCs 
did not cause spontaneous proliferation. 
Klf4 is a member of the Kruppel-like transcription factor family, which is induced in VSMCs by oxidised 
phospholipids (Pidkovka et al., 2007), PDGF-BB and vascular injury (Liu et al., 2005). The Klf4 protein 
targets over 800 genes in VSMCs (Shankman et al., 2015) and is required for hypoxia-induced migration 
(Shan et al., 2019) and regulation of autophagy (Salmon et al., 2019). Klf4 is conventionally seen as a 
VSMC anti-differentiation factor. It inhibits Myocardin/SRF-induced expression of VSMC contractile 
markers (Liu et al., 2005) and directly reduces Tagln expression through binding of its promoter with 
pELK-1 and HDAC2 (Salmon et al., 2012). However Klf4 also has pro-differentiation effects, increasing 
TGFβRI expression via Smad2 and augmenting TGFβ pro-differentiation signals (Li et al., 2010). Similar 
opposing roles exist for Klf4 in VSMC proliferation. On one hand, Klf4 has been shown to suppress 
VSMC proliferation in vitro by upregulation via p53 (Wassmann et al., 2007) and inhibition of PI3K/Akt 
and ERK activation (Zheng et al., 2009). In vivo, however, VSMC upregulation of Klf4 during vascular 
injury is transient (Liu et al., 2005) and both PDGFR activation and hyperglycaemia can overcome Klf4-
induced growth repression (Xi et al., 2019; Zheng et al., 2015). Moreover, Klf4 is upregulated in 
proliferating VSMCs in response to hypoxia and its deletion has been shown to block VSMC 
proliferation and migration in pulmonary hypertension (Sheikh et al., 2015). In light of these findings, 
it is possible that the effects of Klf4 on VSMC phenotype and proliferation may be context dependent. 
I therefore sought to determine its effect on VSMC expansion within the explant model, using single 
cell overexpression via lentivirus transduction to see if its expression could activate or impair VSMC 
proliferation. 
 
To test the effect of Klf4 overexpression in the explant model, a bicistronic Klf4 and GFP expression 
plasmid was constructed, expressing both proteins from the same promoter to ensure that GFP 
fluorescence faithfully represented the level of Klf4 expression. This plasmid (pLenti-GTK) contained 
the coding sequences of Klf4 and GFP separated by the self-cleaving T2A peptide, all under the control 
of the cytomegalovirus (CMV) promoter and was produced using Gibson assembly (see section 3.5.1). 
Non-modified pLenti-GFP was used for control transductions. The GFP in both pLenti constructs was 
cytoplasmic, enabling separation of transduced cytoplasmic GFP+ cells and Confetti nuclear GFP+ 
lineage labelled VSMCs. Overexpression of Klf4 in cells transduced by pLenti-GTK compared to pLenti-
GFP transduction and non-transduced control cells was confirmed by RT-qPCR (Figure 5.20a) and 
western blot (Figure 5.20bii). A signal for GFP was detected in both transduced samples, showing 
increased size in samples transduced by pLenti-GTK due to the addition of T2A peptide (Figure 
5.20biii). Klf4 overexpression was verified by antibody staining in pLenti-GTK versus control virus-






Figure 5.20 - Overexpression of Klf4 using GFP-T2A-Klf4-expressing lentivirus. 
a) Relative expression of Klf4 in HEK293FT cell non-transfected control (NTC) or 72 hours post-
transduction with pLenti-GFP (GFP) or pLenti-GFP-T2A-Klf4 (GTK) determined by RT-qPCR (n=3 per 
sample) and normalised to Yhwaz and Hrpt1 housekeeping genes. Error bars indicate SEM and asterisks 
denote significant differences (NTC-GTK: p=0.0024, GFP-GTK: p=0.0024) by t-test. b) Western blot 
showing expression of β-actin (i), Klf4 (ii) or GFP (iii) in HEK293FT cell non-transfected control (N), or 
cells at 72 hours post-transduction with pLenti-GFP (G) or pLenti-GFP-T2A-Klf4 (K), all n=3. Size of 
marker bands is indicated, expected weight of β-actin is 45 kDa, Klf4 is 56 kDa, GFP 32.7 kDa and GFP-
T2A 34.5 kDa c) Dissociated cultured primary mouse VSMCs fixed 72 hours after transduction with 
pLenti-GFP (left panels) or pLenti-GFP-T2A-Klf4 (right panels) and stained with anti-Klf4 (top panels) or 
isotype control antibody (lower panels). GFP is shown in green and antibody in magenta, images show 
single confocal z scans and scale bars show 20 µm. 
 
To test the effect of lentivirus transduction and Klf4 overexpression on VSMC proliferation in the 
explant model, explants were transduced with 1.04x108 IU/mL pLenti-GFP or pLenti-GTK and 
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compared to non-transduced control after 8 days culture (n=5 each). Both Confetti+ and Confetti- cells 
were transduced by lentivirus (Figure 5.21). In pLenti-GFP transduced explants, many cytoplasmic 
GFP+Confetti+ cells were detected, both in individual cells (Figure 5.22 lower left panel) and in patches 
(Figure 5.22 lower right panel). This indicated that transduction by pLenti-GFP does not prevent clonal 
expansion of individual VSMCs nor does it induce spontaneous proliferation of transduced cells. 
Similarly, cytoplasmic GFP+ cells were visible in pLenti-Klf4 transduced explants, which had not 
spontaneously proliferated to form patches (Figure 5.22 upper right panel). This demonstrates that 
Klf4 induction is not sufficient to induce clonal proliferation in aortic VSMCs. Rather, it supports 
published observations suggesting Klf4-induced VSMC growth suppression, however, reduced 
transduction efficiency in pLenti-GTK transduced explants compared to pLenti-GFP, did not allow 






Figure 5.21 - Explant lentivirus transduction produced both transduced cytoplasmic GFP+Confetti+ 
VSMCs and cytoplasmic GFP+Confetti- cells. 
Explants transduced with pLenti-GFP (top and middle panels) or pLenti-GFP-T2A-Klf4 (lower panels) 
and fixed after 8 days of culture. Panels show Confetti (nuclear green) and lentivirus-induced 
(cytoplasmic green) GFP fluorescence with (left panels) and without (right panels) fluorescent signal 
from the other Confetti proteins. Orange arrows point to cytoplasmic GFP+Confetti- cells and white 
arrows point to cytoplasmic GFP+Confetti+ VSMCs. Images show single confocal z scans and scale bars 





Figure 5.22 - Explant lentivirus transduction produced both single and monochromatic patches of 
cytoplasmic GFP+ VSMCs. 
Non-transduced explant (top left panel) and explants transduced with pLenti-GFP-T2A-Klf4 (pLenti-
GTK, top right panel) or pLenti-GFP (lower panels) and fixed after 8 days of culture showing Confetti 
(nuclear) and lentivirus-induced (cytoplasmic) GFP fluorescence. White arrows point to transduced 





5.7 Summary and discussion of findings from chapter 5. 
5.7.1 Optimisation of lineage traced aortic explants to study single cell behaviour in vitro. 
In this work, a lineage traced VSMC explant model was developed to determine if the VSMC clonal 
expansion observed in diverse in vivo models of vascular injury (Chappell et al., 2016; Clément et al., 
2019; Jacobsen et al., 2017a) could be recapitulated in vitro, to facilitate investigations into this 
behaviour. Usage of conventional explant culture protocols resulted in widespread VSMC death, which 
may explain the slow rate at which this technique produces cells in published work, requiring several 
weeks before subculture (Xu et al., 2009). Instead a Matrigel-embedded model was produced, using 
pieces of Myh11-CreERt2/Rosa26-Confetti lineage traced descending thoracic aorta. This model was 
optimised to maintain VSMC fluorescence during tissue processing, imaging and cryosectioning for 
immunostaining (Figures 5.1-5.4). 
 
Interestingly, the VSMCs showed a remarkable sensitivity to mechanical injury, allowing for production 
of external and internal injury sites for stimulation of cell outgrowth. Outgrowing cells from the explant 
were both lineage positive VSMCs and CD31+ ECs (Figures 5.5-5.6) and their outgrowth was 
proportional to explant size (Figure 5.7). Attempts to block the EC growth specifically using VEGFR2 
inhibitors resulted in a loss of outgrowth of both cell types (Figure 5.8). The observed loss of VSMC 
outgrowth might be due to non-selective inhibition, although the effect was observed at a dose lower 
than the IC50 values of the small molecules for VSMC-stimulating receptors such as PDGFR and EGFR 
(Table 5.1). Inactive VEGFR2 has been demonstrated to dimerise with PDGFRβ, which inhibits PDGF-
induced VSMC migration (Cheng et al., 2012). If similar dimers are present in the tissue explant VSMCs, 
VEGFR2 inhibition may interfere with active PDGFRβ homodimer formation. Alternatively, inhibition 
of VEGFR1 may directly influence VSMC expansion. Whilst conventionally seen as an ‘inhibitory’ decoy 
receptor, there is emerging evidence for activation of intracellular signalling by VEGFR1 (Weddell et 
al., 2017). For example, the VEGF homolog PIGF binds to VEGFR1 and not VEGFR2 and is associated 
with pathological angiogenesis. PIGF knockout impaired angiogenesis in ischaemia, inflammation and 
wound healing (Carmeliet et al., 2001). PIGF has also been demonstrated to activate monocyte 
migration in vitro (Cai et al., 2003; Tchaikovski et al., 2008), which express only VEGFR1 similarly to 
VSMCs, and this effect is predicted to involve PLCγ (Weddell et al., 2017). Other work has shown 
amplification of VSMC stimulus with PIGF and VEGF when compared to VEGF alone, increasing VSMC 
growth both in vitro and in vivo in femoral artery ligation (Luttun et al., 2002). Thus, the concentrations 
of inhibitors used here, in excess of VEGFR1 IC50, may reduce VEGFR1 stimulation of VSMCs in this 
model. Finally, it is possible that VEGFR2 is required in some manner to activate VSMC growth. Despite 
only detecting VEGFR2 transcripts in one VSMC, expression of VEGFR2 has been observed in 
dissociated VSMCs in culture (Grosskreutz et al., 1999; Nomura et al., 1995) and in vivo in VSMCs on 
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the uterine wall (Couper Leslie L. et al., 1997). Furthermore, incubation with VEGFR2 neutralising 
antibody can reduce VSMC proliferation induced by incubation with PDGF and hypoxic EC media 
(Chanakira et al., 2015), and therefore VEGFR2 inhibition here may produce a similar effect. There may 
also be indirect effects of VEGFR2 inhibition through suppression of ECs and their expression of VSMC 
mitogens. In vivo, the endothelium plays a major role in regulation of VSMC contractility and the two 
cell types function to maintain the others quiescence; VSMCs prevent TNFα-mediated activation of the 
endothelium (Wallace and Truskey, 2010) and VSMCs maintain a contractile phenotype through 
endothelial-stimulated Akt signalling (Brown et al., 2005). In injury, however, VSMC-EC interactions 
can induce inflammatory signalling (Chang et al., 2014) and VSMC de-differentiation (Thomas et al., 
2009). Moreover, VSMC proliferation is greater in the presence of ECs during in vitro co-culture 
(Fillinger et al., 1993; Jacot and Wong, 2008). Given the negative effect of VEFGR2 inhibition on VSMC 
proliferation, I did not pursue this strategy further.  
5.7.2 Recapitulation of in vivo VSMC responses in the explant model. 
Proliferating VSMCs were observed at sites of injury in the explant model (Figures 5.9-5.10), a response 
which was amplified by the addition of PDGF-BB (Figure 5.11a). PDGF-BB is a well-characterised 
mitogen for VSMCs, which stimulates their proliferation both in culture (Li et al., 2011) and in in vivo 
injury (Mondy J. Sheppard et al., 1997) or atherosclerosis (He et al., 2015) and therefore this increase 
in VSMC proliferation was expected. However, proliferation only occurred at sites of injury, despite 
application of the PDGF-BB-containing media to the whole culture well (Figure 5.9c), suggesting that 
the non-injured areas may be prevented from proliferation by contact-inhibition. In vivo contact-
inhibition of VSMCs is important to maintain vascular homeostasis; however its disruption in disease 
or injury is poorly understood (Sun et al., 2018). Interestingly, rat vascular explants have previously 
been shown to produce higher cell outgrowth when taken from vessels injured with a balloon catheter 
(Haudenschild and Grunwald, 1985). In addition to PDGF-responsiveness, the explant model also 
replicated regional heterogeneity in VSMC proliferation seen in vivo, producing higher numbers of 
EdU+ cells in AA-derived explants than those from the DT (Figure 5.11b) Previous in vitro testing of 
these two lineages from chick embryos indicated increased proliferation of neural-crest SMCs when 
compared to those from the mesoderm, both with and without serum (Topouzis and Majesky, 1996). 
One explanation for these differences is that the athero-prone environment of the neural-crest-
derived AA exposes the vessels to disturbed blood flow and irregular shear stress, activating 
pathogenic signalling within the VSMCs (Chiu and Chien, 2011). However, in vivo aortic homograft 
transplantation experiments combined with high fat diet in canine vessels indicated that AA tissue 
segments could develop lesions even when transplanted into athero-resistant vessel regions 
(Haimovici and Maier, 1971, 1964; Woyda et al., 1960), indicating that they maintain a primed state 




The explant model also produced monochromatic regions of VSMC expansion (Figures 5.12-5.13), 
analogous to those observed during in vivo injury models. On average, 15 (day 8) or 6 patches (day 15) 
per explant were larger than the day 0 baseline at each timepoint respectively (Figure 5.14c), 
equivalent to 0.17 or 0.04% of total detected monochromatic regions (cells or patches), which is in line 
with observed rates of clonal expansion observed in vivo. Although these results demonstrate that 
patches of each VSMC lineage label colour increase over time, they may not be indicative of the true 
extent of VSMC patch expansion due to technical limitations. In addition to the discussed issue of 
fluorescence loss, Imaris cannot faithfully connect all nearby cells of the same colour in one single 
volume. This is because the fluorescent proteins used in the Confetti construct have different 
localisation within the cell; RFP and YFP are cytoplasmic, GFP is nuclear and CFP is membrane bound 
(Livet et al., 2007).  Accurate merging of these patches would be labour intensive and sensitive to 
inaccuracies; instead I exploited an inherent bias of lineage colour within the VSMC lineage tracing 
system. This bias produces higher numbers of YFP+ and RFP+ cells post-recombination and much lower 
GFP expression (Chappell et al., 2016), resulting in 10-17% variation in the proportion of cells of each 
colour in freshly embedded explants. This proportion was significantly increased after culture, 
supportive of clonal expansion of VSMCs of a single colour (Figure 5.15). Furthermore, expansion of 
single VSMCs could be seen in low-density labelled explants after 8 days of culture, including one 
example with a remarkable extent of outgrowth (Figure 16). Similar rare VSMCs from non-injured 
vessels which are able to divide rapidly have been observed in culture before (Haudenschild and 
Grunwald, 1985), demonstrating that a subpopulation with high proliferative potential may exist in the 
health vessel wall. These demonstrations of selective expansion and monochromatic patch formation 
indicate that the explant model recapitulates in vivo observations and does not suffer from 
spontaneous activation of general proliferation, as seen during in vitro culture. It therefore presents 
an improved method for study of the individual VSMCs which activate proliferation. Finally, the 
selective proliferation seen without the presence of adventitial and immune cells suggests that the 
selective proliferation seen in disease models is not dependent on signals from these cell types. 
5.7.3 Klf4-induced VSMC proliferation was not apparent in the explant model. 
The explant model provides an efficient, small-scale in vitro platform to test the influence of different 
pathways and/or reagents on VSMC expansion. In particular, manipulation of candidate gene 
expression in a subset of cells can interrogate their ability to activate proliferation whilst their 
neighbouring cells remain quiescent. Historically, transfection of VSMCs in vitro has proved challenging 
(Pickering J G et al., 1994) and accordingly transfection of cells in the explant model was inefficient 
(Figure 5.17). To circumvent this barrier, lentivirus transduction of explants was optimised using 
different viral envelope proteins and transduction adjuvants (Figures 5.18-5.19). The MLV viral 
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envelope protein (env), which targets the Slc7a1 basic amino acid transporter for entry into the cell 
(Kim et al., 1991; Wang et al., 1991), showed increased transduction efficiency than that from vesicular 
stomatitis virus G (VSV-G), which targets the LDL receptor family (Finkelshtein et al., 2013). VSV-G env 
is widely used to pseudotype lentivirus particles due to its broad tropism, infecting mammalian cells 
from any species, whilst MLV env is ecotropic, infecting only mouse cells. Both virus env target 
receptors are heterogeneously expressed at similar levels in our VSMC scRNA-seq datasets. However, 
when used in GFP-expressing lentivirus, particles containing MLV env produced more GFP+ VSMCs in 
the explant model at 72 hours post-transduction. Three different adjuvants were also tested for 
transduction efficiency. Many lentivirus protocols utilise the polycationic polymer Polybrene, which 
reduces electrostatic repulsion between a cell and lentivirus particle, resulting in increased virus 
adsorption onto the cell membrane (Davis et al., 2002). However, Polybrene can only be used at low 
concentrations due to its disruption of transmembrane potential leading to cell toxicity. The alternative 
adjuvants tested were synthetic block copolymers Poloxamer 407 and Synperonic F108, which are 
amphiphilic molecules and act as surfactants to fluidize cell membranes. Importantly, they are non-
ionic and less toxic than Polybrene, showing increased lentivirus transduction in human (Dishart et al., 
2003) and bovine (March et al., 1995) VSMCs, as well as murine HSCs (Delville et al., 2018) in culture. 
Using poloxamer concentrations given in the cited literature and 8 µg/mL Polybrene, which is tolerated 
by cultured VSMCs (Chick et al., 2012), both 0.1 mg/mL and 0.5 mg/mL Poloxamer 407 produced 
significantly higher numbers of GFP+ VSMCs than the Polybrene at 48- and 72-hours post-transduction 
(Figure 5.19, 48 hour data not shown). Synperonic F108 was also able to increase the number of GFP+ 
VSMCs in some cases, but had higher variability than Poloxamer 407 and thus the latter was chosen 
for future explant transduction. 
 
Aiming to dissect the relationship between Klf4 expression and VSMC clonal expansion, a dual GFP/Klf4 
lentivirus expression plasmid was constructed (pLenti-GTK), which conferred both GFP and Klf4 
overexpression in transduced cells (Figure 5.20). GFP expression was lower in pLenti-GTK transduced 
dissociated cells than those transduced with pLenti-GFP during lentivirus optimisation, despite the use 
of equal titres as determined by RT-qPCR of viral RNA sequences (seen by reduced protein level in 
Figure 20biii and decreased intensity in Figure 5.20c). A likely explanation for this difference is the 
increased size of viral RNA in pLenti-GTK versus pLenti-GFP. Previous work has shown that viral titres 
decrease with increased viral RNA length, both at the level of virus production and cell transduction 
(Canté-Barrett et al., 2016; Kumar et al., 2001). Transduction of explants with pLenti-GFP control 
produced both pLenti-GFP+Confetti+ VSMCs and pLenti-GFP+Confetti- cells (Figure 5.21). Moreover, 
the transduction did not cause spontaneous VSMC proliferation nor interfere with patch expansion 
(Figure 2.22), indicating that this system could be used to dissect of VSMC proliferative responses. 
Similarly, explants transduced with pLenti-GTK showed pLenti-GTK+Confetti+ VSMCs and pLenti-
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GTK+Confetti- VSMCs; however, none of these transduced cells had expanded into patches. This is 
aligned with an anti-proliferative role for Klf4, although the transduction efficiency of the pLenti-GTK-
expressing lentivirus was sub-optimal and replication of these results with higher transduction rates 
would be required to validate this conclusion. Improvement of VSMC transduction efficiency by pLenti-
GTK-expressing lentivirus and implementation of Klf4 knockdown in the explant model would facilitate 
further investigations into Klf4’s effect on proliferation and selective clonal expansion. Interestingly, in 
our scRNA-seq datasets from carotid ligation and high-fat diet mouse models, Klf4 transcript levels do 
not correlate with Myh11, Acta2 or Tagln downregulation, suggesting that its expression is not critical 
for their repression, nor with levels of p21, Cyclin D1 or Mki67, contrary to its proposed role in 

























6 General discussion and future work 
 
6.1 Activation of a subset of VSMCs from healthy animals, associated with Sca1 expression 
The monochromatic nature of neointimal or plaque-resident VSMCs in confetti lineage traced animals 
is indicative of a clonal origin (Chappell et al., 2016; Feil et al., 2014; Jacobsen et al., 2017a). Here, I 
hypothesised that this clonal response was due to a limited activation of selected VSMCs, which pre-
exist in a primed state within the medial VSMC population from healthy animals. Supportive of this 
hypothesis, in chapter 3 I characterised a small subset of Sca1+ VSMCs from healthy animals using 
scRNA-seq, which were distinct from the wider medial VSMC population and showed reduced 
contractile protein expression. These Sca1+ VSMCs also shared an “activated” transcriptional signature 
with Sca1+ cells from HFD-induced plaque VSMCs (cVSMCneg), containing many genes associated with 
VSMC activation and disease progression. Moreover, Sca1 was demonstrated to be induced during 
VSMC in vitro culture, a model of phenotypic switching, and, in chapter 4, to be expressed in Ki67+, 
proliferative cells post-carotid ligation injury. This work strongly associates Sca1 expression with a de-
differentiated or activated VSMC expression profile and may be suggestive of expansion of pre-existing 
Sca1+ VSMCs during vascular injury to form those within the neointima or plaque.  
 
As discussed in chapter 3.7, Sca1+ progenitors have previously been identified in the adventitia from 
healthy animals (Hu et al., 2004; Kramann et al., 2016; Passman et al., 2008; Yu et al., 2016), but not 
within medial VSMCs. One progenitor population has been found in the medial layer of healthy vessels 
from rats; these are multipotent vascular stem cells (MVSCs) and can be identified by expression of 
markers Sox17, Sox10 and S100β and absence of Myh11 (Tang et al., 2012). MVSCs make up <10% of 
total VSMCs and can produce VSMCs both in vitro and in vivo, also contributing to neointimal cells 
following endothelial denudation injury. Due to the Myh11- nature of MVSCs they would not be lineage 
traced by Myh11-CreERt2 and therefore would not be characterised here. Furthermore, 
immunostaining of MVSCs after 3 days of culture showed them to be Sca1- and thus distinct from the 
Sca1+ population identified here. However, the authors did note that MSVCs would have altered 
expression profiles at different stages of differentiation, contributing to the heterogeneity seen in 
medial VSMCs, and Sca1+ VSMCs profiled here did express S100β. Therefore, it is possible that Sca1+, 
Myh11+ VSMCs represent a distinct stage of MVSC differentiation not characterised in previous work. 
Further experiments to isolate and culture both MVSCs and Sca1+ VSMCs would be needed to establish 
any links between the two populations. Additionally, definitive evidence for the relationship between 
Sca1+ VSMCs from healthy animals and those seen in disease would require more sophisticated fate 
mapping using two recombinases (He et al., 2017) to mark Myh11+Sca1+ VSMCs prior to neointimal 




Although Sca1+ VSMCs from healthy animals express an activated expression signature, further scRNA-
seq at an early timepoint after carotid ligation injury in chapter 4 demonstrated contractile marker 
downregulation across a range of VSMCs, not all of which were Sca1+. A similar gradient was seen in 
the activation of disease associated genes, from Myh11-high VSMCs expressing contractile genes to 
Myh11-low VSMCs with an activated expression profile, including Sca1 and Mki67. Index-sorting of 
proliferative VSMCs post-carotid ligation, using the Ki67-RFP reporter, demonstrated an overlap with 
the activated, Myh11-low VSMCs. Moreover, index-sorted VSMCs from healthy, non-ligated animals 
co-localised with Myh11-high, contractile VSMCs. Using an unbiased algorithm, a linear trajectory 
could be mapped from Myh11-low to Sca1+ and Mki67+ cells, showing activation of disease-relevant 
pathways across the pseudotime produced. There was also heterogeneity in the expression of 
activated gene signatures in S+L+ VSMCs from healthy animals (chapter 3.4). Therefore, although 
Sca1+ VSMCs from healthy animals may represent VSMCs which are primed for activation, they may 
not be a distinct progenitor subpopulation with an alternative phenotype to the wider medial 
population. Instead, I propose that all VSMCs have the ability to become activated to a certain extent 
and those which are Sca1+ in healthy animals may just be further along this activation spectrum. 
Interestingly, Sca1 expression was present in more Ccnd1+ cells than Mki67+ in chapter 4.3, which may 
indicate that Sca1 is expressed upon exit from quiescence, before later down-regulation; although 
these observations would need further validation due to technical limitations of scRNA-seq. Also 
notable is the lack of Sca1 expression in VSMCs from HFD-induced plaques which appear to have trans-
differentiated to chrondrocyte-like or macrophage-like cells in chapter 3.6, again indicating that Sca1 
may mark a limited stage of VSMC activation.  
 
The existence of a phenotypic spectrum in VSMCs, which can be influenced by both genetic 
programming and environmental factors, has long been speculated in the literature (Rensen et al., 
2007). Phenotypic variation has been demonstrated by heterogeneity in contractile protein expression 
in healthy VSMCs in vivo and during in vivo injury or in vitro culture (Christen et al., 1999; Frid et al., 
1994; Hao et al., 2002; Regan et al., 2000). Transplantation of VSMCs from differing aortic regions or 
those with distinct phenotypes in culture into alternative in vivo environments has shown that 
phenotypic differences are maintained despite the new environment VSMCs are placed into 
(Bochaton-Piallat et al., 2001; Haimovici and Maier, 1964). The clonality of outgrowing VSMCs from 
explanted aortic tissue in chapter 5.3 is supportive of this phenotype maintenance, given that only a 
subset of VSMCs activate proliferation, despite many cells at the explant edges are exposed to the 
surrounding extracellular matrix. Preservation of VSMC behaviour in different environments is 
indicative of a epigenetic basis for phenotype maintenance, which has been suggested to define 
phenotypic boundaries between which VSMCs can move transition depending on environmental 
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triggers (Rensen et al., 2007). Determinants of phenotypic boundaries and their maintenance are yet 
to be defined, but it is likely that they are tightly controlled to prevent spontaneous or widespread 
activation of VSMCs. Recent work published from our lab identified H3K9me2 as an epigenetic mark 
which attenuates activation of inflammatory markers such as MMP3 and IL6 (Harman et al., 2019). 
Notably, inhibition of H3K9me2 maintenance by G9A/GLP dimethyltransferases significantly increased 
Sca1 expression in VSMCs at day 7 after CL injury. Therefore, it would be interesting to investigate the 
regulation of Sca1 by H3K9me2 and whether Sca1+ VSMCs from healthy animals have a lower level of 
this epigenetic mark than their Sca1- counterparts. Complementary work within our lab is ongoing to 
compare open chromatin regions between Sca1+ and Sca1- VSMCs from healthy and CL-injured 




6.2  Future investigation of VSMC activation within the in vitro explant model of VSMC 
proliferation and the influence of identified candidate regulators 
Although the findings in chapters 3-4 strongly associate Sca1 expression with a de-differentiated, 
activated VSMC expression profile, its relevance to human disease is limited by the lack of a human 
homologue, due to a large deletion within the Ly6 genomic locus between mouse and rat species 
(Holmes and Stanford, 2007). Moreover, the function or molecular mechanism of Sca1 in stem cell 
populations remains unresolved, despite being speculated to function in receptor-ligand or lipid raft 
signalling interactions (Holmes and Stanford, 2007). Therefore, in chapter 4 I sought to isolate other 
genes upregulated in responding VSMCs, to enable future investigations into the mechanisms of 
selective VSMC expansion. I identified four candidate regulators of VSMC activation (Angptl4, Fbln2, 
Timp1 and Gdf6), which were expressed in mouse CL-induced neointima, mouse HFD-induced plaque 
and in ‘fibromyocyte’ cells from human atherosclerotic plaques. All four factors also had links within 
the literature to vascular injury or vascular disease associated signalling. The in vitro explant model of 
VSMC proliferation developed in chapter 5 would be a useful system in which to test the influence of 
these genes on VSMC selective proliferation. This model is the first lineage traced and matrix-
embedded model of VSMC proliferation capable of recapitulating the clonal expansion seen in in vivo 
vascular disease models. As mentioned in chapter 3.7.1, there may be redundancy in the activation of 
VSMCs and adventitial cells depending on the extent of vascular injury (Roostalu et al., 2018), thus the 
absence of adventitial cells in this model allows for determination of each genes role specifically in 
VSMCs. It may, however, be beneficial to combine the lineage traced explant model with more 
complex in vitro systems, e.g. to incorporate co-culture with other cell types and/or flow (Dorweiler et 
al., 2006; Gu et al., 2019; Robert et al., 2013) to determine the influence of these components. 
 
One caveat to the in vitro explant work is that only vascular proliferation was measured, using the size 
of Confetti protein patches, meaning that VSMC de-differentiation or candidate gene expression in 
proliferating VSMCs were not explored. Both de-differentiation and proliferation are thought to occur 
during VSMC activation in vascular disease, although their regulation in respect to each other is unclear 
(Basatemur et al., 2019). My trajectory analysis based on the CL scRNA-seq dataset suggests that 
downregulation of contractile protein markers occur prior to cell cycle re-entry and proliferation 
(marked by Ccnd1 and Mki67 expression). In contrast, recent characterisation of HFD-induced plaques 
at different timepoints indicated that the plaque fibrous cap is formed from a highly proliferative, 
single aSMA+ VSMC prior to invasion of the plaque core and subsequent de-differentiation (Misra et 
al., 2018). During development it is also thought that proliferation and differentiation can occur 
simultaneously (Lee et al., 1997), so the two processes may not be strictly linked. It would therefore 
be valuable to determine the extent of de-differentiation within the in vitro model, investigating 




In addition to a broader understanding of VSMC activation, the wider implications of this work are in 
the targeting of selective VSMC expansion to prevent vascular disease progression. For example, in the 
context of angioplasty, anti-proliferative chemotherapeutic agents such as everolimus and paclitaxel 
are commonly used to prevent in-stent restenosis (ISR). Although drug-eluting stents have reduced the 
occurrence of ISR to <10%, their usage has drastically increased the rate of stent thrombosis due to 
impaired healing and re-endothelialisation (Lüscher Thomas F. et al., 2007; Pendyala et al., 2009). 
Moreover, ISR still remains a problem in patients with recurrent ISR refractory to treatment (Her and 
Shin, 2018). The use of a combination of agents has been suggested as an alternative therapy for these 
patients, however this also carries an increased thrombosis risk (Waksman Ron and Steinvil Arie, 2016). 
Incorporation of an agent to selectively target proliferating VSMCs without damaging the wider medial 
or endothelial populations would therefore present a targeted and novel ISR therapy with a reduced 
risk of thrombosis. Indeed, the use of adenoviral and lentiviral vectors to deliver a more targeted 
therapy have already been suggested for such applications (Chick et al., 2012). In the context of 
atherosclerosis, it is unlikely that an agent targeting VSMC activation would be able to limit plaque 
development entirely, due to the complexity of atherosclerosis development, involving a range of cell 
types and environmental factors (Ramsey et al., 2010) and its initiation in humans from a very young 
age (McGill et al., 2000). However, in advanced plaques VSMC turnover is critical to maintain the 
stability of the fibrous cap and avoid plaque rupture (Bennett et al., 2016). Therefore, an improved 
understanding of the process by which VSMCs activate proliferation and/or de-differentiation may 
allow for stimulation to increase their numbers within the fibrous cap or to prime them towards a 
beneficial phenotype.  
 
In order to realise such goals, processes common to both mouse and human vascular disease need to 
be isolated. As mentioned, candidate regulators of VSMC activation identified here could be found in 
two models of mouse vascular disease as well as ‘fibromyocyte’ cells from human atherosclerotic 
plaque, suggestive that there is some commonality in VSMC activation in these contexts. Although 
there are marked differences in VSMC localisation and atherosclerosis development between human 
and mouse vessels (Bond and Jackson, 2011), human VSMCs from the DT do display heterogeneity in 
marker expression and proliferative responses (Li et al., 2001). VSMCs within human atherosclerotic 
plaques have also been proposed to have a clonal origin (Benditt and Benditt, 1973), although technical 
limitations of the X-inactivation patterns examined for this study mean that the evidence is not 
conclusive. Newer natural lineage tracing elements such as somatic mutations in mitochondrial DNA 
may allow for a more accurate understanding of human plaque clonality (Ludwig et al., 2019). Finally, 
the use of human aortic explants is commonly employed to provide outgrowing VSMCs for subculture 
and thus may be used to investigate the influence of candidate gene manipulation on human VSMC 
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growth. However, these human cells would require an alternative method of single-cell lineage tracing, 
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Appendix 2.  List of primers used for RT-qPCR. 
 
















































Appendix 3.  List of primers used for lentivirus pLenti-GTK plasmid cloning with NEBuilder HiFi 
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